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Abstract  
The project focused on the hypothesis that degradable, polymer microneedle arrays are a 
promising alternative to traditional drug delivery routes, offering the patient a painless, high 
concentration, and quick delivery of therapeutics through the skin. This project explored 
chitosan-graphene nanocomposites as potential materials for microneedle arrays; the addition 
of graphene to chitosan is believed to yield improved mechanical properties and electrical 
conductivity over pristine chitosan, which will allow for long and slender microneedles and for 
electrically stimulated drug delivery, and may positively affect the degradation and drug 
delivery properties of chitosan.  
Graphene derivatives, such as graphene oxide, reduced graphene oxide, graphene 
quantum dots, and magnetic graphene quantum dots were synthesised and then characterised, 
before they were used as the filler within chitosan nanocomposites. Their effect at varying 
concentrations upon the mechanical properties, electrical conductivity, drug release, and 
enzymatic degradation rate of chitosan were assessed. It was determined that reduced graphene 
oxide was the optimum nanoparticle to reinforce chitosan, achieving the best mechanical and 
electrical conductivity properties of the nanocomposites. 
Chitosan-graphene nanocomposite microneedle arrays were shown to passively release 
small molecular weight drugs at a high delivery quantity and rate. Conductive chitosan-
graphene nanocomposite microneedles were tested to determine the effect of electrical 
stimulation on the release of large molecular weight drugs from the nanocomposite, with 
substantial improvements in the release rate of large molecular weight drugs when compared 
to passive diffusion. The microneedle arrays were shown to survive the force of insertion 
through compressive loading. The depth of penetration of the microneedles was determined 
through cross-sectional analysis of chicken skin.   
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Chapter 1. Introduction 
Compared to the 20th century, people in the 21st century are living longer and healthier lives, 
due mainly to improvements in healthcare [1,2]. This trend has created a boom in the 
biomedical and healthcare sectors, such that these sectors are very lucrative to the economy; in 
the UK, the average increase in public healthcare spending was 6.6% a year between 2000 and 
2011 [3] and global healthcare expenditure is expected to increase 5.3% a year between 2014 
and 2017 [4].  
Within the biomedical and healthcare sectors is the therapeutic drug and drug delivery 
markets. The quantity of therapeutic drugs consumed is increasing; for example, the 
prescription drugs market increased 6.5% between 2005 and 2006 [5].  Smart drugs are being 
developed that can remedy malignancies quicker and more effectively than the previous 
generation of drugs can [6]. These recent developments must be met with improvements in the 
delivery to the body to fully utilise the therapeutic effect [7,8]; such improvements  should be 
painless, should not be constrained to one therapeutic type, and should deliver the therapeutic 
efficiently.  
Therapeutic delivery systems, such as hypodermic needles and oral tablets, are 
commonly used but are limited in their application, efficiency and ease of use [9–11], and as 
such cannot be considered an ideal drug delivery device. This has led to the development of 
other forms of drug delivery to solve the inadequacies of the current drug delivery methods; 
one of these methods is transdermal drug delivery [12,13]: the delivery of therapeutics through 
the dermal layer into the blood circulatory system. Of the many transdermal drug delivery 
devices that are being developed, the most promising of these is the bio-polymer microneedle 
array, a series of micrometre-sized projections made from a biocompatible and biodegradable 
polymer. This system bypasses the hepatic first pass through the stomach, liver and kidney by 
allowing the drug to enter the blood system through the capillaries within the dermal layers. It 
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will limit distress to the patient by being painless and it will promote self-administration by 
being easy to use. 
Simultaneous to the development of smart drugs and new drug delivery devices, the 
application of nanoparticles, such as graphene and iron oxide, in conjunction with therapeutics 
has been investigated. The crossing of smart drugs and drug delivery systems with 
nanotechnology could yield very promising results, such as possible improvements in the 
therapeutic effect of drugs [14], imaging capability [15,16], the ability to track bound drugs in 
vivo [17,18], the ability to target bound drugs to specific sites [19], and the ability to thermally 
ablate tumours [20].  
The overall aim of this project is to develop a new type of microneedle array using 
nanocomposites of a degradable and biocompatible polymer and functional nanoparticles for 
targeted and monitored transdermal drug delivery. These nanocomposites will be optimised in 
terms of their main material properties: an optimised nanocomposite would have increased 
mechanical properties such as Young’s modulus and ultimate tensile strength that would reduce 
the chance of microneedles buckling or bending under force; it would have a sufficiently  
increased electrical conductivity relative to pristine chitosan to allow for electrical stimulation 
of the drug delivery; the nanocomposites would possess similar or higher enzymatic 
degradation rate properties to pristine chitosan; and the nanocomposites would have quicker 
and more efficient drug delivery profiles than pristine chitosan, while also offering stimulus-
responsive release and monitoring functionalities. There are five objectives associated with this 
project which are outlined below: 
 To prepare chitosan-graphene oxide nanocomposites and investigate the effect 
of graphene oxide on the mechanical properties, enzymatic degradation rate and 
drug delivery performance of chitosan. 
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 To reduce graphene oxide using a green, biocompatible method to restore the 
electrical conductivity and mechanical strength of graphene for incorporation 
into chitosan, study the effect of reduced graphene oxide on the mechanical, 
enzymatic degradation and drug delivery performance of chitosan, and 
demonstrate the release of a model drug from chitosan-reduced graphene oxide 
nanocomposite microneedle arrays.  
 To develop electrically conductive chitosan-graphene quantum dot 
nanocomposites with imaging and tracking functionality during drug delivery, 
and investigate the passive release of small molecular weight (< 1000 Da) drugs 
and the electrically stimulated release of large molecular weight (>1000 Da) 
drugs from chitosan-graphene quantum dot microneedle arrays. 
 To develop novel iron oxide-reduced graphene oxide quantum dots with 
intrinsic photoluminescent and superparamagnetic properties that can be used 
for dual modality imaging/tracking and site specific targeting of bound drugs. 
 To prepare electrically conductive chitosan-magnetic quantum dot 
nanocomposites with dual-modality imaging and targeting functionality, create 
a novel design of detachable microneedle array, and study the release of drugs 
from electrically stimulated or detachable chitosan-magnetic quantum dot 
microneedle arrays. 
This research will help advance the fields of transdermal drug delivery and polymer-graphene 
nanocomposites and lead to new designs of degradable microneedle arrays for targeted and 
monitored transdermal drug delivery.   
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Chapter 2. Literature review 
2.1 The current therapeutic delivery routes 
Currently, the main therapeutic delivery routes used are the hypodermic syringe, the perioral 
tablet route, and the nasal inhalation route. The standard hypodermic needle is used to 
administer the therapeutic to either a muscle (intramuscular), into a vein (intravenous), or just 
under the skin of the patient (subcutaneous) [21]. The advantages of hypodermic syringe 
include a quick application procedure and the ability to bypass the hepatic first pass. The 
downsides to hypodermic syringes include poor patient compliance and the risk of blood 
transmitted diseases [10,11,22–25].  
The perioral route of drug administration is achieved through the swallowing of the 
tablet, digestion through the stomach, and then absorption in the intestines and colon. 
Metabolism occurs in the liver and the bioavailability of the drug is lowered due to the hepatic 
first pass, often to a small fraction of the original dose, and can be further lowered by the 
insolubility of the drug within biological fluids in the intestines and colon [9,26,27]. Further 
adding to the complexity of drug development, the way that a drug is metabolised within a 
body will vary from person to person [28], something that must be accounted for during the 
design phase of the drug. As for advantages of the perioral route, the ease of administration 
reduces the need for skilled medical staff to administer the therapeutic. The pain associated 
with oral tablet administration is a lot lower and there is no piercing of the skin with an external 
device like with a hypodermic syringe and this negates the risk of blood transmitted diseases. 
The nasal inhalation route applies the drug through the nostrils to the mucous lining of 
the olfactory region of the superior turbinate (within the inner nostril cavity) which is densely 
packed with blood vessels [9,29,30]. This avoids the hepatic first pass through the liver, 
associated with tablet medications, and allows for easy self-administration of the medicine. 
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The pH of any solution or powder will have to match the pH of the nasal passage or there is a 
risk of irritation and degradation of the mucous layers. The permeability of the mucous layers 
depends on the size of the molecule trying to penetrate, so this limits the size of the molecules 
in a nasal spray to 1000 Daltons [30]. 
2.2 Transdermal drug delivery 
2.2.1 Introduction  
Transdermal drug delivery refers to the administration of drugs through the dermal layer. 
Transdermal drug patches, chemical or mechanical exfoliants, permeation enhancers and 
microneedle arrays have all been used to administer therapeutics transdermally [12,31,32]. In 
the dermis lies a region called the viable epidermis (VE) (Figure 2.1). Within the VE lies a 
dense network of blood capillaries. Drugs delivered to the VE will diffuse into the blood 
capillaries and pass into the main blood system, therefore avoiding the hepatic first pass [12]. 
Once diffused into the main blood vessels from the capillaries, the drug can then be absorbed 
into the cells within the body. The drug would typically arrive to the cells/tissue from blood 
vessels, with the drug entering the tissue from the vessels by diffusion and convection means 
[33]. Once diffused through the vessel wall, the drug will have to move through the lipid 
membrane, the extracellular matrix, and the cellular wall. The rate that drugs achieve this is 
dependent upon the molecular weight (MWt) of the drug, the solubility of the drug in bodily 
fluids (for example, the extra-cellular matrix) or lipids (lipid membrane), the charge of the drug 
molecule, the therapeutic dose administered and the gradient of the drug level difference 
between the blood vessel and the tissue [33,34], and as such, the rate at which various drugs 
enter the cells will differ from drug to drug. 
In the VE, there is a dense population of Langerhans cell, dermal dendritic cells, 
macrophages, and monocytes [35–38]; these will locate and recognise any foreign body that 
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enters through the stratum corneum (SC), engulf the foreign body and present them to the 
lymphocytes which initiate a specific and prolonged immune response to the foreign body. By 
focusing the delivery of therapeutics to the VE, the delivered therapeutics can very quickly 
initiate a substantial response from the immune system of the patient to any vaccine 
administered [39,40].  
 
Figure 2.1: Illustration of the layers of the human skin showing the SC and the nerves, veins 
and arteries deep within the dermis layers. Adapted from Van der Maaden et al. [40] with 
permission from Elsevier Limited, copyright 2012. 
2.2.2 The different types of devices for transdermal drug delivery 
This section will briefly review some recent advances in transdermal drug delivery, including 
topical cream, passive diffusion patches, electroporation, iontophoresis, thermal ablation, 
magnetophoresis, and sonophoresis. A summary is compiled in Table 2.1 of the key findings, 
advantages and disadvantages of the current transdermal drug delivery devices. Microneedle 
arrays will be discussed in Section 2.3.  
Topical cream 
Topically-applied therapeutics are the most basic form of transdermal drug delivery. One of 
the first reported studies on transdermal drug delivery was that of topically-applied 
hydrocortisone dissolved in acetone [41]. Taking the form of therapeutics dissolved in solvents 
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(e.g. hydrocortisone in acetone [41] or perillyl alcohol in water [42]), dispersed in gels 
(methoxalen [43] and tazarotene [44]), in a lotion/emulsion (glucose [45] and betamethasone 
[46]), or in a liposome suspension [47–49], the topically-applied therapeutics are applied 
directly to the outer dermal layers and have been shown to passively diffuse through the SC 
and into the VE. The permeation rate of hydrocortisone varied depending on the thickness of 
the SC at a particular test site and whether there were follicles at the test site [41], but it was 
shown to permeate through all of the test sites at a therapeutic level. Changing the dispersion 
agent from an ointment to a liposome increased the amount of triamcinolone found in the VE 
by 400% [49]. Methoxalen, administered to the patients through a gel, reduced the eczema in 
~89% of patients treated, and was shown to be as effective a treatment as UV irradiation in the 
treatment of eczema [43]. 
 Topical creams can be self-administered by the patient, reducing the cost of the 
treatment as there is no need for specialist healthcare assistance. There is, however, no control 
on the permeation rate of the therapeutic through the SC. The permeation is often slow, only 
milligrams per day [12,35,36]. Due to the low permeability of the SC, the maximum MWt of 
the drug that can be used is less than 1000 Daltons [12,50]. The drug must also be sufficiently 
lipophilic as the main diffusion route is through the intercellular lipid domain within the SC 
[12,51].  
Passive diffusion patch 
A passive diffusion patch is a device that contains an internal reserve of a topically-applied 
therapeutic, a diffusion membrane, and an impermeable backing-cover. This device is attached 
to the outer surface of the skin by an adhesive substance. The diffusion membrane is used to 
control the release of the drug from the reservoir, and in doing so makes the transdermal patch 
different to a topical cream where there is no control mechanism [51]. The rate of drug delivery 
into the skin is dependent on the surface area of the diffusion membrane, the permeability 
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coefficient of the drug, and the concentration gradient between the internal reservoir and the 
skin [12,51]. As a passive diffusion patch is, simplistically, an improved version of the 
topically-applied therapeutic, it has the same advantages and disadvantages as the topically-
applied therapeutic, i.e. it may be self-administered and cheap to use, but the drugs that can be 
used with this system are limited by their MWt and solubility. It can, however, control the rate 
at which a drug diffuses from the internal reservoir. 
Electroporation 
Electroporation increases the permeation of the SC by using an external electric field applied 
to the skin through electrodes; under electrical stimulation, the membrane of a cell will undergo 
a (reversible) chemical change where its permeability increases temporarily [52,53]. The 
therapeutic is then applied to the skin through topical cream or a passive diffusion patch; the 
electrical stimulation and treatment do not occur at same time. 
Electroporation increases the quantity of drug permeated through the SC in comparison 
to passive diffusion. The permeation of the therapeutics dextran, doxorubicin, and fentanyl 
from a passive diffusion patch were greatly improved when the skin was under electroporation 
stimulation in comparison to passive diffusion without electroporation stimulation [54]. It was 
noted that electroporation created less skin damage/side effects than using tape to strip the SC 
from the test site, which was an alternative route to increase the permeability of the skin [54]. 
Electroporation increased the delivery rate of calcein fourfold over passive diffusion [55]. 
Similar improvements were noted for gadolinium-labelled albumin [56] and hormones [57] 
when they were applied to electroporated skin. Electroporation can be used to administer 
deoxyribonucleic acid (DNA) vaccines, with a 100% survival rate for mice treated with the 
pox-virus vaccine [58]. There was a 100 times improvement in the plasmid DNA levels within 
mice that underwent electroporation treatment than those that did not undergo electroporation 
treatment [59]. 
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Electroporation offers significantly improved permeation rates when compared to 
topical cream or passive diffusion, but the equipment required may prohibit its widespread use 
as it may be more expensive than topical cream or passive diffusion. It may also be too complex 
for self-administration; stimulation of the nerves and muscles within subjects as well as 
superficial burning of the SC is possible with electroporation if incorrect parameters are used 
[52]. If the electrode resistance is too high, the electrode can burn the skin [60,61].  
Iontophoresis 
Iontophoresis is the stimulation of drug transfer through the SC by the application of an electric 
current directly to the SC [12,62–64]; the therapeutic reservoir is built into the positive 
electrode and the electric current transfers the drug from the reservoir through the SC by 
electro-repulsion for charged molecules and/or by electro-osmosis for molecules with no 
charge. The stimulation and treatment occur at the same time, contrary to electroporation 
treatment.  
 Iontophoresis increased the quantity of hydroxocobalamin delivered through the skin 
in test patients, with 1469 µg delivered over 4 h with iontophoresis stimulation and 181 µg 
delivered by passive means [65]. Similarly, dexamethasone phosphate and gentamicin sulphate 
could be transdermally delivered via iontophoresis, and dexamethasone phosphate had a ~2.5 
times higher delivery quantity than the value achieved by passive diffusion [66]. Lidocaine 
hydrochloride (LH) administered by electroporation and iontophoresis achieved local 
anaesthesia [61], but it was noted that iontophoresis obtained the greater depth of anaesthesia. 
A linear relationship (Figure 2.2) between the drug delivery of ketorolac and the current density 
applied via iontophoresis was found, showing that the delivery was current dependent and 
could be controlled to achieve a specific delivery rate [67]. The therapeutic effect of 
methylprednisolone sodium succinate was noted by 88% of test subjects that were treated with 
iontophoresis [68].  
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Figure 2.2: Effect of current density on the transferred amount (“permeated”) of ketorolac 
across a membrane under iontophoresis stimulation. Adapted from Gratieri et al. [67] with 
permission from Elsevier Limited, copyright 2014. 
The advantages (improved and controllable drug delivery) and disadvantages 
(possibility of skin irritation and the cost/complexity of the device) of the electroporation 
device are relevant to the iontophoretic device. Skin irritation and damage was noted in patients 
whilst using an iontophoretic device to stimulate drug delivery [12,61,65].  
Magnetophoresis 
Magnetophoresis is the process of using an external magnetic field to force a drug through the 
SC [62,69]; this is achieved through magneto-repulsion which induces the movement of 
diamagnetic drugs and magneto-hydrokinesis which induces the movement of the solvent 
constituent of the topical cream through the pores in the SC. 
 The transfer of LH through skin over 8 h was shown to be dependent on the density of 
the magnetic flux used [69]. The drug transfer using a 300 µTesla magnetophoresis device 
transferred 12 times the amount that passive diffusion could achieve in the same time frame 
[69]. A 3 fold increase in LH transfer was recorded for a magnetophoresis patch in a similar 
experiment [70]. Krishnan et al. [71] researched the drug delivery profile of naltrexone using 
a 250 µTesla magnetophoresis device compared to a passive patch, reporting a 5-6 times 
increase in the drug concentration levels for magnetophoresis when compared to a passive 
patch. The main problem with magnetophoresis is that for the drug to be transferred across by 
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magneto-repulsion, the drug needs to have a stronger diamagnetic tendency than a 
paramagnetic tendency, which is not always feasible. 
Sonophoresis 
Sonophoresis is the process of increasing the permeability of the SC by using ultrasonic energy 
to induce gas cavitation, heat, convection currents, and pressure differences in the SC 
[13,36,62]. Sonophoresis can be achieved by low or high frequency ultrasound [72,73], and the 
equipment required would typically consist of a signal generator, ultrasound transducers, and 
possibly an amplifier to increase the signal from the generator.  
A sonophoresis device will deliver one standard dose of insulin in less than 20 min, 
whereas by passive diffusion the same dosage will take just under 3 h [74]. The quantity of 
cyclosporine A transferred when under sonophoresis stimulation was 7 fold higher after 30 min 
than the amount transferred under passive diffusion [75], whilst heparin was transferred with a 
21 fold higher flux than passive diffusion over 25 h [76]. The quantity of salicylic acid 
transferred when under high frequency sonophoresis was 4 times higher than for passive 
diffusion [73]; in this work, the author claims that a lower frequency sonophoresis device did 
not noticeably improve the transfer of salicylic acid across the SC. Other therapeutics that were 
investigated were BSA [77], insulin [78],  sulforhodamine B [79], and calcein [80]. A 
comprehensive list of therapeutics tested and that showed promising drug permeation 
behaviour when under sonophoresis stimulation is compiled in the work of Polat et al. [81].  
Similar to electroporation and iontophoresis, the equipment required to use 
sonophoresis may be prohibitively expensive and complex for widespread use. Joshi et al. [36] 
noted that as the gas level in the SC decreases, the permeability of the SC decreases as well. 
This implies that there is a maximum usage level per application site, meaning that a new 
administration site will have to be found on the patient when the previous site becomes 
12 
 
unusable. This may be a hindrance for patients who require frequent drug administration, for 
example diabetics.  
Thermal Ablation 
Thermal ablation is the selective removal of the SC by localised, controlled extreme heat 
sources, subsequently followed by the application of therapeutics in the form of passive 
diffusion patches or topical cream [82–84]. The skin exposed to the heat field is vaporised and 
pores are temporarily created through the SC. Thermal ablation of the SC can be achieved by 
running a current through a highly resistive material [85] or via laser induced thermal ablation 
[86].  
The antigen response after vaccination was stronger when administered through 
thermally ablated skin than through intact skin [82]. The delivery of BSA through full thickness 
human cadaver skin was studied [87], with the amount released from passive diffusion (~0 µg 
ml-1) increasing to ~650 µg ml-1 through the use of thermal ablation on the SC. Similar results 
were achieved for sulforhodamine B. Human growth hormone [88] could permeate through 
thermally ablated skin but not through intact skin, and the bioavailability of the therapeutic was 
measured as 75% in rats and 33% in guinea pigs, when compared to the subcutaneous injected 
therapeutic. The thermal ablation of skin increased the permeation of granisetron hydrochloride 
(~30 times higher than passive) and diclofenac sodium (~9 times higher than passive) [89].  
Similar to iontophoresis and electroporation, there are a lot of variables to consider 
when applying thermal ablation to the skin and this could be a limitation regarding its 
widespread use; if the procedure is not undertaken properly, if the time of application is too 
long, or the temperature is not controlled adequately, then heat damage could potentially occur 
to the skin layers, the blood vessels, the nerves and the muscle/tissue around the treatment site.  
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Table 2.1: Comparison table of transdermal drug delivery devices 
Type Method  Advantages Disadvantages  
Topical cream Passive diffusion  Cheap  
Simple to build and operate 
Limited to < 1 kDa drugs 
No control over diffusion rate 
Low diffusion rate  
Passive diffusion patch Passive diffusion Cheap  
Simple to build and operate 
Diffusion of drugs can be controlled 
Limited to < 1 kDa drugs 
Low diffusion rate 
Electroporation Electrical stimulation No drug size limits 
Control over diffusion rate 
Costly 
Poor design or operation can harm patients 
Iontophoresis Electrical stimulation No drug size limits 
Control over diffusion rate 
Costly 
Poor design or operation can harm patients 
Magnetophoresis Magnet stimulation No drug size limits 
Control over diffusion rate 
No risk of harm to patient 
Costly 
Not all drugs are suitable for use 
Sonophoresis Sound-energy 
mediated delivery 
No drug size limits 
Control over diffusion rate 
No risk of harm to patient 
Costly 
Sites on body can be used for a limited time 
Thermal ablation Thermal removal of 
skin layers 
No drug size limits 
Control over diffusion rate 
Costly 
Poor design or operation can harm patients 
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2.3 Microneedle arrays 
2.3.1 Introduction to Microneedle Technology 
 
Figure 2.3: An illustration of first and second generation microneedle arrays. The first 
generation microneedle arrays are made from non-biodegradable material and the drug is 
delivered (A) through a transdermal patch and (B) through a powder coating on the external 
surfaces of the array. (C) Second generation microneedles that are made from a biodegradable 
polymer can deliver their encapsulated drug payload through biodegrading into the tissue. 
Adapted from Arora et al. [84] with permission from Elsevier Limited, copyright 2008. 
The simplest design of a microneedle patch is an array of solid, conical micrometre-sized 
projections (Figure 2.3 and Figure 2.4) that pierce through the SC to create micro-channels for 
drugs to permeate through to the VE where there is both a dense network of blood capillaries 
to diffuse into and a dense population of immune system cells for vaccines to utilise (Section 
2.2.1). Transdermal drug delivery with a microneedle array can offer an improvement in the 
delivery of vaccines and therapeutics over conventional drug delivery methods like hypodermic 
needle delivery [38,90–92]. Another advantage over hypodermic syringes is that microneedle 
arrays have a high level of patient compliance, with minimal pain or irritation recorded in 
previously reported tests compared to hypodermic syringes [37,93,94]. 
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Of the current transdermal drug delivery devices, microneedle arrays offer the best 
mixture of cost effectiveness, ease of use, and delivery performance [84,94–96]. Microneedle 
arrays can be cheap, requiring no additional electrical equipment to operate, unlike 
electroporation, iontophoresis or sonophoresis devices. Microneedle arrays can be used to 
deliver a wide range of therapeutics of various molecular sizes and solubility, from vaccines 
like the human-papillomavirus vaccine [97], the recumbent anthrax protective antigen [29], 
and the “Chimera-Vax” vaccine [98], to therapeutics like plasmid DNA [99], desmopressin 
[100], calcein [35], naltrexone [101], methyl nicotinate [102], insulin [103], ovalbumin [37], 
lysozyme [104], sulforhodamine [104,105], bovine serum albumin (BSA) [104,105] and β-
galactosidase [105].  
2.3.2 First generation microneedle arrays  
The first practical study on microneedle drug delivery was calcein delivered via reactive ion 
etched silicon microneedle arrays [35]. This design and other microneedle arrays made from 
metals and silicon are often termed “first generation”. These simple devices are often produced 
using the same low cost, high production manufacturing processes as for microchips in the 
computer industry (e.g. microlithography and etching, see Section 2.3.5). The drug is applied 
after the piercing of the SC by the microneedle array through a topical cream, a transdermal 
patch (see Figure 2.3A), or a dried therapeutic powder applied to the exterior of the microneedle 
projections themselves (see Figure 2.3B).  
The delivery of therapeutics have been tested with first generation microneedles, such 
as desmopressin (mean bioavailability of microneedle delivered therapeutic was 85%, 
compared to 0.1% for oral and 3.4% for nasal administration) [100], calcein (with higher 
quantities delivered through microneedle administration than through passive diffusion) [35], 
as well as tests that confirm that naltrexone [101], methyl nicotinate [102], LH [106], insulin 
[103], and ovalbumin [37], can all be delivered via a first generation microneedle. 
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Figure 2.4: Images showing first generation microneedles; (A) Metal conical microneedle 
projections, adapted from Corbett et al. [97] with permission from PLOS under the Creative 
Commons Attribution License 2010; (B) Penetration of metal microneedles through the SC, 
adapted from Henry et al. [35] with permission from John Wiley and Sons, copyright 2000; 
(C) In-plane microneedle array coated with a Hepatitis C (Hep C) vaccination powder, adapted 
from Gill et al. [107] with permission from Nature Publishing Group, copyright 2010. 
First generation microneedles were tested in conjunction with vaccinations, DNA or 
ribonucleic acid (RNA) gene therapies, proteins and other molecules. Vaccinations against 
various threats to humans (for example human influenza virus [38,90,91], human-
papillomavirus [97], anthrax [29], and Japanese Encephalitis, Dengue Haemorrhagic fever and 
Yellow fever [98])  would be ideal therapeutics to be administered through microneedle array 
technology, due to ease of administration and the heightened immune response from delivering 
a drug to the VE [35–38]. Koutsonanos et al. [38] showed that for a similar 10 µg dose of the 
vaccine, mice in the microneedle administered group had higher haemagglutination inhibition 
(HAI) and lgL titers (which are both signs of an efficient influenza specific immune response 
to a vaccine) than the intramuscular injected group. Alarcon et al. [90] showed higher influenza 
specific titer counts for all intradermal microneedle doses than the traditional intramuscular 
injection route in blood samples taken 3 weeks, 6 weeks and 8 weeks after administration. Zhu 
et al. [91] recorded comparable titer levels for subjects administered with an inactivated 
influenza virus through a microneedle and a hypodermic syringe. 
First generation microneedle delivery of gene therapies have interested people as large 
molecular treatments may be tough to administer with standard transdermal techniques and 
oral delivery is limited as the hepatic first pass may damage the therapeutic. A low dose of a 
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plasmid DNA therapeutic administered through microneedles (3.2 µg) was comparable to a 
high dose administered through an intramuscular hypodermic syringe injection (100 µg) in 
reducing the size of tumours in mice [107]. Other reports have shown that gene therapies can 
be successfully transported into the test subject, such as β-galactosidase [108], and plasmid 
DNA encoded firefly luciferase [109]. 
Despite the many advantages of the first generation microneedle array over hypodermic 
syringes and other transdermal drug delivery devices like iontophoresis and electroporation, it 
does have disadvantages due to the materials that they are made from. For example, first 
generation microneedle arrays made from metal, ceramics, or silicon do not biodegrade and are 
sharp and therefore they must be disposed of properly; if improperly disposed of, (for example, 
in a landfill site) the microneedle array may prove to be a blood borne pathogen risk to people 
who come into contact with the microneedle array [11] or if someone reuses the microneedle 
array [110].  
A second issue with the material is that the therapeutic must be applied to the outer 
surface of the array, or administered after the microneedle array has been inserted (see Figure 
2.3). Neither of these methods of therapeutic application is optimised; for example, coating the 
therapeutic onto the outer surface of the microneedle array means that the therapeutic might 
either break off or rub off of the array and onto the outer stratum layers during initial insertion. 
Also, as only a thin layer on the outer surface of the microneedle can be used, the quantity of 
drug that can be applied with each microneedle array is limited in comparison to the volume 
within the microneedle itself. This issue can be partially solved through the development of 
hollow microneedle arrays, such as those created from glass [111], silicon [112], or from metal 
[103], where liquid solutions of drugs can be stored in reservoirs to flow through the shaft when 
the SC is perforated by the microneedle arrays themselves. This type of microneedle array 
solves the problem of limited drug quantities, but the first problem (disposal of the microneedle 
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array) remains unsolved for this generation. The hollow microneedle array are often used in 
conjunction with a piezoelectric pump [113,114], which may add to the price and complexity 
of the microneedle array and may limit the widespread use of these types of microneedle arrays.  
2.3.3 Second generation microneedle arrays 
A second generation of microneedles (Figure 2.3C and Figure 2.5) were designed from 
biodegradable and biocompatible polymers to alleviate the problems of the first generation, 
e.g. no biodegradation and limited therapeutic-loading capacity. Some polymers can be 
biodegraded through enzymes within the body, such as chitosan [115] and poly(glycerol 
sebacate) [116]. Others by environmental conditions, such as poly(acrylic acid)  [117]. Some 
polymers are water soluble, such as poly(vinyl alcohol) (PVA)[118]. This aids in the post-
administration waste treatment of the second generation microneedle array. These new 
microneedle arrays also have the advantage where the drug can be encapsulated within the 
polymer; this means that more drug can be stored per microneedle array than would be possible 
if the drug was coated on the microneedle exterior, and the drug release is now dependent on 
the drug diffusing from the polymer and the drug is released straight into the VE.  
 
Figure 2.5: Images showing second generation microneedles; (A) Polymer microneedle 
projections made from amylopectin to allow for biodegradation, adapted from Lee et al. [104] 
with permission from Elsevier Limited, copyright 2008; (B) An array of polymer microneedles 
beside a 26 gauge hypodermic syringe needle allowing for a comparison in size, adapted from 
McAllister et al. [95] with permission from National Academy of Sciences of the United States 
of America, copyright 2003; (C) Poly(vinyl-pyrrolidone) (PVP) microneedles with the 
encapsulated drug sulforhodamine to allow for transdermal drug delivery, adapted from 
Sullivan et al. [105] with permission from John Wiley and Sons, copyright 2008. 
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Biocompatible polymers such as poly(l-lactide) acid (PLA) [95], poly(glycolic acid) 
(PGA) [95], poly(lactic-co-glycolic acid) (PLGA) [95], poly(vinyl-pyrrolidone) (PVP) [92], 
and carboxymethylcellulose (CMC) [104] have been used in the development of microneedle 
arrays. PLA  and CMC microneedles were used to deliver sulforhodamine B (see Figure 2.6), 
BSA, and lysozyme [104]. The enzymatic activity of lysozyme that was added into a CMC 
microneedle array and stored at room temperature for 2 months was shown not to be 
substantially degraded in comparison to fresh lysozyme, which is an important result as 
therapeutics may be stored in microneedles for a substantial amount of time prior to use. The 
delivery of sulforhodamine into the skin by CMC microneedles can be seen in Figure 2.6, 
where the sulforhodamine can be seen under fluorescent light to have diffused from the surface 
into the VE layers under the SC. Similar diffusion results were achieved for the delivery of 
sulforhodamine B and BSA with PVP microneedles [105]. PLGA microneedles were used for 
the delivery of ovalbumin [119], silk protein microneedles were used for the encapsulation of 
the enzyme horseradish peroxidase and tetracycline [120], and for BSA and sulforhodamine 
[121], and hyaluronic acid microneedles were used for the delivery of fluorescein 
isothiocyanate labelled dextran [122]. Dextrin microneedles were used to deliver heparin and 
insulin [123,124]. A microneedle made from starch/gelatin (1:1 weight ratio) was used for the 
release of insulin, with the microneedle treated rats exhibiting a similar hypoglycaemic effect 
as subcutaneous injected rats [125]. It was also noted that the insulin retained a 92% 
bioavailability and was delivered in a pharmacologically suitable quality [125].  
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Figure 2.6: (A) image of the microneedle array, (B) sulforhodamine staining of the skin after 
application, and (C) histological cross section of skin showing fluorescence. Adapted from Lee 
et al. [104] with permission from Elsevier Limited, copyright 2008. 
A vaccination against the PR8 influenza virus was administered by PVP microneedle 
arrays into mice, with the humoral immune response titer levels found to be statistically similar 
between microneedle and hypodermically administered groups [92]. CMC microneedles were 
used to deliver an influenza vaccine, with strong immune response recorded 102 days post 
application via the microneedle [126]. Vaccinations against tetanus were encapsulated within 
thermoplastic starch microneedles [127], as well as the encapsulation of goat anti-human IgG 
antibodies into maltose microneedles [128].  Microneedles made from PVA, trehalose and 
maltitol (2:3:3 weight ratio) were used to administer recombinant protective antigen to rats, 
with higher titer counts noted after microneedle application than after intramuscular or 
intradermal injection [129]. 
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PLA microneedles were coated with a poly(o-nitrobenzyl-methacrylate-co-methyl-
methacrylate-co-poly(ethylene-glycol)-methacrylate) film which was left within the dermal 
layers upon application of the PLA microneedle; this film was used to deliver DNA and RNA 
therapeutics into the dermal layers of (in vivo) mice and (ex vivo) macaque monkeys [130]. 
Plasmid DNA encoded with firefly luciferase was successfully administered to mice via PLGA 
microneedles, with a rapid delivery shown by an increase in luciferase activity after 5 minutes 
post application [99]. β-galactosidase was encapsulated and subsequently released from PVP 
microneedles [105].  
While second generation microneedles made from PLA, PVP, PLGA, etc., have many 
advantages over the first generation microneedles, they are not fully optimised for transdermal 
drug delivery. A problem with standard second generation microneedle arrays is that the 
diffusion of the drug from the polymer depends on a number of things such as the rate of water 
uptake into the polymer, the dissolution rate, MWt and solubility of the drug, and the rate that 
the polymer is degraded by enzymes within the body or dissolved by the bodily fluids 
[131,132].  
2.3.4 Electrically-stimulated microneedle arrays  
Recently, there has been an increase in the studies of microneedle arrays that work in unison 
with another transdermal drug delivery system to improve the drug release performance 
relative to either separate device. An example of such a system is a combined iontophoresis–
microneedle array system for the delivery of various drugs, such as insulin where the stainless 
steel microneedles were both the positive electrode for the iontophoresis device and the means 
of perforating the skin to create microchannels in the SC [133]. Using iontophoresis increased 
the quantity of insulin transferred by 3-5 times the value transferred without iontophoresis 
stimulation [133]. The delivery of BSA into the skin was ~3 times higher when a microneedle 
was combined with an iontophoresis device than without [134]. Small MWt drugs can 
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passively diffuse from microneedle arrays into the SC, and as such there was no noticeable 
increase in drug delivery rate when the microneedle array was combined with iontophoresis 
compared to passive diffusion [134,135].  
Another possible combination is the electroporation-microneedle array combination 
that can have hollow microneedles to allow for therapeutic flow from an internal reservoir 
[136,137] or have the therapeutic applied to the outer surface of solid microneedles [58,138]. 
Such devices can be used for the electroporation of specific cells [138,139] or for the 
electroporation of the SC [140]. Therapeutics that were delivered successfully and in a higher 
quantity than the amount achieved by passive diffusion include dextran [140], calcein and BSA 
[139] and DNA vaccines [58,138]. There was a 140 fold increase, in comparison to passive 
diffusion, in the quantity of dextran that permeated the skin when an electroporation-
microneedle array was used; this compares favourably to microneedle only (7 fold increase) 
and electroporation only (20 fold increase) [140]. It was found that increasing the voltage to 
the device when electroporating prostate cells would increase the uptake of calcein and BSA 
into these cells [139].  
Electrically-stimulated microneedle arrays have improved drug delivery performance 
over standard first generation microneedle arrays and over passive diffusion, as well as the 
ability to modulate the delivery by varying the electrical stimulus, but they are more expensive 
than standard microneedle arrays (due to the equipment required) and are liable to the same 
problems as those discussed for electroporation/iontophoresis machines and first generation 
microneedles on their own (Section 2.2). 
2.3.5 Manufacture of microneedle arrays 
Microneedle arrays have been designed in their first and second generation forms for almost 
two decades, and in that time several different manufacturing processes have been used to 
manufacture the microneedle arrays. For second generation microneedle arrays, an original 
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version of the design is often produced from a metal/silicon/ceramic material initially. This 
original microneedle array would be replicated using silicone and a vacuum oven to create 
numerous female moulds; these female moulds would then, in turn, be filled with the chosen 
polymer and the drug to create second generation microneedle arrays [141]. The different 
processes used to create microneedle arrays can be summarised as microlithography, etching, 
laser fabrication, and 3D printing, of which brief descriptions of the processes are included 
below.  
Microlithography 
Microlithography was conceived to transfer complex shapes onto wafers by the selective 
removal of photo resist polymer material. Microlithography is mainly used in the computer 
chip, electronics, and semiconductor industries. Microlithography has been used previously in 
microneedle array projects [92,95,105]. 
Microlithography can be split into two classifications; (1) parallel and (2) serial. Parallel 
lithography refers to photolithography, where the UV light source is used to change the material 
properties of the photo resist material, allowing for selective removal by “developer” solvents. 
Serial lithography refers to either “electron beam direct write” lithography or focused ion beam 
lithography [142,143]. For an electron beam direct write lithography device, the beam is 
focused on a polymer material that is chemically changed by electrons passing through it. Upon 
the application of a developer solution, the undesired polymer is removed. A focused ion beam 
lithography device works either to remove a layer or to construct a layer. The ion beam has 
enough power to impinge and remove a small section of the wafer down to a certain depth. The 
ion beam also has the power to reduce the environmental gas within the chamber to a solid at 
specific points, allowing for the precise placement of solid material to form upright objects 
[144].  
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Etching 
Etching uses the selective removal of a sacrificial material to form objects of high resolution 
for use within the electronics and semiconductor industries. Etching relies on the chemical 
reaction of etchants like sodium hydroxide and hydrofluoric acid with a sacrificial material 
coating.  Wet etching uses solvents to achieve a controlled removal of specific material from a 
substrate wafer. This level of control is afforded by the use of a mask made from a material 
that is resistant to the solvent and by knowing the etch rate of the etchant. Silicon wet etching 
has been used previously to create microneedle arrays [145,146].  
Reactive ion etching achieves higher resolution by using radical particles to remove the 
chemically reactive sacrificial material not protected by a reaction inhibitor mask. The radical 
particles are created by the ionisation of the gas within the chamber by a combination of low 
pressure and radio frequency electromagnetic stimulation. The ions from the gas plasma 
bombard the substrate, both reacting chemically with the sacrificial material and forcibly 
ejecting (sputtering) any material with a lower binding energy than the kinetic energy of the 
ion. These two processes combine to etch away the desired pattern [142]. Reactive ion etching 
has been used previously to create microneedle arrays  [95,146].  
Laser Microfabrication 
UV laser cutting or drilling is a dry micromachining process [147]. UV laser microfabrication 
was used in previous literature to create microneedle arrays [38,99,103]. Light energy from the 
laser is targeted at specific points on the target material and the material is melted and ejected 
by a shockwave from its original position. By modifying the laser power and by knowing the 
thermal properties of the target material, the depth of each penetration impact can be changed 
to allow shallow or deep impacts.  
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3D printing 
Two-photon photo-polymerisation relies on the raising of the photo-initiator molecules within 
a photo-curable resin from the ground state to a higher energy state via the absorption of 
photons, with the polymerisation occurring at the focal point of a highly focused laser of 
sufficient wavelength. Femtosecond direct laser writing was used to produce 3D scaffold 
structures for cell growth, with feature sizes 50 µm high and 7 µm wide achieved [148,149]. 
Similarly sized features, this time in the form of cantilevers and pyramids, were created by 
picosecond laser pulses for use as optical data storage devices [150].  
Additive polymer printing techniques require the local heating of a polymer filament 
and the extrusion of the melted polymer through a fine nozzle, with horizontal layers of 
deposited polymer building up to form 3D structures. These printers do not provide the same 
resolution or size of detail as two-photon polymerisation can, often with limits of 0.1 mm 
resolution, but produce objects much quicker.  
Replication procedures for the microneedle arrays 
Typically, the initial microneedle array that was produced by 3D printing, microlithography, 
etching, or other methods, would be replicated using silicone and a vacuum oven to create 
numerous female moulds. This can be achieved by inserting the original microneedle array 
fully into uncured silicone, using a vacuum oven to remove bubbles and voids, and then 
subsequently curing the silicone.  
Once the mould has been replicated, commonly the mould is filled by using either a 
vacuum oven or a centrifuge; either method will ensure that the voids will be filled and that the 
microneedle will be fully formed. In some instances, it is easier to use a vacuum oven to fill 
the voids, for example filling the mould with molten polymer [141] or filling it with a photo-
curable resin [105]. In other circumstances, such as those where heat is not required, a 
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centrifuge can be used to fill the voids of the mould [104,119,151,152], which is the process 
employed in this thesis. 
2.4 Functional Nanoparticles 
In this section, recent publications will be discussed that report on nanoparticle-assisted drug 
delivery, bio-imaging, and thermal ablation applications; the nanoparticles of particular interest 
are carbon nanotubes (CNTs), graphene, iron oxide (IO), hybrids of graphene-IO, and other 
nanoparticles such as gold and quantum dots (QDs).  
In this project, the drugs will be bound to graphene and subsequently released from the 
nanocomposite into the body in this form, so it is important to study the literature on 
nanoparticle-assisted drug delivery. Publications on nanoparticle-assisted drug delivery focus 
on the interactions between the drug and the nanoparticle, the potential for targeting the 
nanoparticle to a specific site, and the diffusion of the drug from the nanoparticle once at the 
target site. Studies on the imaging potential of nanoparticles have assessed their applicability 
to various imaging modes such as magnetic resonance imaging (M.R.I.), computed 
tomography (CT), positron emission tomography (P.E.T.G.), fluorescent and optical 
microscopy, and photo-acoustic. Studies on thermal ablation applications investigate the 
interaction between nanoparticles and external stimulations such as NIR irradiation or an AC 
magnetic field, and the efficiency that the nanoparticles convert the stimulating energy to heat 
in order to damage tumours and cancer cells [153].  
The biocompatibility of nanoparticles will also be discussed in their sections, as it is 
important for future biomedical applications. It is well known that ultrafine particulate matter 
in the air have adverse effects on the humans and animals that inhale them, ranging from 
cardiovascular, pulmonary, respiratory, and cancer problems [154–156]. The effect that CNTs, 
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graphene, IO, hybrids of graphene-IO, gold, and QDs have on the body must be checked for 
similar effects. 
2.4.1 Carbon Nanotubes 
CNTs are carbon allotropes that are in essence “rolled up” sp2 carbon nanosheets (Figure 2.7). 
CNTs have recently been researched as potential drug delivery systems [157], as imaging 
agents [158], and as thermal ablation agents [159].  
 
Figure 2.7: A sheet of carbon atoms, arranged in a hexagonal arrangement, can be formed into 
other carbon nanostructures like CNTs, fullerenes and graphite. Adapted from Geim et al. [160] 
with permission from Nature Publishing Group, copyright 2007. 
CNTs were coated with a Platinum IV anticancer drug and were shown to have a pH 
sensitive release of the drug after the CNTs had entered cancer cells [157]. The presence of the 
free drug itself did not notably decrease the cell viability (with a maximum decrease of ~10% 
with a 0.5 µM concentration), but when delivered by CNTs the drug reduced the cell viability 
by ~85% at a 0.5 µM concentration of the drug. The drug, per mg of protein, was measured at 
23 ng within the cytosol region and 36 ng within the nucleus after 3 h, values that were twice 
as high as for free Platinum IV [157]. Fluorescein labelled RNA attached to CNTs were used 
to target HeLa cells in mice [161], with the RNA working within one week to reverse the 
growth and reduce both the size and weight of the tumours when compared to control mice 
tumours.  
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CNTs can be used to image tumours in mice [158]. By coating the CNTs with a copper 
isotope (to allow for P.E.T.G. imaging) and an antagonist of integrin (to provide targeting 
functionality), CNTs were able to target and image with high resolution the tumours within the 
mice. Welsher et al. [162] used functionalised CNTs and NIR light stimulation to monitor the 
flow of blood through a mouse. Figure 2.8 shows the progression of the PEG coated CNTs 
from the insertion point at the tail vein to the lung and then from the lung to the spleen via the 
kidney and the liver, demonstrating that these nanoparticles can be used to monitor blood flow 
and to determine if there are any blockages within the veins.  
  
Figure 2.8: The path of blood flow through the lung, kidney, liver and then to the spleen. Upper 
row is in the plan view and lower row is in the side view. Adapted from Welsher et al. [162] 
with permission from National Academy of Sciences of the United States of America, 
copyright 2011. 
 CNTs were used to photothermally ablate 4T1 tumours in mice using NIR irradiation 
[159]; this would only occur when CNTs were used in conjunction with NIR irradiation and 
not with CNTs or irradiation on their own. Similarly, PEG coated CNTs achieved photothermal 
ablation of mice, with those treated with CNTs and laser irradiation surviving the duration of 
the study: their tumours decreased in size and mass unlike the control mice that died from 
tumour growth after thirty days [163]. 
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The biocompatibility of CNTs can depend on whether there are any impurities on the 
CNTs after production, which may limit the usefulness of CNTs in biomedical applications. 
Shvedova et al. [164] applied CNTs, containing trace amounts of iron derivatives, to human 
epidermal keratinocytes. The unpurified CNTs damaged the cells when introduced in doses 
from 0.06-0.24 mg ml-1 through OH free radical interaction with cells. Reactive oxide species 
(ROS) can lead to oxidative stress which may lead to cell apoptosis [165–168], DNA damage 
[169], and some diseases of the brain [170] and the cardiovascular system [171]. The ROS in 
the unpurified CNTs is from the manufacturing process and can lead to changes to the structure 
of the cells (nucleus, mitochondria and the tonofibril) after 18 h [164]. Monteiro-Riviere et al. 
[172] assessed purified CNTs (without any iron derivatives present) with human epidermal 
keratinocytes; the cell viability reduced to 70% with a high dose (0.4 mg kg-1). This shows that 
if the impurities of CNTs can be reduced to negligible levels, the cell viability can be 
maintained. Radomski et al. [173] noted that CNTs at concentrations of 0.2-300 µg ml-1 
induced platelet activation and clotting of the blood. Li et al. [174] suggested that CNTs 
administered in doses of 10 to 40 µg per mouse can inflict ROS damage on the mitochondrial 
DNA and that this led to an increase in atherosclerosis in the mice. Yokoyama et al. [175] 
recorded that granulomas surrounded implanted CNTs after 1 week and these granulomas 
developed to fibrous tissue formations after four weeks. These results suggest that the CNT 
manufacturing process and the concentration of CNTs within the body must both be carefully 
monitored in order to avoid cytotoxicity.  
2.4.2 Graphene 
Graphene is a carbon allotrope in the form of a sheet of sp2 carbon atoms arranged in a 
hexagonal arrangement that can be formed into other carbon nanostructures like CNTs, 
fullerenes and graphite, as demonstrated in Figure 2.7 [160]. Graphene possesses the highest 
ultimate tensile strength (UTS) (130 GPa) and Young’s modulus (E) (1 TPa) of any natural 
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substance, as well as a theoretical surface area of 2,630 m2 g-1, an electron mobility greater than 
10,000 cm2 v-1 s-1, resistance value of 6 kΩ, conductivity of 20 x 103 S cm-1, and a thermal 
conductivity value of ~4,000-5300 W mK-1 [160,176–182]. Pristine graphene was originally 
isolated by Geim and Novoselov in 2004 via mechanical exfoliation of graphite [178], but other 
methods have been developed such as growing graphene via chemical vapour deposition onto 
substrates and epitaxial growth [183], or the solvent exfoliation of graphite [184,185]. Pristine 
graphene was not used in this project and therefore these methods will not be discussed further. 
Graphene oxide (GO) is created by oxidising graphite and exfoliating the resultant 
graphitic oxide to create single layer GO (the structure of which is shown in Figure 2.9) [186–
188]. The degree of oxidation can change many aspects of the structure of GO [189], with an 
increase in oxidation often met with an increase in the ratio of sp3 to sp2 carbon domains and 
an increase in the quantity of hydroxyl, carboxyl, and epoxide groups present. The oxidation 
process gives GO ample functional groups that improve the bonding of GO to other molecules 
[190] and excellent dispersibility within many solvents [191], though the defects within the 
structure caused by the oxidation do reduce the mechanical properties; as the degree of 
oxidation varies, so too does the regularity of defects that interfere with and reduce the sp2 
domains [189]. The idealised sp2 carbon structure gives pristine graphene its strong E value, 
and as such, GO which has limited sp2 domains may not match the E of pristine graphene. The 
reported E of GO varies in the literature from 207 GPa [192] to 380-470 GPa for ordered and 
290-430 GPa for amorphous GO [193], but the values are always less than the value associated 
with pristine graphene. GO has an electrical conductivity value 6 orders of magnitude lower 
than pristine graphene, with conductivity values of 1-5 x 10-3 S cm-1 [194] and resistance values 
of ~1 x 1012 Ω [195] due to the defects in and the reduction of the size of the sp2 domains; the 
conductivity is so low that GO is often considered an electrical insulator [196,197]. 
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Figure 2.9: Illustration of the perceived chemical structure of GO [198,199]. Adapted from He 
et al. [198] with permission from Elsevier, copyright 1998. 
Typically, the method of producing GO is to oxidise graphite through the Hummers 
method [186] or a modification of that method [187,200]. A standard Hummers oxidation 
reaction would involve the addition of graphite to an agitated mixture of sulphuric acid H2SO4, 
sodium nitrate NaNO3, and potassium permanganate KMnO4 [186]. Some modifications to the 
Hummers method include the addition of phosphoric acid H3PO4  when adding the sulphuric 
acid [187], or a pre-oxidisation step where a 80 oC mixture of sulphuric acid, potassium 
persulfate K2S2O8, and phosphorus pentoxide P2O5 was used to oxidise the graphite before the 
main Hummers method [200]. Once a sufficient amount of time has passed (predetermined by 
the method used) the graphite oxide slurry is typically either diluted with water [186] or poured 
onto ice [187], before treatment with hydrogen peroxide H2O2.  
To partially restore the excellent properties of graphene to GO whilst maintaining the 
dispersibility of GO, the GO can be reduced to “reduced graphene oxide” (rGO) by removing 
the functional groups created during the oxidation of graphite [201–203]. Reduction can be 
achieved by a number of methods, such as using toxic chemicals such as ammonia, hydrazine 
and diazene [204–206], by using biomolecules, or by hydrothermal reduction. The 
biomolecules route uses biomolecules such as glucose that contains hydroxyl groups [207,208], 
green tea polyphenol that contains pyrogallol and catechol groups [209], gelatin that contains 
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amine groups [210], ascorbic acid that contains hydroxyl groups [211–213], chitosan that 
contains amine groups [214], and BSA that contains phenolic groups [215] to reduce the GO. 
The usage of biomolecules to reduce the GO to rGO is ideal for the biomedical industry as it 
will often coat the rGO with the biomolecule by chemical grafting, which will improve the 
biocompatibility of the rGO [216].  
The hydrothermal reduction route uses a supercritical solvent, for example water, to 
reduce the functional groups of GO [217]. At supercritical temperatures, water behaves like a 
strong electrolyte with a high diffusion coefficient and a high dielectric constant comparable 
to polar organic solvents [218]. The proposed method of hydrothermal reduction of GO is 
through heterolytic bond cleavage, where both of the electrons involved in the bond remain 
with the most electronegative of the oxidation-reduction pair [218]. The hydrothermal 
reduction route is advantageous in comparison to other methods such as hydrazine reduction 
as it is environmentally friendly with no toxic chemicals, is a ‘one pot’ procedure requiring just 
the addition of a suspension to an autoclave, and the end product can be fine-tuned easily by 
varying the reduction temperature and time. 
Graphene, GO and rGO have found use in biomedical applications such as drug 
delivery, imaging and thermal ablation of tumours [219,220]. A popular application for GO 
and rGO is therapeutic delivery, where it has been shown that using graphene based 
nanoparticles as the drug carrier can increase the efficiency of the drug that is delivered, relative 
to free/unbound drug [216,221,222]. GO bound with the anti-cancer drug ethyl-
hydroxycamptothecin (SN38) showed a 50% cell viability reduction at a drug concentration of 
6 nanomoles, which was comparable to the control of Irinotecan (CPT-11, the oral 
administration version of SN38) at a concentration of 10 µmoles [14]. Zhang et al. [223] found 
that the cytotoxicity for GO-doxorubicin or GO-campothecin was much higher than for either 
free standing drug on its own. Hypocrellin A and SN-38 were bonded together onto GO, and 
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this combined treatment showed a better cytotoxic effect to A549 cells than either drug bonded 
to GO on its own, showing the benefit of dual-therapeutic treatment [224]. The pH sensitive 
release of Ibuprofen or 5-fluorouracil in either the stomach or a tumour could be achieved from 
chitosan coated GO [216]. Similar pH sensitive release was noted for epirubicin bonded to 
hyaluronic acid-GO, with this pH sensitivity allowing for an increased release of the drug into 
the nucleus of the cells [225]. The pH of the solution is a critical factor on the successful loading 
onto and the release of doxorubicin from GO, with a neutral solution shown to be the best for 
loading and an acidic solution best for the release of doxorubicin [226]. Other therapeutics that 
were studied include resveratrol [227] and chlorin e6 [228], while there were further studies on 
doxorubicin with rGO-PEG-poly(ethylenimine) (PEI) [229], PEI-poly(sodium 4-
styrenesulfonate) coated GO [230], hyaluronic acid-rGO [231], and PEG alginate-GO [232].  
Once bonded to graphene, the drug will gradually diffuse from the graphene 
nanoparticle. The manner of the diffusion type, i.e. Fickian (molecular diffusion), non-
Fickian/anomalous, or case II relaxation controlled transport [233–235], can vary in the 
literature as the type of drug (and therefore the type of bonding to graphene) and the pH of the 
release medium may vary the release rate and release profile of the drug [234]. Changing the 
pH of the release medium changed the type of diffusion that occurred when rhodamine B was 
released from GO from case II (pH = 7.4 ) to anomalous diffusion (pH = 4.5 ) [234]. The 
authors believed that the pH sensitivity is due to the changes in the hydrogen bonding between 
the graphene and the rhodamine B due to the protonation of the COOH group. In the case of 
gentamicin and graphene, the pH (either pH = 3, 7.4 or 10) of the release medium did not 
change the diffusion type (Fickian) when analysed, suggesting that the bonds between that 
particular drug and graphene were not pH sensitive; similarly, the diffusion type of rhodamine 
B from carbon black or CNTs remained Fickian, regardless of the pH of the release media 
[236], due to the different type of bonding (π-π) used between those nanoparticles and 
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rhodamine B in comparison to the aforementioned study on GO and rhodamine B (hydrogen 
bonding) [234].  
 
Figure 2.10: (A) Free molecular beacons and (B) graphene - molecular beacons, showing the 
difference in transfection of the cells due to the presence of graphene. Images are fluorescent 
microscopy images overlayed onto bright field optical microscopy images. Adapted from Lu 
et al. [237] with permission from The Royal Society of Chemistry, copyright 2010. 
Gene therapies can also be delivered in conjunction with GO, with the loading of DNA 
onto GO found to be dependent on certain factors, with higher loadings achieved when the 
DNA helix was short, the solvent had a low pH and a high ionic strength [238]. Plasmid DNA 
and siRNA were transferred via PEG-PEI coated GO [239,240], with both papers noting that 
the transfection of the cells with the gene therapies could be improved by using NIR laser 
irradiation. Similar transfection rate increases into HeLa cells were noted for DNA and RNA 
gene therapies that were bonded to graphene than for the free therapeutic [221]. Zhang et al. 
[222] used GO functionalised with PEI to transfer short interfering RNA therapeutics into BcL-
2 cancer cells during an in vitro experiment. GO bonded to trimethyl-chitosan was conjugated 
to folic acid, which acted as a targeting mechanism against cancer cell lines with folate 
receptors, and the GO could then be used to deliver doxorubicin or plasmid DNA into HeLa 
cells [241]. The imaging of cells could be achieved by using molecular beacons bonded to 
graphene; the successful transfection of the cells with the gene therapy could be determined 
through fluorescence imaging as shown in Figure 2.10 [237]. Graphene increased the transfer 
of the therapeutic to the cells, as shown by the stronger fluorescence for cells treated with the 
35 
 
graphene bound therapeutic than for the free molecular beacon solution. The delivery of 
molecular beacons by GO was similarly noted by Lu et al. [237], who also showed that the GO 
could prevent the enzymatic cleavage of the molecular beacon by preventing the cleaving 
enzyme from binding to the molecular beacon. Cells could also be probed by a molecular probe 
consisting of aptamer-carboxyfluorescein coated GO [242]. 
 
Figure 2.11: (A) GO and (B) CNTs under NIR laser stimulation, showing a reduction in the 
cell viability of cancer cells. The time required to achieve ~80% photothermal ablation of the 
cells was less for GO than for CNTs, showing GO to be a better photothermal ablation agent. 
Adapted from Markovic et al. [243] with permission from Elsevier Limited, copyright 2011. 
Markovic et al. [243] tested GO as a thermal ablation agent for the treatment of cancer 
cells. Within 3 minutes of NIR stimulation, at least 75% of the cells had been killed for each 
concentration of graphene. After 5 minutes, all concentrations of graphene (2.5 µg ml-1, 5 µg 
ml-1, and 10 µg ml-1) had killed between 80-100% of the cells present (Figure 2.11). Yang et 
al. [244] used PEG coated GO and a NIR laser to thermally ablate tumours in mice, similar to 
Robinson et al. [245] who used GO coated with PEG and the targeting ligand RGD to target 
U87MG cancer cells for thermal ablation. Robinson achieved an 80-90% reduction in cancer 
cell viability. 
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Figure 2.12: Light micrograph after 40 days showing no damage to the kidney, liver, spleen, 
heart, intestine, or the lung after treatment with 20 mg kg-1 of PEG coated GO. Adapted from 
Yang et al. [244] with permission from American Chemical Society, copyright 2010. 
Wang et al. [246] analysed the effects of GO on human fibroblast cells and mice. Doses 
of 20 µg ml-1 or lower did not induce toxicity in the human fibroblast cells, but doses of 50 µg 
ml-1 or higher induced severe toxicity through a decrease in cell adhesion and an increase in 
cell apoptosis. Below the concentration of 0.4 mg per mouse, there was no notable toxicity 
within the mice, but at 0.4 mg per mouse there were signs of severe chronic toxicity, including 
granuloma formations within the lung, liver, spleen and kidney of the mice. Similarly, Zhang 
et al. [247] noted no toxicity in the liver, spleen or the kidney in mice treated with 1 mg kg-1 or 
10 mg kg-1 of GO over a 2 week time span. It was noted, however, that there was granuloma 
formation and inflammation within the lungs for the higher dosage of GO. A haemolysis assay 
showed that there was no ill effect at doses of 10 and 80 µg ml-1 on haemoglobin and that GO 
did not harm red blood cells [247]. The aspiration of 50 µg per mouse of graphene nanoplatelets 
formed granulomas in the bronchiolar lumen and inflammation in the chest wall, and ultimately 
resulted in cell apoptosis through ROS [248].  
Coating GO or rGO with biomolecules can improve the biocompatibility of the 
nanoparticles [222,249–252]. After a treatment of 20 mg kg-1 of PEG coated GO, there was no 
obvious signs of chronic toxicity after 40 days within mice (Figure 2.12) [244]. Human 
mesenchymal stem cells [253] and osteoblasts [254] were shown to proliferate when in the 
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presence of chitosan coated graphene. Mice treated with 20 mg kg-1 of PEG coated GO did not 
suffer hepatic nanotoxicology after 3 months, with white blood cell, red blood cell, platelet, 
and haemoglobin counts similar to control samples of untreated mice [249]. Yang et al. [249] 
analysed the whole body biodistribution of PEG-GO and its concentration in the liver, spleen, 
urine and faeces, showing that the majority of the GO was excreted though urine within 2 days 
and that the main congregation point within the body was the spleen. 
2.4.3 Iron oxide 
IO nanoparticles, such as magnetite Fe3O4 and maghemite γ-Fe2O3, have use within 
biomedicine as imaging contrast agents, drug delivery systems, thermal ablation agents and 
filtering agents for biological assays [255–257]. Their small size allows them to migrate 
through blood vessels and into tumours. Typically, IO nanoparticles such as magnetite and 
maghemite are superparamagnetic, a phenomenon where they hold no residual magnetic force 
(they will not aggregate together through their own magnetic force), but can be manipulated 
by external forces. 
IO nanoparticles have been used before as targeted drug delivery carriers as IO can be 
manipulated by external magnetic fields to collect in specific sites [19,258]. Alexiou et al. [19] 
attached the anti-cancer drug mitoxantrone to IO and used an external magnetic field to attract 
the IO to tumours within rabbits. Within the tumour, 4.71 µg ml-1 of mitoxantrone was 
measured when a treatment of 5 mg m-2 IO-mitoxantrone was administered to the rabbit, 
compared to 0.58 µg ml-1 of mitoxantrone when 10 g m-2 of free mitoxantrone was 
administered. This showed that a substantial increase could be achieved in the amount of drug 
delivered to a tumour when the drug is targeted to a specific site. IO loaded with doxorubicin 
could be manipulated by an external magnet to aggregate close to the magnet [259]; cell 
viability analysis confirmed that the cell viability was lower closer to the magnet site than it 
was far from the magnet, which was attributed to the presence of IO-doxorubicin. Hu et al. 
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[258] researched polyallylamine nanocapsules encapsulating IO and doxorubicin 
hydrochloride. Purushotham et al. [260] used poly-n-(isopropyl acrylamide) (PNIPAM) to 
form a polymer layer around magnetic IO and doxorubicin. Other drugs that have been bonded 
to IO for drug diffusion and drug release tests include vitamin B2 [261], vitamin B12 [262], 
fluorescein sodium [263], and theophyllinec [118]. Gene therapies have been investigated for 
use with IO; the Sendai virus, a RNA virus that can be used as a gene therapy vector, was 
bound to maghemite nanoparticles and was shown to effectively transfer luciferase plasmid 
into BHK-21 cells without an increase in cell cytotoxicity (when compared to unbound gene 
therapy vector) [264].   
  
Figure 2.13: (Left) A transmitted light microscopy image and (right) fluorescent light 
microscopy image of IO NPs within phagocytic cells. Adapted from Corr et al. [265] with 
permission from The Royal Society of Chemistry, copyright 2006. 
IO can be used for M.R.I. of tumours and the circulatory system [266,267]. Cheong et 
al. [16] showed that IO could successfully image the liver, the spleen and the inguinal region 
of mice, while Lim et al. [268] imaged metastatic breast cancer cells within mice. Park et al. 
[269] imaged tumours and vital organs in mice, and determined that smaller IO nanoparticles 
are removed from the body quicker than larger nanoparticles, a finding that could be beneficial 
in optimising the ability of IO as a contrast agent. These results show that IO is an effective 
contrast agent for body organs for imaging purposes. Corr et al. [265] investigated whether IO, 
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bonded to fluorescent markers, could be consumed by osteoblast cells and phagocytic cells, 
and the cells can be seen very clearly in Figure 2.13. 
The use of IO in thermal ablation is owed to the superparamagnetic behaviour; if 
manipulated by an AC magnetic field, the IO will revolve on their primary axis and generate 
heat [270], with chitosan coated IO nanospheres used in cancer ablation therapy [20,271]. 
Babincov et al. [272] tested IO coated with cisplatin to reduce the cell viability of sarcoma cells 
(Figure 2.14). Thermal ablation reduced the cell viability by ~20%, while free cisplatin would 
reduce cell viability by 20-25%. When the effects of the thermal ablation and bound drug were 
combined into one nanohybrid, the cell viability was reduced by 75-80% 
 
Figure 2.14: Reduction in cell numbers of control, hyperthermia on its own, cisplatin on its 
own, and a combination of cisplatin and hyperthermia. Adapted from Babincov et al. [272] 
with permission from IEEE, copyright 2008.  
Brunner et al. [273] found that pristine IO had a high level of cytotoxicity to human 
mesothelioma cells when exposed to a concentration of 10 µg ml-1 or higher, which they 
suggested was due to ROS toxicity of pristine IO. This ROS toxicity did not affect all cell 
types, as mice fibroblast cells had a 75% cell viability up to the dose of 30 µg ml-1. Zhang et 
al. [274] showed that IO nanoparticles with and without a surface coating of PEG can enter 
both mouse macrophage and human breast cancer cells. Uptake by macrophage cells was lower 
for the PEG coated IO than for the uncoated IO, but this trend was reversed for human breast 
cancer cells. Similar results for the increase in cell viability by the passivation of IO by 
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biomolecules coating were noted for pullulan coated IO [275], dimercaptosuccinic acid coated 
IO NPs [276], and for silica coated cobalt ferrite nanoparticles [277]. Park et al. [269] analysed 
the biodistribution of IO nanoparticles within the body of mice. The highest concentrations of 
the IO were found in the lymph nodes and in the spleen, suggesting that the body was removing 
the IO from the blood through the reticuloendothelial system (RES) and the macrophages 
within it. A high concentration, around 13%, was still in the blood. Low uptake in the brain 
and the lungs shows that, in this case, the nanoparticles did not accumulate to dangerous levels 
in two very sensitive areas of the body. Weissleder et al. [266] recorded similar biodistribution 
patterns after 24 h for IO in mice, showing high uptake in the lymph nodes and the spleen, 
similar to the findings of Park et al. [269]. Weissleder et al. [278] noted no body weight loss, 
no reduction in food consumption, no increase in mortality or morbidity when rats were 
injected with a maximum of 160 µg kg-1 of IO. No tissue damage was noted in the liver, spleen 
or the lymph nodes, though the level of haemoglobin in the blood slightly increased as both the 
dose and the time of the test increased.  
2.4.4 Graphene-iron oxide nanoparticles 
IO can be chemically deposited onto GO to form a nanohybrid GO-IO [279–281]. If the GO 
has been reduced to rGO during the deposition process, it may become rGO-IO [282]. These 
nanohybrids combine the interesting functions of IO and GO/rGO; namely the 
superparamagnetic properties of IO and the abundant functional groups/high surface area of 
GO. GO-IO have found use in biomedicine as targeted drug carriers, imaging agents, and 
photothermal agents [279–282]. 
GO-IO was bonded with PEG and doxorubicin to create a targeted drug delivery carrier 
[280]; the GO-IO-PEG-doxorubicin could be manipulated and aggregated by the presence of a 
magnet, and subsequent fluorescent imaging of the bound doxorubicin showed a higher 
quantity of doxorubicin within cells close to the magnet than there was farther away. This 
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reduced the cell viability of the cancer cells close to the magnet, in comparison to cells farther 
away, showing the possibility to target a drug to a specific site. GO-IO loaded with doxorubicin 
could be manipulated to aggregate at a specific spot by a magnet [279]. The anti-cancer drug 
5-fluorouracil was bonded to rGO-IO and the nanohybrid was shown to be capable of entering 
HepG2 cells, into which it would use pH sensitive drug release to release the drug [283]. The 
degree of pH sensitivity was such that in a pH = 4 environment, there was a ~55% release of 
the drug after 8 h, but in a neutral environment the release was only ~15%. The nanohybrid 
was also shown to be biocompatible, with a ~100% cell viability achieved with rGO-IO 
concentrations up to 80 µg ml-1. GO-IO was also bound to 5-fluorouracil, with similar results 
[284]. Insulin was bonded to GO-IO and was shown to have a pH sensitive release, high 
biocompatibility, and similar enzymatic properties to free insulin [285]. The delivery of 
doxorubicin using GO-IO has been studied before [286–288], with additional targeting 
mechanisms such as folic acid [286,289] reported as well as chitosan functionalisation to 
improve biocompatibility [287]. 
Tri-modal imaging was achieved with rGO-IO [282], with photo-acoustic and M.R.I. 
imaging from the rGO-IO and fluorescent imaging achieved through bonding the rGO-IO with 
a cyanine dye. The rGO-IO achieved within 1 day the full ablation of 4T1 tumours in mice 
using the strong NIR absorbance of the rGO-IO and a NIR laser (5 min exposure at 0.5 W cm-
2 power) [282]. GO-IO-PEG was used as a photothermal ablation agent [280]. Once imaged 
using M.R.I., the nanohybrid could be targeted to a site in the body for thermal ablation using 
NIR irradiation [280]. The nanohybrid achieved a ~90% cell viability reduction using 5 min of 
2 W cm-2 irradiation. Campothecin and methotrexate were both bound to GO-IO as an anti-
cancer nanohybrid, which achieved a high cell reduction for HepG2 and L02 cell lines and a 
tumour volume reduction of ~40% without NIR irradiation  and ~74% with NIR irradiation 
[290].  
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2.4.5 Other nanoparticles 
As well as the carbon and iron oxide based nanoparticles, other nanoparticles such as gold and 
quantum dots (QDs) have been used for drug delivery, bio-imaging and thermal ablation 
applications. 
Gold 
Nanoparticles of gold can be used as both drug delivery carriers, imaging agents and as 
photothermal ablation agents in the bioengineering sector [291–294]. Rhodamine B was 
bonded to and subsequently released from gold nanoparticles under NIR laser irradiation [295]. 
The co-application of gold nanoparticles with rhodamine B aided the permeation of the drug 
through the SC [296]. The liver specific release of amino-coumarin was achieved with gold 
nanoparticles that had both lactose and the drug bonded to the surface [291]; the lactose was 
used to target the nanoparticles at hepatic stellate cells in the liver. PEG functionalised gold 
nanoparticles had an improved ability to enter into and deliver oxaliplatin to the nucleus cells 
than either the free drug or non-functionalised, pristine gold delivering the drug [297]. 
Similarly, glutathione functionalised gold achieved the cellular uptake and release of a 
fluorescent dye; this was not achievable for the free dye [298]. PEG functionalised gold could 
deliver the drug silicon phthalocyanine 4 into tumours at a higher quantity than the free drug 
achieved by itself [299]; the PEG-gold also increased the water solubility of the hydrophobic 
drug. Gold nanoparticle drug delivery was also studied with paclitaxel [300], nitric oxide [301], 
and with phthalocyanine [302]. 
Gold nanoparticles have been investigated as a gene transfer agent [292,303,304]. 
Takahashi et al. [292] showed that plasmid DNA can be absorbed onto the surface of gold 
nanorods and subsequently released from the gold nanorods by near-infrared (NIR) laser 
irradiation, allowing for the possibility of targeted release of therapeutics at specific sites, 
similar to other studies on NIR laser irradiation stimulated release of DNA attached to gold 
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nanoparticles [303,304]. The intracellular release of RNA from gold nanoparticles could be 
achieved in the presence of glutathione [305]; there was minimal release of the RNA when the 
gold nanoparticles were in a solution with glutathione concentration at that of the extracellular 
matrix, but the RNA was released at therapeutic levels when the glutathione was at a 
intracellular concentrations.  
 
Figure 2.15: Confocal image of (A) HeLa and (B) A549 lung cancer cells showing specificity 
in nanoparticle targeting. Adapted from Zhang et al. [293] with permission from Elsevier 
Limited, copyright 2010. 
Zhang et al. [293] bonded folic acid targeting ligands to gold nanoparticles to provide 
a means to image specific cancer cell lines, such as targeting HeLA cells but not A549 lung 
cancer cells. Figure 2.15 shows a confocal microscopy image of (At) HeLa cells and (B) A549 
lung cancer cells. There is a clear difference in the concentration of gold nanoparticles 
surrounding the HeLa cells and the A549 cells, which shows that this cell specific targeting 
does work. Huang et al. [294] used a targeting ligand to target malignant cells with gold 
nanoparticles, successfully imaging malignant oral epithelial HOC 313 and HSC cell lines and 
then thermally ablating the cells with a NIR laser. 
Gold nanoparticles (4 nM concentration) could achieve the photothermal ablation of 
cancer cells when irradiated with a 800 nm laser for 2 min at a relatively low power level of 
1.1 mW, compared to 22.2 mW to photothermally ablate cells without a gold nanoparticle 
treatment [306]. Gold nanoparticles bonded to doxorubicin were used to kill breast cancer cells 
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under NIR laser irradiation [307]. The gold nanoparticles alone under NIR laser irradiation 
achieved a ~10% reduction in cell viability, but with doxorubicin this dropped to ~55%. 
Peptides were used to selectively target gold nanoparticles, with bonded doxorubicin, against 
specific cell types [308], with a focus on targeting HeLa and A549 cells more efficiently.  
Quantum dots 
 
Figure 2.16: Main image: Fluorescent (A, C, E) and optical (B, D, F) microscopy images of 
GQDs (diamter of 5-10 nm) within cells under 405 nm light. Inset: (1) GQD suspension in 
water and (2) GQD suspension under 405 nm light. Adapted from Zhang et al. [309] with 
permission from The Royal Society of Chemistry, copyright 2012. 
QDs are semiconductor nanocrystals that emit a dimension-dependent luminescence due to 
quantum confinement effects, and semiconductor QDs would typically be <10 nm in radius 
[310–313]. These semiconductor QDs, without a polymer or biomolecule passivation coating, 
are of little use for biomedical applications as QDs like cadmium selenide (CdSe), cadmium 
sulphide (CdS) or cadmium telluride (CdTe) are cytotoxic during in vitro cell tests due to the 
photolysis release of cadmium ions whilst also being shown to uncoil DNA helical strands 
[314–317]. Alternatives to CdSe or CdTe are QDs made from silver-selenide (700-820 nm 
emission) or silver-sulphur (1060 nm emission) or sulphur-zinc sulphide (1155 nm emission) 
[318–320], indium-arsenic with zinc-selenide or CdSe (all 700-900 nm emission) [321–323], 
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or (indium-phosphorous)-(zinc-sulphide) (emission 620 nm) [324,325]. These alternatives are 
not as common as the CdSe or CdTe QDs though, and since CdSe or CdTe are cytotoxic an in 
depth discussion of these types of QDs are not included in this work; CdSe or CdTe will only 
be discussed briefly in terms of magnetic QDs (MQDs), where CdSe and CdTe are very 
important.  
MQDs can be synthesised by either doping conventional QDs (for example CdSe, 
indium phosphorous or CdTe) with metal elements (for example with manganese [326], 
chromium [327], cobalt [328], nickel [329], or gadolinium [330]) or by encasing conventional 
QDs with magnetite [331] or maghemite [332] in silica spheres. These MQDs possess the 
photoluminescent (PL) properties of conventional QDs and the magnetic properties of the 
doping agent or the encapsulated IO, but they contain the cytotoxic compounds CdSe or CdTe 
and therefore cannot be called biocompatible without a passivation coating. An example of 
passivation would be the amino-PEG and carboxyl-PEG used on Ni doped CdTeSe-CdS that 
greatly improved the biocompatibility of the QDs, allowing for the MQDs to be used for cell 
sorting and imaging [329]. MQDs were shown to be suitable for M.R.I. imaging, with studies 
on Mn doped CdSe-ZnS [333]  and Gd doped CdSe [330] showing that they were a suitable 
M.R.I. contrast agent as well as possessing PL properties (emission ~570-580 nm). MQDs were 
investigated as drug delivery carriers, with MQDs consisting of magnetite and CdSe-ZnS in a 
silica sphere bonded to ibuprofen, with the drug released fully over 80 h [334]. 
A second type of QDs are those derived from carbon, such as carbohydrates [15], 
nanodiamonds [335], and graphene [217,336–338]. Graphene QDs (GQDs) can be created by 
ultrasonication [336], chemical reduction [337], photo-reduction [338], and hydrothermal 
cutting [217]. These carbon QDs emit the same level of luminescence as the cadmium QDs, 
but do not carry the same cytotoxic risk and therefore can potentially be used by the biomedical 
industry. 
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The main use for QDs in the biomedical industry is for in vivo imaging. It has been 
shown that GQDs could enter cells but did not enter the nucleus of stem cells during in vitro 
tests; they maintained a high (80%) viability for neurosphere and pancreas progenitor cells up 
to 100 µg ml-1 after 72 h, and could image neurospheres (Figure 2.16 A-B), pancreas progenitor 
cells (Figure 2.16 C-D), and cardiac progenitor cells (Figure 2.16 E-F) successfully under 405 
nm wavelength irradiation [309]. In vitro imaging of HeLa cells have been reported from 
carbohydrate derived carbon dots [15], as well as in vitro imaging of N1H-3T3 cells using 
nanodiamond derived carbon dots, in which the author noted that they entered cells and stayed 
in the cytoplasm [335]. GQDs were also shown to enter the cell membrane and cytoplasm of 
A549 cells during in vitro imaging [338]. Carboxylated GQDs caused no acute toxicity to rats 
after 22 days post injection at a concentration of 10 mg kg-1 and were shown to image in vitro 
KB cancer cell lines and in vivo KB tumours in mice, which  allowed for the imaging of the 
tumour as well as the liver, kidney, spleen, heart and lung [339]. The carboxylated GQDs 
maintained a high (80%) cell viability of various cell lines up to a concentration of 500 µg ml-
1 and noticed no acute toxicity within rats when haemoglobin, white blood cells, and platelet 
levels as well as urea levels were analysed after 22 days post injection with 10 mg kg-1 of GQDs 
[339]. Carbon QDs can be excreted rapidly from the body after being administered through 
intravenous, intramuscular or subcutaneous injections [340].  
Further protection for cells against the effects of QDs can be acquired from passivation; 
the cell viability of nanoparticles can be improved upon by coating with a biocompatible 
organic compound. Polydopamine coated GQDs were shown to be distributed into the main 
organs (liver, lung, heart, spleen and the kidney) after 4 h and to circulate longer in the system 
than uncoated GQDs allowing for longer in vivo imaging [341]. Amine functionalised GQDs 
[337] significantly improved the cell viability of GQDs. Passivation of conventional QDs has 
reduced their cytotoxicity, with CdSe QDs being treated with lactose [342] and with PEG [343–
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346] to lower cytotoxicity. Lactose coated CdSeS-ZnS QDs showed no noticeable cytotoxic 
effect after 24 h when HeLa cells were treated with 0.5 mg ml-1 [342].  
2.5 Polymer nanocomposites 
2.5.1 Introduction to polymer nanocomposites 
A good definition of a composite is given by Hull et al. [347] in their book, which states that a 
composite consists of at least two (i.e. the matrix and the filler) physically distinct and 
mechanically separable materials which, when combined together by dispersing the filler in the 
matrix, gives the composite material optimised properties that are superior to or distinctive 
from the properties of either of the individual constituents. An example of a property that might 
be improved is the mechanical properties of a polymer by using strong and stiff carbon fibre to 
reinforce the polymer [348].  
A “nanocomposite” is a composite where the filler component is a nanoparticle, such 
as GO [190], montmorillonite clay [349], CNTs [350], or IO [351]. These nanocomposites have 
found use as structural materials, in biomedical applications such as drug delivery and 
scaffolds, and as conductive materials for energy storage or electromagnetic interference 
shielding [352–358]. Nanoparticles can make highly effective fillers for polymer composites 
for a number of reasons: as they are exfoliated, nanometre size nanoparticles, they possess a 
much larger specific surface area than the micro-scale fillers [359–361], allowing for a much 
larger interfacial zone than what can be achieved with a micro-scale filler, therefore 
maximising the interactions between the filler and the matrix as well as the load transfer 
between the matrix and the filler. Nanoparticles can have their functional groups tailored to 
specific polymers, in order to increase the bond strength between the polymer and the 
nanoparticle [362]. 
Improvements in mechanical properties can be achieved with a lower weight percentage 
(wt.%) of nanofiller than with micro-scale filler, making the resultant nanocomposite lighter 
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than a conventional composite [360,361]. The addition of a small amount of nanoparticles may 
also improve the thermal and electrical conductivity and/or the barrier properties of the polymer 
matrix [363–365]. 
2.5.2 Processing of polymer nanocomposites 
There are three main ways to prepare nanocomposites; solvent processing, melt processing, 
and in-situ polymerisation. Solvent processing of nanocomposites involves the stirring and 
dispersion of nanoparticles into a solvent, mixing this solvent-nanoparticle suspension under 
high shear stresses into a low-viscosity polymer-solvent solution, casting the suspension into a 
mould of the required shape, and the subsequent drying of the suspension and hot pressing 
where necessary to form the desired form (i.e. a film, test specimens, etc.) [366]. Polymers that 
have been used to create nanocomposites through this method include PVA [367,368], gelatin 
[369–371], thermoplastic polyurethane [372,373], polystyrene (PS) [374], and poly(methyl 
methacrylate) (PMMA) [375]. 
Melt processing involves the dispersion by shear mixing of nanoparticles in powder 
form into a molten polymer within a heated extruder [366]. The resultant nanocomposite can 
then be processed using other means, like injection moulding. Due to the higher viscosity of 
the molten polymer, the dispersion of the nanoparticle within the matrix may be poorer than 
what was achieved with solvent processing, but melt processing is quicker, easier to scale up 
to industrial levels of production and does not involve the use of solvents [366]. Examples of 
nanocomposites formed by melt processing are poly(ethylene terephthalate)-clay (PET) [376], 
polyamide-clay [377], polyester-GO [378], polycarbonate-GO [379], and thermoplastic 
polyurethane-clay [380]. Nanoparticles such as GO may, however, be unintentionally reduced 
to rGO by the high temperatures used within melt processing, limiting the functional groups of 
the GO/rGO available for bonding between the polymer and the graphene in some cases [381]. 
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In-situ polymerisation can be used to prepare nanocomposites, where the nanoparticles 
are dispersed within the monomers or precursor polymer and an initiator/curing agent is added 
[366]. Typically, energy in the form of heat (or light for photo polymerisation) is a requirement 
for the polymerisation to occur. Examples of in-situ polymerisation nanocomposites are 
PMMA-GO [382], PS-GO [383], PS-clay [384], or PVA-clay [385] nanocomposites. 
Thermosetting polymer-graphene nanocomposites can also be produced using this method. For 
example, epoxy-graphene nanocomposites were prepared by adding curing agents to a 
suspension of epoxy resin and GO [386].  
Depending on the application of the nanocomposite, some of these production methods 
may not be suitable. For example, if the nanocomposite is to be used for drug delivery purposes 
such as in this thesis, then the use of high temperatures may damage the drug that was present. 
In this instance, the best production method might be to use a thermoplastic polymer that is 
soluble in water or another suitable non-toxic solvent, preferably at a low temperature. 
2.5.3 Polymer-graphene nanocomposites 
The benefits of using nanoparticles as the nanofiller for a nanocomposite were discussed in 
Section 2.5.1. Polymer-graphene nanocomposites can have improved mechanical properties 
(such as improved Young’s modulus (E), ultimate tensile strength (UTS), elongation to break 
(εb), and energy to break), electrical conductivity (Celec), thermal conductivity, and permeability 
properties than their pristine polymer counterparts [352,366]; this is because graphene and its 
derivatives make promising nanofillers as they have high aspect ratios, high surface area and a 
high E, high electrical conductivity, and high thermal conductivity [160,176–179].  
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Table 2.2: Percentage improvements in mechanical properties of polymer-graphene 
nanocomposites relative to the pristine polymer 
Polymer Graphene (wt.%) E / % UTS / % εb / % Ref. 
PVA rGO (0.7 wt.%) 48.4 46.7 -39.3 [387] 
PVA GO (3.5 wt.%) 44.7 324 -78.8 [388] 
PVA GO (5 wt.%) 46.1 290 -33.1 [367] 
Cellulose GO (0.2 wt.%) 7.2 50.0 - [389] 
Polycarbonate rGO (0.25 wt.%) 11.1 3.8 - [390] 
Polyimide (PI) GO (5 wt.%) 1761 1211 -76.3 [363] 
PI rGO (5 wt.%) 1265 985 -73.5 [363] 
PI rGO (5 wt.%) 803 699 -71.3 [363] 
PI rGO (5 wt.%) 635 450 -78.2 [363] 
Bisphenol-A epoxy Graphene (0.1 wt.%) 33.9 45.5 - [386] 
E44 epoxy GO (2 wt.%) 116 - - [391] 
Epon 828 epoxy GO (0.4 wt.%) 59.9 54.1 - [392] 
Polyethylene (PE) GO (0.5 wt.%) - 0.5 1.8 [393] 
PET Graphene (0.08 wt.%) 22.9 42.3 19.0 [394] 
PCL rGO (5 wt.%) 109 30.1 -74.4 [395] 
Chitosan GO (1 wt.%) 18.3 36.0 110 [396] 
Chitosan GO (2.5 wt.%) 33.0 36.1 51.2 [396] 
Chitosan GO (1 wt.%) 51.3 92.7 40.4 [397] 
Chitosan GO (1 wt.%) 64.3 122 57.0 [398] 
Chitosan rGO (1 wt.%) 61.5 20.6 -55.3 [209] 
Chitosan rGO (1 wt.%) 17.2 3.3 -10.5 [399] 
Gelatin GO (1 wt.%) 64.9 83.9 47.2 [369] 
Gelatin GO (2 wt.%) 100 86.7 43.2 [369] 
PLA GO (1 wt.%) 20.5 51.9 18.7 [400] 
PLA GO (2 wt.%) 59.6 27.5 -21.8 [400] 
 
Table 2.2 shows some examples of changes in E, UTS, and εb for polymer-graphene 
nanocomposites at their optimum wt.% of graphene, relative to their pristine polymer. In 
general, the highest E and UTS occur for a nanocomposite when there is a good dispersion of 
graphene within the polymer, a strong interface between the graphene and the polymer, and the 
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optimum wt.% of graphene has been achieved, as discussed in Section 2.5.1. An example of 
where the importance of dispersion and a strong interface to mechanical properties is the study 
on PI-GO and PI-rGO nanocomposites [363]; Ha et al. [363] state that the better mechanical 
properties of the PI-GO in comparison to PI-rGO are due to the higher concentration of 
functional groups on GO that creates a strong interface between the two constituents and can 
also improve the dispersion of the nanoparticles within PI by restricting phase separation of the 
two constituents. As the reduction degree increases for the different types of rGO used in that 
study, the percentage improvement relative to pristine for the mechanical properties decreases 
[363].  
Also of importance to the mechanical properties of a nanocomposite is the E of 
graphene, with the different graphene derivatives having different mechanical properties, as 
discussed in Section 2.4.2. Istrate et al. [394] report that a very low concentration (0.08 wt.%) 
of pristine graphene can improve the mechanical properties of PET, with a 22.9% increase in 
E, 42.3% increase in UTS, and a 19.0% increase in εb relative to pristine PET. A similar 
increase in E and UTS for GO/rGO nanocomposites typically required a higher wt.%, such as 
1 wt.% GO [396,400] or 0.7 wt.% rGO [387].   
Within a nanocomposite, stresses applied to the polymer matrix can be transferred to 
the graphene when there is a strong interfacial bond between the polymer matrix and the 
graphene [401], utilising the superior mechanical properties of the graphene. For polymer-
graphene nanocomposites, the εb may change relative to the pristine polymer. An increase of 
the εb may be explained by the ability of the graphene to realign and translate with the polymer 
chains when the nanocomposite is under stress [369,400]; the graphene within the 
nanocomposite has retained its mobility within the matrix. A decrease in the εb may be 
explained by the inability of the graphene to translate and realign with the chains [369,400], a 
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poor bonding interface between the graphene and the polymer [363,402], or by possible 
aggregation of the graphene in the polymer matrix.  
Table 2.3: The electrical properties of polymer-graphene nanocomposites.  
Polymer Graphene  0 wt.% 
Celec / S m-1 
Max. obtained  
Celec / S m-1 
Percolation 
threshold / wt.% 
Ref. 
PMMA rGO - 0.1 at 1 wt.% 0.2 [382] 
Polypropylene 
(PP) 
rGO - 0.3 at 4.9 wt.% 4.9 [403] 
PP rGO 1 x 10-9 0.08 at 0.2 vol.%  0.033 (vol.%) [404] 
PS rGO 6.7 x 10-14 3.49 at 1.1 vol.% 0.0075 (vol.%) [405] 
PS rGO 1 x 10-10 0.029 at 2 wt.%  2.0 [383] 
PE rGO 2 x 10-13 2.11 at 3 vol.%  0.47 (vol.%) [406] 
PCL rGO 1 x 10-11 1 x 10-4 at 8 wt.%  0.5 [407] 
PI rGO 1 x 10-13 1.4 x 10-4 at 5 wt.% - [363] 
PI rGO 1 x 10-13 3.3 x 10-2 at 5 wt.% - [363] 
PI rGO 1 x 10-13 3.3 x 10-1 at 5 wt.% 0.45 (vol.%) [363] 
PI GO 1 x 10-13 6.2 x 10-5 at 5 wt.% 0.45 (vol.%) [363] 
  
Graphene can improve the electrical conductivity of a nanocomposite, in comparison 
to the pristine polymer. Pristine graphene has excellent electrical properties, as discussed 
previously in Section 2.4.2, and a relatively small wt.% of graphene is capable of forming a 
conductive network through the polymer matrix to turn an insulating, pristine polymer into a 
conductive nanocomposite; this wt.% is termed the percolation threshold, pc [366,408]. Potts 
et al. [366] state that the percolation threshold for a nanocomposite is dependent on the 
nanoparticle shape and size, the quality of its dispersion/distribution within the polymer, and 
the volume fraction of the nanoparticle. A review of electrical conductivity increases is shown 
in Table 2.3 that shows considerable increases in conductivity for nanocomposites containing 
graphene derivatives, when compared to the pristine polymer. The highest increases in 
conductivity were achieved by using conductive rGO that were well dispersed within the 
polymer at a high enough concentration to establish a percolation network. For example, 0.2 
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vol.% of rGO increased the conductivity of polypropylene by about seven orders of magnitude, 
with a percolation threshold at 0.033 vol.% [404]. Similarly, 5 wt.% of ascorbic acid reduced 
rGO increased the conductivity of PI by about twelve orders of magnitude [363]. In the same 
work, the less-conductive GO also increased the conductivity of PI at a 5 wt.% loading of GO 
by about eight orders of magnitude over pristine PI, showing that the electrically conductive 
rGO nanoparticle increased the conductivity of the polymer by more than GO. As discussed 
previously in Section 2.4.2, GO has a significantly lower conductivity value than pristine 
graphene or rGO, being effectively an electrical insulator.  
A dispersion of large-aspect ratio nanoparticles within a nanocomposite may decrease 
the permeability of the nanocomposite to gases and liquids, in comparison to pristine polymers 
[409–412]. This dispersion of nanoparticles may reduce the permeation through polymers 
courtesy of the “tortuous path” model [413]; the nanoparticles impede the permeation of 
molecules directly through the polymer matrix and the molecules must go around the 
nanoparticles in order to permeate fully through the nanocomposite. To improve the barrier 
properties of a nanocomposite, nanoparticles should possess a high aspect ratio and should be 
well exfoliated and dispersed throughout the polymer matrix [364,413]. The permeability of 
nitrogen through polyurethane decreased by 90% with the addition of 3 wt.% rGO [372], the 
permeability of hydrogen through PEI with the addition of rGO [414], and the permeability of 
moisture  through PI from 181 g mm-2 day-1 to 31 g mm-2 day-1 with the addition of 0.001 wt.% 
GO [415]. The permeation of oxygen and water vapour reduced by 98% and 68%, respectively, 
for PVA-GO at 0.72 vol.% GO loading in comparison to pristine PVA [364]. A PS-GO 
nanocomposite of 0.02 vol.% GO could reduce the permeability of oxygen by ~35% in 
comparison to pristine PS [416]. A loading of 2.27 vol.% reduced oxygen permeability from 
~1000 cm3 m-2 day-1 to 380 cm3 m-2 day-1. 
54 
 
2.5.4 Polymer-iron oxide nanocomposites 
IO is not a common nanoparticle for use within a nanocomposite, but the previous work 
suggests that polymer-IO nanocomposites retain the superparamagnetic properties of the IO 
nanoparticles, as noted with PMMA-polypyrrole-IO [417], ‘Nafion 117’-IO [418], PMMA-IO 
[351], and PVA-IO [419] nanocomposites. The encapsulation of IO can increase the electrical 
conductivity of the nanocomposites such as poly(3,4-ethylenedioxythiophene)/poly(styrene 
sulfonate)-IO [420,421] and PMMA-polypyrrole-IO [417].  
Limited studies of polymer-IO nanocomposites for structural applications exist, but it 
was shown that a polyphenylene oxide-IO nanocomposite with a 10 wt.% loading of IO had a 
10.4% higher UTS than the pristine polymer [422]; the εb decreased at this loading in 
comparison to the pristine polymer by 26.5%, which the authors believe was due to the 
restricted movement of the polymer chains due to the increasing adherence of the polymer 
chains to the IO. Similar decreases (~20%) in the εb were noted for PI-IO nanocomposites of 
1-3 wt.%, in comparison to pristine PI, but contrary to the previous report, the UTS also 
decreased by ~8% [423]. The authors suggested that the poorer mechanical properties may be 
because of IO aggregation and a poor interfacial interaction between the IO and the PI [423]. 
PVA-IO nanocomposites of 1.2 wt.% and 2.4 wt.% possessed the same E as pristine PVA, but 
had lower εb and energy to break than the pristine polymer [424]. The εb decreased by 20% for 
the 1.2 wt.% nanocomposite, and ~60% for the 2.4 wt.% nanocomposite, similar to the other 
reviews of polymer-IO nanocomposites [422,423]. The UTS of the 2.4 wt.% nanocomposite 
did not change in comparison to the pristine polymer, but the 1.2 wt.% nanocomposite reduced 
by ~10% [424]. The storage modulus of ethylene vinyl acetate-IO nanocomposites and the 
resistance to thermal degradation both increased as the loading of IO increased, relative to the 
pristine polymer [425].  
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2.5.5 Polymer-quantum dot nanocomposites 
Polymer composites containing QDs focus mainly on the PL properties of the QDs within the 
nanocomposite. Polymer-QDs nanocomposites retain the PL behaviour of the QDs, such as 
CdS in PET [426], CdTe in PVA [427,428], CdSe/zinc-sulphur in PVA [428], and other 
polymer-QDs nanocomposites [429–433], allowing for the transparent and PL films to be used 
for optoelectronic devices. McDonald et al. [434] reported that lead-sulphur QDs in poly(2-
methoxy-5-(2’-ethylhexyloxy-p-phenylenevinylene)) can be used to convert NIR light into 
energy and act as a nanocomposite photovoltaic device, with a 3 fold increase in internal 
quantum efficiency over previous thin film studies. Zhu et al. [435] demonstrated a 
temperature-dependent fluorescent emission from a flexible and transparent poly(ether ether 
ketone)-CdSe/zinc-sulphur nanocomposite film.  
PVA nanocomposites containing 6 wt.% zinc-oxide QDs possessed 3.9 times higher E, 
a 2.8 times higher toughness to break, a 87% increase in the εb, and a 86% higher UTS than the 
pristine PVA [436]. Poly(styrene-butadiene-styrene)-1 wt.% CdTe QDs nanocomposites 
possessed a 4% increase in the εb and a 27% higher UTS than the pristine poly(styrene-
butadiene-styrene), whilst retaining the PL behaviour of the QDs [437]. PMMA with a 6 wt.% 
CdS QDs loading possessed a 47% higher E and a 57% higher UTS than the pristine PMMA 
[438]. Contrary to the previous results, the presence of CdSe-CdS QDs in PLA affected the 
mechanical properties of the nanocomposite [439], which the authors suggest is due to a poor 
interface between the PLA and the QDs. A 3.6 wt.% loaded PLA nanocomposite possessed 
23% lower E, a 9% lower toughness to break, a 20% increase in the εb, and a 35% lower UTS 
than the pristine PLA [439]. The PLA-(CdSe-CdS) QD nanocomposites did, however, retain 
the PL behaviour of the CdSe-CdS QDs.  
56 
 
2.6 Chitosan and chitosan-graphene nanocomposites 
2.6.1 Introduction to chitosan 
 
Figure 2.17: Chemical structure of the polymer chitin and the derivative chitosan. Adapted 
from Ravi Kumar et al. [440] with permission from Elsevier Limited, copyright 2000. 
The polymer used within this project is chitosan, chosen because it is strong, biocompatible, 
enzymatically degradable, and simple to process into a desired shape without extreme heat or 
toxic solvents [441,442]. Chitosan, commonly denoted as linear (1-4)-2-amino-2-deoxy-β-D-
glucan, is a cationic polysaccharide and a derivative of chitin (the material that makes up the 
shells and exoskeletons of some sea crustaceans and of some insects) [441,443,444]. Chitosan 
is processed from chitin by a deacetylation process using concentrated sodium hydroxide [441]. 
Figure 2.17 shows the chemical structure of chitosan, with NH2 amine and CH2OH hydroxy-
methyl groups visible. Chitosan possesses an orthorhombic unit cell structure, with four 
glucosamine units per unit cell [441,445]. The dimensions (a, b, c) of the unit cell are 0.828 
nm, 0.862 nm, and 1.043 nm [441,446]. Chitosan is soluble in certain acidic solutions (such as 
acetic, lactic, citric, and ascorbic acid), due to the protonation of the amine group when exposed 
to an acidic solution [440,441,443,444]. This gentle manufacturing process is important if the 
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chitosan is to be used for drug release applications like microneedle arrays. Extreme heat, toxic 
chemicals or irradiation may damage delicate drugs, like DNA/RNA gene therapeutics, within 
the microneedle arrays. 
Chitosan is a polymer that can be degraded by in vivo conditions [447]. Degradation of 
polymers can occur through photo-degradation, thermal degradation, mechanical degradation, 
or through chemical degradation and typically result in bond scission or chemical 
transformations of the polymer [448]. Photo-degradation occurs through the absorption of UV 
light or γ-irradiation by the polymer, which can raise the electrons of molecules within the 
polymer to a higher electronic state; this can cause the oxidation of the polymer and bond 
cleavage. Thermal degradation can lead to the scission of polymer bonds along the polymer 
chain. Mechanical action, such as stretching or bending, can cause the mechanical degradation 
of the polymer and lead to crazing, cracking and delamination of the polymer. Chemical 
degradation, an important degradation route for in vivo application, occurs via the hydrolysis 
scission of the polymer backbone through ingression by water or it can be catalysed by acid 
[448]. The degradation of chitosan can be catalysed by acids that can use either free radical or 
oxidation routes to degrade chitosan [447], but more commonly chitosan is degraded through 
enzymes (either lysozyme or chitosanases) via the hydrolysis of the β-glycosidic linkages 
between the acetyl units [447]. Lysozyme can be found naturally in blood plasma and urine 
[449]. Funkhouser et al. [450] reported that the human DNA has 8 glycoside hydrolase 18 
(GH18) chitanases / chitosanases that can degrade chitosan or chitin in the body. The presence 
of molecules that can degrade chitosan is important as the chitosan within the microneedle 
array may enter the body and may need to be degraded and excreted.  
Onishi [451] showed that chitosan could be excreted from the body, with the excreted 
chitosan of a reduced MWt relative to the original chitosan. Chitosan was found not to 
accumulate in the liver, spleen, or blood plasma. The chitosan was excreted through the kidney 
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via urine and complete excretion was achieved within 12 h of the chitosan dose being 
administered. Richardson et al. [452] also reported rapid clearance from the blood, with only 
32.2% of the original dose remaining after 1 h. Chitosan showed no cytotoxicity to human 
lymphoblastic leukaemia and human embryonic lung cells in an in vivo experiment and no 
haemolysis effect within solutions of chitosan and red blood cells [452]. Blood tests by Rao et 
al. [442] showed that no haemolysis effect was noted during their tests; also, a skin and eye 
irritation test showed no irritation to the chitosan solution for the test animal.  
Chitosan has been studied for biomedical applications such as to stimulate the 
formation of blood clots [441,442]. Chitosan nanoparticles have delivered the drugs tamoxifen 
[453,454], endoxifen [453], paclitaxel [455], and epirubicin [456], as well as others [457–461] 
and have been studied as a potential gene transfer agent [462]. In these works, it was noted that 
chitosan nanoparticles could enter and be retained within cells [455,457,458] and that the 
nanoparticles have a pH sensitive release of the therapeutic [454,455,460]. Methotrexate, 
bonded to chitosan nanoparticles, could be delivered to the brain through the blood-brain 
barrier [463]. Chitosan microspheres containing furosemide [464], mitoxantrone [465] and 
sodium diclofenac [466] were studied, with the chitosan-sodium diclofenac microspheres 
showing pH sensitive release that would allow for colon specific release of the drug. Chitosan 
micelles were used to contain the hydrophobic drug paclitaxel [467] and 6-mercaptopurine 
[468]; the 6-mercaptopurine release from the chitosan micelle was dependent on the local 
concentration of glutathione, a feature that made it effective against HL-60 human promeloytic 
leukaemia cells [468]. Chitosan chains could also be directly conjugated to drugs like exendin-
4 [469], insulin [470], and paclitaxel [471] for oral administration and with the anti-HIV drug 
d4T Stavudine [472]. 
Chitosan hydrogels were used to study the release of lidocaine and LH [473], and the 
encapsulation of BSA [474], methotrexate [463], heparin sodium, LH, metronidazole, 
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hydrocortisone, clotrimazole, estradiol, progesterone and piroxicam [475]. BSA had a pH 
sensitive release from a chitosan hydrogel that would allow for the site specific delivery of the 
drug into the intestines [474]. Ishihara et al. [476] used a chitosan hydrogel to encapsulate 
fibroblast growth factors and heparin, and showed that the therapeutics could be released from 
the hydrogel into mice. Chitosan films were created that encapsulated nifedipine [477] and 
calcein and BSA [478]. Oral tablets made from compressed, powdered chitosan were 
developed with pH sensitivity for the delivery of timolol maleate, ephedrine, propranolol 
hydrochloride, acetylsalicylic acid, naproxen, sulphadiazine, indomethacin and pindolol [479], 
insulin [480], and indomethacin [481]. 
2.6.2 Chitosan-graphene nanocomposites 
Chitosan has been used previously as the polymer matrix to form chitosan-graphene 
nanocomposites [209,396,397,399,482]. The processing of the chitosan-graphene 
nanocomposites would typically involve the dispersion of the nanoparticles in water to form a 
suspension; this suspension is then stirred into a dilute acetic acid suspension 
[209,396,397,399,482]. Chitosan is fully soluble in acidic solutions (such as acetic, lactic, 
citric, and ascorbic acid) [440,441,443,444]. This chitosan-graphene suspension is then poured 
into a mould and allowed to dry and solidify to the required shape.  
Chitosan-graphene nanocomposites show improved mechanical strength over pristine 
chitosan [209,396,397,399,482]. Section 2.5.1 discussed the properties that make graphene an 
efficient nanofiller, i.e. high aspect ratios, high surface area and a high E, and Section 2.5.3 
discussed previous studies on polymer-graphene nanocomposites and how graphene could 
improve the properties of the nanocomposites. It can be seen from Table 2.2 that chitosan-GO 
nanocomposites show increases in E, UTS and εb over pristine chitosan [396–398]; chitosan-
rGO nanocomposites show increases for E and UTS but a decrease for the εb [209,399], which 
will be discussed below. 
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The increases in E and UTS vary from report to report presumably due to the different 
types of chitosan used, with MWt and deacetylation degrees varying for each work. For 
example, chitosan of 95% deacetylation and MWt of 600,000 Da was used in a nanocomposite 
that showed 18.3%, 36.0% and 110% increases in E, UTS and εb respectively [396], but 
chitosan with 87% deacetylation and MWt of 186,000 Da showed 51.3%, 92.7% and 40.4% 
increases in E, UTS and εb respectively [397], despite the nanocomposites containing the same 
1 wt.% of GO and using the same preparation procedure to make the nanocomposite. This can 
make the comparison between chitosan-based nanocomposites difficult as the molecular 
weight and crystallinity can affect the material properties, such as mechanical strength [483], 
electrical conductivity [484], and degradation behaviour [115,447,485,486]. Nevertheless, it 
can be seen from the increases in E and UTS that graphene can act as a suitable stress transfer 
agent within chitosan when there is a strong bond interface (in the case of chitosan-GO, the 
bonding was hydrogen bonding [396,397,482]) between the two and there is an adequate 
dispersion of the graphene.  
For the chitosan-GO nanocomposites, the increase in εb can be associated with the 
mobility of the GO within the chitosan; the GO can realign and translate within the chitosan 
when the nanocomposite is under stress [369,400]. For the chitosan-rGO nanocomposites, the 
rGO cannot realign under stress and the nanocomposites become more brittle than the chitosan-
GO nanocomposites, which possibly is due to a reduction in the quantity of functional groups 
on rGO compared to GO which will reduce the bonding interaction between a polymer and the 
rGO [363]. 
It was reported that the addition of GO to chitosan would afford the chitosan 
nanocomposite better mechanical rigidity and a better resistance to solubility when submerged 
in water than pristine chitosan [482]; this was attributed by the authors to GO increasing the 
stability of the film by decreasing the interaction between water molecules and the hydroxyl 
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groups of chitosan. Chitosan-rGO showed a higher resistance to acidic conditions than pristine 
chitosan by resisting dissolution in acetic acid conditions that caused the dissolution of pristine 
chitosan [209]; this was attributed by the authors to the rGO acting as a physical cross linker 
between the chitosan chains, stopping the chains from entering solution despite the protonation 
of the amine groups. Decreasing the susceptibility of the nanocomposite to water/acid 
ingression and weakening is important if chitosan-GO nanocomposites are to be used for 
structural purposes. 
Other notable studies on chitosan-GO nanocomposites have shown that the 
nanocomposites are biocompatible and are not cytotoxic; chitosan-GO nanocomposites with 
up to 6 wt.% GO were shown to be biocompatible with murine osteoblasts, with the addition 
of GO improving the proliferation of the cells and lowering the cytotoxicity to the cells, relative 
to pristine chitosan [398]. Similar results were noted for chitosan and pristine graphene 
nanocomposites, where the cell viability tests showed that nanocomposite with a 0.6 wt.% 
loading of graphene has a similar cytotoxicity to pristine chitosan when incubation times were 
48 h [487], and where a chitosan-PVA-GO nanocomposite with 1 wt.% GO loading showed 
similar biocompatibility to pristine chitosan and the proliferation of the cells after 7 days was 
highest for the nanocomposite containing 6 wt.% GO [488]. A chitosan-GO aerogel was 
created by freeze-drying an aqueous solution of chitosan-GO, and this aerogel possessed a high 
porosity (a nanocomposite aerogel with 3 wt.% GO had a porosity of ~80%) and could be used 
to absorb doxorubin [489]. The subsequent release of doxorubicin was found to be pH 
sensitive, with a faster release in acidic conditions. Chitosan-GO nanocomposites could 
potentially work as an electrochemical biosensor, with the cyclic voltammetry results 
dependent upon the wt.% of GO [490].  
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2.7 Characterisation techniques 
During this thesis project, the nanoparticles and the nanocomposites were characterised in 
terms of mechanical properties, chemical properties, physical properties, and biological 
properties.  
2.7.1 Mechanical properties 
Chitosan-graphene nanocomposites, cut into dog-bone shaped specimens, were tensile tested 
to determine their Young’s modulus, their elongation to break, and their ultimate tensile 
strength. Microneedles were compression tested between two metal platens to determine the 
force required to fail the microneedle arrays. 
2.7.2 Chemical properties 
The chemical properties, such as bond type and chemical analysis, were studied for chitosan-
graphene nanocomposites and for graphene nanoparticles through molecular spectroscopy, the 
study of  how the internal energy of a molecule is affected by the absorption or emission of an 
applied, external electromagnetic radiation [491]. Fourier transform infrared (FTIR) 
spectroscopy is the study of the change in vibration-induced electric dipole moment of a 
molecule [492]. Raman spectroscopy is the study of the change in polarisability of a molecule, 
caused by a rotational-vibrational motion [491]. UV-Vis spectroscopy is a measure of the 
electronic changes of a molecule when a valence electron increases its orbit due to it absorbing 
an irradiation source in the visible or UV region (190 to 800 nm wavelength) [491,492]. PL 
spectroscopy is the study of electronically excited molecules that lose vibrational energy but 
maintain acquired electronic energy, and subsequently proceed to release this electronic energy 
to return to the ground electronic state; this electronic energy is released as a longer wavelength 
radiation energy than the original radiation energy [491]. Energy dispersive spectrometry 
(EDS), a by-product of transmission electron microscopy imaging, is the identification of 
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characteristic x-ray emissions from an irradiated atom due to inelastic scattering of an incident 
electron by an electron in an atom in a sample [493]. 
2.7.3 Physical properties 
The physical properties, such as crystalline structure, nanofiller dispersion and the surface 
topography, of chitosan-graphene nanocomposites and graphene nanoparticles were assessed. 
X-ray diffraction (XRD) was used to investigate the crystalline structure of nanoparticles and 
chitosan nanocomposites; this was achieved by identifying the angles of incidence (Bragg 
angles, θ) that were produced by constructively interfered waves of irradiation passing through 
the test sample [493]. TEM uses a beam of condensed and focused electrons to irradiate and 
pass through a thin specimen, during which the TEM can selectively allow only transmitted 
electrons through to the imaging apparatus to give a brightfield image of the test specimen, the 
type of imaging used in this thesis [493,494]. In scanning electron microscopy (SEM), the 
condensed and focused electron beam does not pass through the sample but is simply scanned 
over the sample surface in a raster fashion, interacting with the atoms on and just below the 
surface within an “interaction volume” and producing the secondary electrons that are used to 
image the surface of the sample [494,495]. AFM measures the physical interaction of a tip with 
the specimen surface while the tip is scanned along the surface of the sample in a raster fashion, 
i.e. the tip moves along a horizontal scan line [496].  
2.7.4 Biological properties  
Biological properties, such as the enzymatic degradation of polymers and the cytotoxicity of 
graphene nanoparticles, were studied. The enzymatic degradation of chitosan and chitosan-
graphene nanocomposites by an aqueous lysozyme solution was studied [497]. The 
cytotoxicity of graphene towards specific cell lines were analysed by MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5- diphenyltetrazolium bromide) assay; cells that were incubated with 
graphene were treated with the tetrazolium salt solution which metabolises in the presence of 
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viable cells to a formazan, the concentration of which can be measured through UV-Vis 
spectroscopy. 
2.8 Summary of the literature review 
Currently, the main therapeutic delivery devices used are hypodermic syringes and perioral 
tablets; these devices have disadvantages that include poor patient compliance, poor 
bioavailability and poor delivery performance. A very promising alternative was shown to be 
transdermal drug delivery. This is the delivery of drugs through the dermal layers to the viable 
epidermis, an area rich in blood vessels and antigen presenting cells that can provide a strong 
immune response to therapeutics. The microneedle array was shown to be particularly 
promising as a transdermal drug delivery device as it is painless when compared to most other 
delivery routes and it can offer both dose sparing and a quicker immune response when 
compared to the current therapeutic routes. Recent developments in microneedle array design, 
such as the change from metal/ceramic based arrays to biodegradable polymer based arrays, 
were reviewed and the studies on their drug delivery performance were promising, therefore 
microneedle arrays were chosen to be developed further in this project.  
After reviewing the microneedle array, it was determined that microneedle arrays 
currently lack functionality, such as the ability to encapsulate drugs within the microneedle 
array itself and to stimulate/control their release, the ability to target the drug to key sites within 
the body to maximise efficiency, and the ability to track/monitor the drug in vivo once released 
from the microneedle array. It was determined that nanoparticles, when bound to the drug and 
encapsulated within a polymer, would add these abilities to microneedle arrays. Recent 
advances in nanoparticle-assisted drug delivery were critically analysed, in which 
nanoparticles have been used to intelligently deliver drugs to specific sites of the body. Of 
particular interest within this thesis were graphene and iron oxide, with graphene of interest to 
drug delivery applications because of the large specific surface area and abundant functional 
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groups to bond drugs to. Iron oxide is of interest due to its intrinsic magnetic properties that 
allow for M.R.I. imaging and targeting by an external force. The effect that nanoparticles can 
have in vivo was examined, with key findings from recent papers on nanoparticle cytotoxicity, 
the distribution of the nanoparticles during the treatment, and the excretion route discussed. As 
these drug-bound nanoparticles will be encapsulated within a polymer, the ability of 
nanoparticles to improve the mechanical and electrical conductivity properties of polymers was 
researched. 
The polymer chosen for use within a microneedle array needed to be degradable, with 
a desired degradation timescale of 1 or 2 months, to allow for safe disposal after use, 
biocompatible to prevent complications during use, easy to process to avoid excessive heat or 
toxic solvents, and mechanically strong as the microneedle array needs to survive insertion into 
the skin layers. The chosen polymer, chitosan, was analysed for its potential use as the polymer 
in microneedle arrays and as the matrix within a chitosan-graphene nanocomposite; previous 
studies on chitosan-graphene nanocomposites were reviewed, as well as recent publications on 
the toxicity, biodistribution, and excretion paths of chitosan within the body.  
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Chapter 3. Chitosan-graphene oxide nanocomposites  
3.1 Introduction  
The focus of this chapter is the development of chitosan-GO nanocomposites that have 
improved mechanical (with an E of 1-1.5 GPa) and drug release properties (an increase in 
efficiency and delivery rate), relative to pristine chitosan. The addition of GO to chitosan 
should improve the mechanical properties of chitosan due to the large aspect ratio of GO and 
the functional groups on the surface of GO which should promote a strong interface between 
the chitosan and the GO. The functional groups of GO allow for the bonding of therapeutics to 
the surface of GO and will aid in the dispersion of GO and bound drug within fluids, which 
may improve the release of the drug from chitosan.  
GO was synthesised by a modified Hummers method and then characterised to 
determine the functional groups, the crystal structure, and the dimensions and thickness of the 
nanosheets. A chitosan-GO nanocomposite was created by dispersing GO into water and then 
dispersing the suspension into a dilute acetic acid suspension. The effects of GO on the 
mechanical properties and enzymatic degradation rate of chitosan-GO nanocomposites relative 
to pristine chitosan were investigated. The effect of GO on the drug release profile of chitosan 
was analysed, as well as the effect of varying the drug loading ratio onto GO. The model drug 
chosen for this chapter was fluorescein sodium (FL), selected due to its good dispersibility 
within aqueous mediums and distinct absorption peaks between 450 to 500 nm that would aid 
with quantitative analysis. The drug was used to study the release rate of small MWt drugs 
from chitosan-GO nanocomposites. 
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3.2 Experimental section  
3.2.1 Materials  
Chitosan powder (MWt = 100,000-300,000, Acros Organics, deacetylation degree ≥ 90% as 
determined by free amine groups) and phosphate buffered saline (PBS) were used as purchased 
from Fisher Scientific. The following chemicals were used as purchased from Sigma Aldrich; 
acetic acid (> 99.7%), sulphuric acid (95-98%), hydrogen peroxide (29-32% in H2O), 
potassium permanganate (97%), sodium nitrate (> 99%), fluorescein sodium, lysozyme (from 
chicken egg white, ~100,000 units mg-1) and graphite powder (≤ 20 μm).  
3.2.2 Preparation of graphene oxide 
GO was synthesized from a modified Hummers method and subsequently purified, exfoliated 
and freeze dried [186,187]. Briefly, graphite (3 g) was added to sulphuric acid H2SO4 (69 ml) 
and sodium nitrate NaNO3 (1.5 g). The mixture was stirred vigorously for 30 min in an ice 
bath. Potassium permanganate KMnO4 (9 g) was added slowly, and when fully added the 
mixture was heated to 35 oC and stirred for 12 h. Potassium permanganate (9 g)  was added to 
the mixture and stirred for 12 h before being poured over a mixture of ice (400 ml) and 30% 
hydrogen peroxide H2O2 (3 ml). The graphite oxide suspension was centrifuged at 8000 rpm 
for 1 h in an Eppendorf 5804 with the supernatant being discarded. The graphite oxide was 
dispersed in fresh distilled water for a total of five cycles to remove residue chemicals from the 
production process. Graphite oxide was dried in a vacuum oven and stored in powder form in 
a desiccator. When required, graphite oxide was exfoliated in distilled water for 2 h by a 
Fisherbrand sonication bath (230 V, 50 Hz) and centrifuged at 8000 rpm for 30 min to remove 
larger than desired particles. The supernatant dispersion was collected and lyophilized in a 
Labconco FreeZone Triad freeze-dryer to be stored in powder form in a desiccator 
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3.2.3 Loading of drug onto graphene oxide  
Fluorescein sodium powder was added to a 2 wt.% solution of GO in water and stirred for 24 
h. Unbound FL in the supernatant was removed from the solution through intense 
centrifugation at 8000 rpm for 1 h. This process was repeated to ensure the removal of all 
unbound FL. The FL coated GO (GO-FL) was then re-dispersed in distilled water by stirring 
for 1 h.  
3.2.4 Preparation of chitosan-graphene oxide nanocomposites 
Chitosan powder was added to a solution of 2 wt.% acetic acid in distilled water and stirred for 
24 h to prepare the chitosan solution. Then, the required concentration (0.25, 0.5, 1, 2, and 5 
wt.%) of nanoparticle filler was added to the chitosan solution and mixed for 12 h. The resultant 
dispersion was degassed in a sonication bath for 30 min. The dispersion was poured into a 
Teflon mould and allowed to air dry. Prior to testing, film was conditioned in an oven for 1 h 
at 50 oC. Drug loaded GO was also used to produce nanocomposites of GO-FL and chitosan 
using GO-FL nanohybrids containing 2 wt.% GO and various amounts of FL.  
3.2.5 Structural characterization of graphene oxide and nanocomposites 
FT-IR spectroscopy of nanocomposite films and GO-FL powder was achieved through a Perkin 
Elmer Spectrum 100 with ATR at a resolution of 1 cm-1 and an accumulation of 5 scans. XRD 
analysis of the crystal structure was achieved by using a Stoe Stadi P with Cu-Kα1 irradiation 
(0.154 nm wavelength) with an Imaging Plate detector. A Veeco Dimension 3100 AFM with 
Olympus AC160TS probes was used in tapping mode at 0.5 Hz to analyse the thickness and 
dimensions of GO sheets laid on a mica substrate. Laser scattering (LS) particle sizing of 
particles from 0.1 to 900 μm was achieved through a Coulter LS130 using 3 one minute runs 
of nanoparticles in a dispersion of GO (0.4 mg ml-1). TEM analysis was achieved using a F.E.I. 
Tecnai Biotwin using bright field imaging at an accelerating voltage of 80 kV. TEM samples 
were prepared using a Reichert-Jung Ultracut E microtome. UV-Vis was performed on 
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dispersions of nanoparticles by a Perkin Elmer Lambda 900 spectrometer between 200-800 nm 
at a resolution of 1 nm. A Horiba Fluoromax 4 with excitation source of 480-500 nm (max 
excitation shown to be 495 nm) and emission readings from 500-600 nm was used for PL 
spectroscopy (using solutions of 45.6 wt.% loaded GO-FL at 1 mg ml-1, GO at 0.545 mg ml-1, 
and unbound FL at 0.456 mg ml-1). Zeta potential was measured using a Brookhaven 
ZetaPALS, with solution concentrations of 1 mg ml-1 and 5 cycles of 10 runs per sample. SEM 
analysis of the gold sputter coated fracture surface of the nanocomposite films was achieved 
with an F.E.I. Inspect F50 with an accelerating voltage of 5 kV.  
3.2.6 Tensile testing of nanocomposites 
Tensile testing was performed on a Zwick Roell Z005 twin column tensometer using a 5 kN 
load cell and a 1 mm min-1 strain rate in accordance with ISO-527. Specimens (number (n) = 
10) were created using a punch of a dog-bone shape with the narrow test section between grips 
measuring 22 mm in length, 2.7 mm in width and 1 mm in thickness. The tensometer was 
calibrated against a stainless steel specimen of the same dimensions as the polymer specimens 
(Figure 3.S1). 
3.2.7 Drug release from nanocomposites 
Nanocomposite specimens (n = 5) were placed in a phosphate buffered saline (PBS) solution 
(30 ml) at 37 oC to simulate in vivo conditions and gently agitated at 100 rpm in a Stuart SI500 
shaking incubator. A known quantity (2 ml) of solution from the container was removed after 
every time step, making sure to replace it with the same amount of fresh PBS solution. UV-Vis 
in a Perkin Elmer Lambda 900 determined the release rates of the drug from the nanocomposite 
in neutral (pH = 7.4) and acidic (pH = 2, 5.5, and 6.5) conditions. The quantity of FL was 
determined by comparing the absorbance peak at 450 nm of the test samples with solutions of 
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free FL of known concentration (from 0.001 to 1 mg ml-1) in water, similar to the procedure 
used to measure the quantity of FL in solution during the loading of the drug onto the GO.  
3.2.8 Enzymatic degradation tests 
Enzymatic degradation tests have been described elsewhere [497,498]. Briefly, the polymer 
films were submersed in a PBS solution (pH = 7) at 37 oC containing the enzyme lysozyme at 
a natural concentration within the body, 1.5 μg ml-1  [449,499]. Samples were maintained at 37 
oC and were gently agitated. At regular intervals, each specimen was removed from the beaker, 
washed with distilled water, dried in a vacuum oven, and the mass measured. The sample was 
placed into fresh PBS and lysozyme solution to maintain constant enzymatic activity. For each 
sample type, there were 5 specimens for mass analysis and two sacrificial specimens for 
characterization analysis.  
3.2.9 Statistical analysis 
Statistical analysis (standard deviation and 95% confidence intervals) were calculated using 
MatLab 2012a software. 
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3.3 Results and discussion  
3.3.1 Characterisation of GO 
 
Figure 3.1: (A) FT-IR spectra and (B) XRD traces for GO, graphite oxide and graphite. 
GO, produced through exfoliation of graphite oxide created from a modified Hummers method, 
was characterized by FTIR, XRD, AFM, and LS to confirm the chemical bonds present, the 
interlayer spacing, and the dimensions of the GO respectively. The process of oxidation 
introduces additional functional groups to graphite; these can be identified by FTIR to verify 
the successful oxidation. The graphite curve has two main peaks, one at 3400 cm-1 (O–H bonds) 
from absorbed, free water and a second at 1640 cm-1 (C=C bonds). The process of oxidation 
introduces a peak at 1043 cm-1 (C–O bonds) and at 1727 cm-1 ( C=O bonds) on the graphite 
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oxide and GO curve, as well as the 1628 cm-1 for C=C bonds and at 3400 cm-1 for O–H bonds 
from retained free water in the sample [187,210]. The oxidation process should change the 
chemical structure of graphite and will increase the interlayer spacing; the changes can be 
identified through XRD (Figure 3.1B). The (002) peak of graphite oxide is at 2θ = 11o 
corresponding to an interlayer spacing of 0.8 nm and the (002) peak of graphite is at 2θ = 26o 
corresponding to an interlayer spacing of 0.34 nm, similar to the published literature [214]. 
This shows that the oxidation procedure has increase the interlayer spacing of graphite. The 
low intensity of the peak at 2θ = 10o on the GO curve shows that the majority of nanosheets 
were exfoliated from graphite oxide to GO nanosheets [352,397].  
 
Figure 3.2: (A) AFM image and height profiles of GO nanosheets and (B) laser scattering 
particle sizing profiles of GO nanosheets and graphite in an aqueous solution. 
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An AFM image of single layer thick GO nanosheets is shown in Figure 3.2A. The 
thickness of each layer is around 1.0 nm thick, as determined from several AFM images, 
showing the exfoliation of graphite oxide into single layer GO nanosheets [397]. The thickness 
of GO is thicker than the reported thickness of graphene (0.37 nm [500]), showing that the 
oxidation process has increased the thickness of GO relative to pristine graphene. 
  The lateral size of GO nanosheets can be measured as approximately between 0.2 to 
0.6 μm. This is a representative of a small sample size of the GO sheets. The LS size distribution 
of a greater sample size of GO sheets is shown in Figure 3.2B, showing that the majority of 
sheets range in size from 0.6 to 2 μm. The difference in size range between the AFM and LS 
values can be attributed to the fact that LS analysis measures the hydrodynamic diameter of 
GO particles and that it assumes these particles are spherical in shape. Graphite powder 
measured in size between 1 to 20 μm, showing that the oxidation and dispersion processes have 
successfully led to the production of smaller GO. 
3.3.2 Characterisation of chitosan-GO nanocomposites 
Chitosan nanocomposites of 0.25, 0.5, 1, 2, 5 wt.% GO were created by dispersing known 
quantities of GO in chitosan solution and air drying to form a film. Characterization of the 
nanocomposites will allow for an analysis of the interfacial interactions (FTIR), the 
crystallinity of the nanocomposites (XRD), and the GO dispersion (TEM). An FT-IR analysis 
of chitosan nanocomposites containing 0-5 wt.% GO is shown in Figure 3.3A. Prominent peaks 
show strong C = C (1620 cm-1), C = O (1720 cm-1) and O–H bonds (3300 - 3400 cm-1). An 
additional range of peaks can be seen at 2400-3200 cm-1, which are N–H bonds from 
ammonium ions created by the deacetylation process, and at 1530-1540 cm-1, which are amino 
groups from the chitosan [466]. At 1400 cm-1, C–OH bonds can be seen and at 1000-1100 cm-
1 C–O bonds can be seen [482]. The C–O bonds (from 1018 to 1012 cm-1 and 1088 to 1084 
cm-1 for pristine chitosan and the nanocomposites respectively) and the amino group (from 
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1539 to 1531 cm-1 for pristine chitosan and the nanocomposites respectively) have shifted 
significantly, indicating a strong hydrogen bonding between these two groups and the 
functional groups in GO [396,482], implying a strong interface between the chitosan and the 
GO.. 
 
Figure 3.3: (A) FT-IR spectra, (B) XRD traces of chitosan nanocomposites containing 0-5 
wt.% GO. 
Crystallinity can affect the degradation of chitosan, and as such it is important to 
analyse the effect that GO can have on chitosan crystallinity. This can be acquired from XRD 
analysis of the nanocomposites. An XRD analysis of the nanocomposites containing chitosan 
and GO is shown in Figure 3.3B. An amorphous structure for the chitosan powder can be 
identified as the broad peak at 20o [216]. Diffraction peaks for all nanocomposites can be seen 
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at 8, 11, 16, 18 and 23o, in keeping with the literature [396,397]. Peaks at 8, 11 and 18o are the 
result of a crystalline structure in chitosan while 16o and 23o are due to an amorphous structure 
in chitosan film [396]. Assuming no peaks for GO were present in the nanocomposite due to 
their low content and the strong interaction between GO and chitosan which may lead to nearly 
full exfoliation [396], the crystallinity percentage, χc, of nanocomposites can be determined 
from analysing the diffraction peaks of chitosan, as shown in Equation 3.1 [501,502]. 
𝜒𝑐 =  
𝐼𝑐
𝐼𝑐 + 𝐼𝑎
                                                                     (3.1) 
where Ic is the peak area of the crystalline region and Ia is the peak area of the amorphous 
region. The crystallinity values of chitosan nanocomposites are 30.5, 32.0, 23.3, 25.4, 27.3, 
and 21.5% for pristine chitosan and chitosan nanocomposites of 0.25, 0.5, 1, 2, 5 wt.% GO 
respectively.  
 
Figure 3.4: TEM micrograph of 2 wt.% GO chitosan nanocomposite, showing a good 
dispersion of GO nanosheets. 
The TEM micrograph in Figure 3.4 shows a good dispersion of GO nanosheets (shown 
as black lines within the matrix, as per the literature [362,503]), within the 2 wt.% GO chitosan 
nanocomposite, the majority of which are exfoliated, confirming the validity of the assumption 
of a good dispersion. Solution casting has created crystalline regions within the chitosan film, 
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which differentiates from the amorphous chitosan powder (curve 1, Figure 3.2B). The presence 
of 0.25 wt.% GO slightly increased the crystallinity, owing to its nucleation effect [504]. 
However, nanocomposites of higher GO contents have lower crystallinity than pristine chitosan 
films. Presumably, GO reduces the crystal growth by hindering the mobility of the chitosan 
chains, which outweighs the nucleation effect [504]. The lowest crystallinity was measured for 
the sample with 5 wt.% GO.  
 
Figure 3.5: Representative tensile stress versus strain curves for chitosan nanocomposites 
containing 0-5 wt.% GO. 
The nanocomposites can use GO as a structural reinforcement to improve mechanical 
properties as well as a drug carrier. Mechanical testing will allow for a determination of the 
optimum GO concentration to be used for the nanocomposite-based transdermal drug delivery 
devices which will require mechanical strength during application, such as microneedle arrays. 
The representative tensile stress-strain curves for chitosan and GO nanocomposites are shown 
in Figure 3.5. The behaviour of the nanocomposites under strain varies depending on their GO 
content. Pristine chitosan samples undergo elastic deformation, yielding and necking without 
strain hardening. Chitosan-0.25 wt.% (curve 2) and chitosan-2 wt.% (curve 5) strain soften and 
then proceed to work harden before failing. The nanocomposites containing 0.5 wt.%, 1 wt.% 
and 5 wt.% do not strain soften after yielding but proceed straight to work hardening before 
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failing. The introduction of GO increases the ductility and ability of the samples to work harden 
when compared to the pristine chitosan sample.  
The mechanical properties are summarized in Table 3.1. The pristine chitosan film fails 
at an average strain of 14.5%. The samples containing 0.25 to 5 wt.% GO fail at between 17.7-
35.1% strain, demonstrating substantial increases in ductility of chitosan which are attributable 
to the orientation and delamination of graphene sheets under tension [505]. Chitosan-0.25 wt.% 
and chitosan-2 wt.% have the highest E value of the sample range, with average E values of 
1.23 GPa and 1.30 GPa respectively. GO has a higher E than chitosan, 207 GPa versus 1 GPa 
[192], and a high aspect ratio, a large specific surface area and abundant functional groups, 
thus acting as an effective reinforcement filler in these two cases. In contrast, the chitosan-0.5 
wt.% and chitosan-1 wt.% present lower modulus values. Both the effective volume fraction 
of GO and the effect of GO on polymer crystallinity affect the E of the final nanocomposite 
[506]. The former takes into account the contribution from the interfacial region and is 
therefore dependent on both the GO content and the dispersion degree of GO [506]. Lower GO 
contents, e.g. 0.25 wt.%, are expected to lead to better dispersion and therefore more efficient 
reinforcements.  
Table 3.1: The mechanical properties of chitosan-GO nanocomposites.  
GO content / wt.% E / GPa UTS / MPa εb / % 
0 1.00 ± 0.10 24.2 ± 1.4 14.5 ± 2.7 
0.25 1.23 ± 0.12 34.5 ± 1.4 19.0 ± 2.2 
0.5 0.86 ± 0.08 30.4 ± 1.8 25.9 ± 4.2 
1 0.93 ± 0.13 32.4 ± 1.2 35.1 ± 2.6 
2 1.30 ± 0.14 33.2 ± 2.2 17.7 ± 2.6 
5 0.46 ± 0.11 21.9 ± 1.1 22.4 ± 3.3 
 
In comparison, the lower moduli exhibited by chitosan-0.5 wt.% and chitosan-1 wt.% 
nanocomposites can be attributable to their lower crystallinities. Chitosan-5 wt.% shows the 
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lowest modulus, presumably due to the presence of defects and aggregates in addition to the 
low crystallinity, which is further discussed below. With the exception of chitosan-5 wt.%, the 
addition of GO increased the UTS. Again, chitosan-0.25 wt.% and chitosan-2 wt.% present the 
highest tensile strength among the materials tested, with increases of 43% and 37% compared 
to the value for their polymer counterpart. The strong bonding between GO and chitosan has 
allowed for an efficient transfer of stress from the chitosan to the GO nanosheets. Similar 
increases are expected for flexural modulus, flexural strength, and fracture toughness for the 
nanocomposites as the GO content increases [507].  
 
Figure 3.6: SEM micrographs of the tensile fracture surface of chitosan GO nanocomposite 
films containing (A) 0 wt.%, (B) 0.25 wt.%, (C) 0.5 wt.%, (D) 1 wt.%, (E) 2 wt.%, and (F) 5 
wt.%. (Scale bar = 20 µm) 
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An analysis of the fracture surface of tensile specimens (Figure 3.6) shows that the 
nanocomposites containing 0-2 wt.% GO show a uniform morphology throughout the fracture 
surface which suggests that there were no voids or aggregations in these nanocomposites, while 
voids and aggregations can be seen in the image for the sample with 5 wt.% GO which may 
explain its inferior mechanical properties. 
Based on the above mechanical results, the two nanocomposites that possess the best 
mechanical properties are chitosan-0.25 wt.% and chitosan-2 wt.%. As a higher concentration 
of GO allows for a higher quantity of drug to be loaded onto GO than would be achievable 
with a lower concentration, the optimum nanofiller concentration for load-bearing drug 
delivery devices such as microneedle arrays is considered to be 2 wt.% and therefore it is used 
for subsequent drug delivery and enzymatic degradation tests. 
3.3.3 Drug loading and release analysis 
Drug coated GO was created through a mixing procedure and the removal of excess drug. The 
successful bonding of FL onto GO surface can be confirmed by UV-Vis, FT-IR, 
photoluminescence spectroscopy and AFM. Figure 3.7A shows the UV-Vis spectra of GO at 
the concentration of 0.4 mg ml-1 to allow for an analysis of absorption peaks. The peak at 230-
235 nm can be attributed to π → π* conjugations of C = C bonds and the peak at 300 nm is the 
n → π* conjugation of C = O bonds [187]. A comparison of unbound FL, GO-FL hybrid, and 
GO nanosheets in Figure 3.7A shows that the characteristic peaks of FL at 450 and 480 nm are 
present with a shift to 445 and 475 nm on the GO-FL hybrid curve while a shoulder peak at 
270-275 nm of the FL curve has been transposed onto the GO-FL curve but is not present on 
the GO curve. 
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Figure 3.7: (A) UV-Vis spectra, (B) FT-IR spectra of unbound FL, GO, and 45.6 wt.% loaded 
GO-FL hybrid.  
FT-IR spectroscopy analysis of GO-FL and FL powders are shown in Figure 3.7B. In 
this figure, peaks characteristic of GO can be seen (C=O at 1720 cm-1, C=C bonds at 1600 cm-
1 and C–O bonds at 1000-1100 cm-1) for the 45.6 wt.% FL loaded GO-FL nanohybrid. Peaks 
characteristic of FL can be seen on the GO-FL curve below 1600 cm-1 and there is a shift in 
wavenumber on peaks (from 1738 for FL to 1726 cm-1 for GO-FL, from 1572 to 1530 cm-1, 
and from 1088 to 1066 cm-1) which can be attributed to both physical absorption of the drug 
onto the surface and an overlapping of FL peaks with GO peaks. The bonding between GO and 
FL is π→π stacking (electrostatic and hydrogen bonding), as reported in the literature [508]. 
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Figure 3.8: (A) Photoluminescence spectroscopy of unbound FL, GO, and 45.6 wt.% loaded 
GO-FL hybrid. (B) AFM image of a GO-FL sheet from the 45.6 wt.% loaded GO-FL solution, 
showing a sheet of 8.3 nm, 9.4 nm, and 8.7 nm thick at the green, red and black arrow points.  
Photoluminescence spectra are shown in Figure 3.8A, showing the quenching effect of 
GO on GO-FL in comparison to free FL. The solutions of unbound FL and pristine GO were 
of a concentration equal to the quantity of FL or GO on the GO-FL in the 45.6 wt.% FL loaded 
GO-FL nanohybrid solution. GO-FL has a PL property courtesy of the FL, as can be seen by 
comparing to the GO, again suggesting successful bonding of FL onto GO. An AFM image of 
a single GO-FL sheet from the 0.84:1 solution is shown in Figure 3.8A. It shows a sheet of an 
approximate thickness of 8.7 nm. The increase in thickness from 1 nm for GO is due to the 
coating of FL on the surface, which can be seen to be rough and uneven across the surface (for 
further images, see Figure 3.S2 in S.I.). Zeta potential readings were taken before and after the 
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synthesis of the 0.84:1 ratio solution, with values of -53.58 (± 0.96) mV for GO and -54.54 (± 
0.76) mV for GO-FL, implying both have good stability in aqueous solutions and that the 
electrical charge of GO is only slightly decreased by the addition of FL. 
 
Figure 3.9: Drug loading chart of fluorescein sodium onto GO nanosheets as a function of 
initial FL concentration after 24 h of bonding. Inset: UV-Vis Spectroscopy analysis of FL in 
water solution. 
The quantity of FL was determined by UV-Vis spectroscopy analysis by measuring the 
absorbance percentage of the characteristic peak (450 nm) of FL (Figure 3.9 inset). To calculate 
the drug loading ratio (FL:GO), the amount of unbound FL present in the supernatant prior and 
after to absorbing onto GO was measured against the spectra of standard FL solutions with a 
known concentration. Drug loading ratio was calculated by Equation 3.2: 
𝐷𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =  
𝑂𝑟𝑖𝑔𝑖𝑛𝑎𝑙 − 𝑢𝑛𝑏𝑜𝑢𝑛𝑑 𝐹𝐿 (𝑚𝑔)
𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦 𝑜𝑓 𝐺𝑂 (𝑚𝑔)
                                 (3.2) 
The drug loading ratio of FL to GO is dependent on the original concentration of the 
drug in the solution within the experiment time frame of 24 h. Figure 3.9 shows the increase in 
drug loading ratio when the original concentration of FL is varied from 0.1 mg ml-1 to 50 mg 
ml-1, allowing for the selection of initial concentrations to make GO-FL powders with defined 
loading ratios. Initial concentrations of FL of 2.5 mg ml-1, 12.5 mg ml-1  and 49 mg ml-1 were 
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used to create nanohybrids with the loading ratios (FL:GO) of 0.28:1 (21.9 wt.%), 0.84:1 (45.6 
wt.%), and 1.4:1 (58.3 wt.%), respectively. 
 
Figure 3.10: UV-Vis spectra of free FL, GO-FL loaded into the nanocomposites and FL 
released into PBS during drug release testing. 
The release rate and quantity released are important to determine for a drug delivery 
mechanism, which can be analysed using UV-Vis spectroscopy. Figure 3.10 shows a 
comparison of free FL, GO-FL encapsulated nanocomposites and the FL released during 
testing. The characteristic peaks of the FL at 450 nm and 480 nm in the free FL have shifted 
back from 445 nm and 475 nm for the GO-FL after being released from the nanocomposite 
into the PBS medium, which indicates a possible unbinding of FL from GO after release and 
is coincident with previous speculation of drug diffusing away from GO [509]. The peaks at 
450 nm were used to calculate the drug release amounts according to the method described in 
the experimental section, and the results are discussed subsequently. 
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Figure 3.11: (A) Percentage of drug released from chitosan-2 wt.% GO-FL nanocomposites in 
comparison to a non-GO Chitosan-FL hybrid in a neutral (pH = 7.4) environment as a function 
of drug loading. (B) Higuchi equation simulation of drug release from chitosan-FL and chitosan 
GO-FL nanocomposite. 
Figure 3.11A shows the cumulative quantity (%) released in a neutral environment (pH 
= 7.4) over 144 h. There are different release profiles for the samples containing the following 
loading ratios; FL equal to 21.8 wt.%, 45.6 wt.%, and 58.3 wt.% of the GO-FL nanohybrid 
while the GO content in the nanocomposite is fixed at 2 wt.%. The sample containing a 21.8 
wt.% loading reaches a drug level plateau after 9 h of 66% of the drug in the sample, or 75 μg 
ml-1. The sample containing a 45.6 wt.% loading is slower to reach the plateau, achieving 
maximum release at 24 h, 62% of the drug in the sample or 2.2 μg ml-1. After 12 h, a 59% 
release has been achieved, showing the possibility of a rapid but strong drug delivery system 
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of 2 μg ml-1 in 12 h. The nanocomposite containing a 58.3 wt.% drug loading took 96 h to reach 
the maximum release level (60% of total available drug or 3.75 μg ml-1). There is a relationship 
between the degree of drug loading and the time taken to reach the plateau that can be explained 
by the drug concentration gradient. Initially, the release medium has 0% drug concentration 
and therefore the diffusion from the nanocomposite to the release medium is fast. As the drug 
concentration in the release medium increases, the diffusion of the drug from the 
nanocomposite decreases. By varying the loading of the drug onto the GO the drug release rate 
can be altered to suit the application (i.e. fast release of anaesthetic for pain relief or sustained 
release of a therapeutic drug). The 45.6 wt.% loading percentage sample was chosen to undergo 
further analysis in acidic drug release conditions and enzymatic degradation analysis as it 
offered the optimum combination of strong, efficient and fast delivery of a drug as well as drug 
loading efficiency. The incomplete release of the drug can be attributed to the incomplete 
release of the GO from the chitosan matrix. The drug is attached to the GO and therefore cannot 
be released into the medium. There is a strong hydrogen bonding between the chitosan and the 
nanoparticles, as shown in Figure 3.5, which shows a shift in the 1539 and 1018 cm-1 peak for 
pristine chitosan to 1530 and 1016 cm-1 for 58.3 wt.% loaded GO-FL in chitosan. This strong 
bonding restrains the nanoparticles and restricts their movement and subsequent dissolution 
from the chitosan. A similar effect is noted in the enzymatic degradation analysis later in this 
paper.  
          A hybrid of chitosan and unbound FL was created that contains the same mass of FL as 
the nanocomposite sample containing a 45.6 wt.% loading of FL in GO-FL hybrid (Figure 
3.11A). This sample was used to investigate the improvement that bonding a drug to GO can 
have on the drug release performance. The sample of free FL encapsulated in chitosan has a 
plateau after 72 h at 36% of the drug in the sample or 1.2 μg ml-1. The unbound FL was unable 
to diffuse fully through the polymer film and out into the release medium within the 150 h, 
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presumably due to the strong hydrogen bonding between FL and chitosan. In contrast, the 
nanocomposite sample containing the same amount of FL has both a quicker and more 
substantial (62% versus 36%) delivery of the drug than the sample of free FL. The hydrophilic 
GO sheets may have increased the diffusion coefficient of the GO-FL in comparison to 
unbound FL (see below), raising the speed and the amount of the drug release.  Similar to the 
case in chitosan film, the incomplete release of the drug from the nanocomposite film may be 
attributed to the strong bonding between GO-FL and chitosan. This strong bonding restrains 
the GO-FL hybrid from being released into the PBS medium. 
To further understand the improvement in drug delivery performance that grafting to 
GO offers, release profiles of drugs in the polymer and nanocomposite were estimated by drug 
diffusion equations that are commonly used such as the Higuchi equations [510,511]. The 
standard Higuchi equation defines the cumulative amount of drug released, Mt, as: 
𝑀𝑡 = 𝑘𝐻  ×  √𝑡                                                              (3.3) 
where t is the time elapsed and kH is the Higuchi constant, defined as: 
𝑘𝐻 = 𝐴 ×  √2 × 𝐶𝑖𝑛𝑖𝑡 × 𝐷 × 𝐶𝑠                                          (3.4) 
where Cinit is the initial concentration of the drug within the matrix, A is the cross sectional 
area of the diffusion matrix, Cs is the drug solubility and D is the drug diffusion coefficient in 
water, namely 500 mg ml-1 and 0.42 × 10-5 cm2 s-1 respectively for pristine FL [512]. The result 
of the modelling analysis for unbound FL and its release from chitosan is shown in Figure 
3.11B, showing a close correlation to the experimental results and confirming the accuracy of 
the experimental data. However, they do not model the experimental results for the GO-FL 
chitosan nanocomposite due to the variations in the drug diffusion coefficient. Using the 
Higuchi equation, an approximation of the diffusion coefficient for FL in the nanocomposite 
can be made, with an initial value of 0.22 × 10-3 cm2 s-1 up to 10 h and then a lower diffusion 
value of 0.1 × 10-5 cm2 s-1 until the end of the test. The ability to increase the diffusion 
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coefficient could allow for drugs with poor diffusivity in water to be released more efficiently 
than they would be as an unbound drug. A quicker and more substantial release of these drugs 
would improve the therapeutic effect of treatments.  
GO-FL might have been released together from the nanocomposite into the PBS 
medium, which can be identified by the change of the colour of the PBS, thereby increasing 
the initial diffusion coefficient of the drug. After having been released into the PBS, FL 
gradually detached from GO and presented as free FL, as determined from the UV-Vis spectra 
(Figure 3.10). This suggests that the free released FL can then diffuse into the cell membranes, 
leaving the GO to be excreted from the body through the renal system [244]. The above 
calculations consider FL as the drug. If GO-FL is considered as a single drug entity, the Cs x 
Cinit will remain the same because the new Cs for GO-FL is 45.6% of the original Cs while the 
new Cinit is the 1/45.6% of the original Cinit, which means the above theoretical values for D 
will stand.  
 
Figure 3.12: Percentage of drug released from GO-FL nanocomposites in an environment with 
differing pH. 
 Figure 3.12 shows the cumulative quantity of drug released in an acidic environment 
(pH = 2, 5.5 and 6.5) from a nanocomposite containing a 45.6 wt.% loading of FL in GO-FL 
hybrid. The nanocomposite placed in the pH = 2 solution released the drug initially in a profile 
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similar to the profile for neutral conditions. A steady release of drug was recorded until a 
plateau was reached at 48 h (27% of drug within the test samples or 0.84 μg ml-1). The pH = 
5.5 and 6.5 samples released the drug slowly but steadily, where final release quantities were 
46% (1.43 μg ml-1) at 144 h and 59% (1.84 μg ml-1) at 120 h respectively. Presumably the pH 
=2 conditions rapidly dissolved the surface of the test specimens which then released the drug 
that was encapsulated in that region, but then the layers did not exfoliate and the hydrophilic 
GO became hydrophobic and tended to aggregate together, presumably through electrostatic 
attractions [513,514], thus hindering the release of FL. In the neutral environment, chitosan 
swelled in the medium; the presence of the hydrophilic GO facilitated the release of FL as 
discussed above. The surface dissolution did not occur as rapidly when the specimens were 
placed in solutions of pH = 5.5 and 6.5, and neither did the specimens exfoliate as rapidly as 
the specimens in the neutral solution. The slower dissolution and exfoliation hindered the rapid 
release of drug, but the higher pH values did not cause as strong an electrostatic attraction as 
for the pH =2 specimens, and therefore did not hinder the release of FL. A reduction in the 
maximum drug release amount when in an acidic medium offers the possibility of a selective 
release device with limited release in gastric juices (pH of 1-2) and then a more substantial 
release when in the neutral media of the intestines (pH = 6-7) or in a targeted disease area 
where the pH is 5.5-7.4.  
 The bonding of FL onto GO increases the maximum drug release amount by 72% when 
compared to unbound FL from a chitosan matrix. The drug release tests show that the drug 
release behaviour can be altered by varying the drug loading ratio onto the GO. The release 
profile is sensitive to the pH of the release medium, with the quantity of drug released reduced 
substantially (by 48%) when in an acidic medium. 
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3.3.4 Enzymatic degradation analysis of chitosan-GO nanocomposites  
 
Figure 3.13: Mass change during enzymatic analysis of nanocomposites containing prisitne 
chitosan, 2 wt.% GO, and GO-FL with 45.6 wt.% FL loading over 4 weeks. 
The effect that GO will have on the enzymatic degradation rate of a polymer has not been 
analysed in the literature. Pristine chitosan and specimens of nanocomposites containing 2 
wt.% GO and 2 wt.% GO-FL with 45.6 wt.% FL loading were submerged in a solution of hen 
egg white lysozyme and PBS to simulate in vivo conditions. Hen egg white lysozyme possesses 
a similar main chain formation and binding sub-sites as human lysozyme [515]. The by-product 
of the degradation process is a lower MWt chitosan [516,517].  
During the enzymatic degradation analysis, the mass of the samples dropped at different 
rates (Figure 3.13). Pristine chitosan showed the quickest degradation rate of those tested, 
losing 70 wt.% of their initial mass after one week compared to 22 wt.% for chitosan-2 wt.% 
and 43 wt.% for the GO-FL with 45.6 wt.% FL loading samples. A change in the colour of the 
PBS solution containing the GO-FL with 45.6 wt.% FL after one week confirmed the release 
of the drug into the medium containing the enzyme during the enzymatic degradation test. The 
initial high degradation rate for all the profiles can be attributed to the lysozyme reaction to the 
abundant chitosan chains containing at least 3 acetyl units [516,517]. Lysozyme degrades 
polysaccharides like chitin and chitosan through enzymatic hydrolysis of the β-(1→4) 
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glycosidic linkages through the hexameric sugar ring binding sites of lysozyme [497,516]. 
Once the number of suitable sites has been reduced, the rate of degradation slows between 
week one and week two and then again between week 2 and week 3 for all specimens. Pristine 
chitosan reduced to 15 wt.% of their original mass after 2 weeks, compared to 67 wt.% and 43 
wt.% respectively for chitosan-2 wt.% and the GO-FL with 45.6 wt.% FL loading samples. 
The degradation rate for all samples plateaued around week 2, after which the mass of samples 
varied no more than 2%. The mass loss curve for pristine chitosan is similar to the literature 
[497].  
The difference in mass loss between the samples can be explained by the presence of 
the nanoparticles GO and GO-FL. Nanoparticles like graphene and GO are impermeable to 
most molecules [410]. They may decrease the rate at which the enzymes permeate through a 
nanocomposite through the tortuous path model that predicts an increase in the barrier 
properties of nanocomposites (as discussed in Chapter 2, Section 2.6). Furthermore, the 
adsorption of the chitosan molecular chains to the GO via strong hydrogen bonding and 
electrostatic forces can restrict the chain movement, similar to the physical crosslinking effect 
of the oxygen groups of GO on polyacrylamide hydrogels [518]. Crosslinking can act to slow 
down the cleaving and enzymatic degradation of these macromolecules [519], hence the mass 
loss is lower for the nanocomposites than for the pristine chitosan. The difference in mass loss 
between chitosan-2 wt.% and GO-FL with 45.6 wt.% FL loading can be attributed to the 
presence of the drug coating in the latter which limited the bonding sites between GO and 
chitosan dissolved in the solution.   
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Figure 3.14: SEM images of the top surface of (A-B) chitosan, (C-D) chitosan and 2 wt.% GO, 
and (E-F) chitosan and GO-FL with 45.6 wt.% FL loading. The images A, C, and E were taken 
before the test and the images B, D, and F were taken after one week of the enzymatic 
degradation test. (Scale bar = 20 µm) 
The effects of GO and GO-FL on the enzymatic degradation of chitosan can also be 
seen in Figure 3.14, which shows the surface morphology of the films before the enzymatic 
degradation test began and 1 week after the test. Among the three samples analysed, chitosan-
2 wt.% GO-FL suffered the least pitting and crevassing on the surface during enzymatic 
degradation, confirming its enhanced resistance to enzymatic activity. As the chitosan-2 wt.% 
GO-FL nanocomposite is degraded, it is eroded by the dissolution of the chitosan into solution. 
This will leave chitosan-coated GO-FL nanosheets partially exposed which are still anchored 
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in the chitosan. High aspect ratio extrusions appear in the sample for chitosan-GO-FL (Figure 
3.15) which are chitosan-coated GO-FL nanosheets.  
 
Figure 3.15: SEM images of the fracture surface of chitosan GO-FL nanocomposite showing 
chitosan coated GO sheets. (Scale bar = 20 µm) 
 There is no correlation between enzymatic degradation rate and the release rate of the 
drug as the pristine chitosan film was the fastest to degrade over the course of the first week 
during which it lost more mass (70%) than the nanocomposite of GO-FL, but in the form of a 
drug eluding polymer it had the slowest release rate and a lower efficiency of delivery with a 
plateau of delivery after 72 h. The difference between drug delivery performance and 
enzymatic degradation rate can be explained by the tortuous path that slowed the enzymes 
progression into the nanocomposite containing GO-FL and by the chitosan chains that are 
bound onto the GO surface, making them more difficult to break. The mass loss curve for the 
sample containing 45.6 wt.% FL in GO-FL hybrid over 4 weeks is important to consider when 
studying drug release from nanocomposites. Over the first week, the nanocomposite lost 43% 
of its original weight (Figure 3.13) and released 62% of the available drug (Figure 3.11(A)). 
The nanocomposite will stay intact within the body long enough for a steady and controlled 
drug delivery to occur before degrading and being excreted, as can be seen in SEM analysis 
after one week (Figure 3.14 and Figure 3.15). 
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3.4 Conclusions  
GO was synthesised by a modified Hummers method and the characterisation studies on GO 
in this chapter served as a benchmark for changes in chemical/physical structure, dimensions 
and functionality of other graphene derivatives through this thesis. Enzymatically degradable 
chitosan and chitosan nanocomposite films with 0.25 to 5 wt.% GO were prepared by solution 
casting. The nanocomposite containing 2 wt.% GO exhibited the best combination of 
mechanical properties and drug loading capacity, with the Young’s modulus raising from 1 to 
1.3 GPa, UTS from 24 to 34 MPa, and εb from 14.5% to 17.7% compared to the pristine 
chitosan. Improvements of the mechanical properties were attributable to the high stiffness, 
strength, specific surface area and ample functional groups as well as the mobility of GO sheets 
under tension. 
 Drug release tests show that the release profile of the drug from the polymer matrix is 
dependent on two key factors: the loading ratio of the drug to GO and the pH of the solution 
that the drug is being released into. In a comparison to chitosan with the same amount of FL, 
the GO-FL nanohybrid containing 45.6 wt.% FL loading released 72% more of the drug and 
achieved maximum delivery in a shorter timespan than the conventional composite sample. 
Different drug release profiles were noted during testing in neutral and acidic media with a 
decrease in release rate and a reduction of release quantity by 48% during the acidic test, 
showing a pH sensitive release functionality. Nanocomposites of GO and GO-FL degraded 
slower than pristine chitosan, with about 70% and 45% of their original mass remaining at 
week 2 compared to 18% for chitosan, due to the strong bonding of the GO with chitosan and 
the effect of the tortuous path model on the permeability of the enzyme. 
In conclusion, chitosan-2 wt.% GO nanocomposites showed improved mechanical 
properties and drug release properties in comparison to pristine chitosan, while also showing 
pH and drug-loading-ratio sensitive release. These improvements could allow for chitosan-GO 
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nanocomposites to be used for drug delivery applications such as microneedle arrays, where 
the increased strength would be needed to maintain microneedle rigidity and the drug release 
properties would allow for a quicker release of the drug into the body in comparison to what a 
pristine chitosan microneedle could achieve. 
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Chapter 4. Chitosan-reduced graphene oxide nanocomposites 
4.1 Introduction 
The chitosan-GO nanocomposites from Chapter 3 possessed improved mechanical properties 
and drug release rates over pristine chitosan, but the presence of GO did not impart new 
functionality, such as electrical conductivity, to the nanocomposite. As discussed in Section 
2.4.2, the electrical conductivity of GO is around 6 orders of magnitude lower than pristine 
graphene and so did not increase the conductivity of the resultant chitosan-GO nanocomposites. 
The focus of this chapter was on improving both the electrical conductivity and mechanical 
properties of chitosan-graphene nanocomposites by synthesising a reduced graphene oxide that 
is suitable for use for drug delivery purposes such as microneedle arrays. Central to this chapter 
is the facile and biocompatible manufacturing process of the rGO, achieved by mixing a 
chitosan solution and a GO dispersion at 37 oC for 72 h (see Scheme 4.1), which allows for the 
reduction of GO into rGO. This process does not require excessive heat, toxic solvents, or 
irradiation yet allows for the pre-loading of drugs into the material.  
Once synthesised, the rGO was characterised to compare it to GO and the effectiveness 
of the reduction technique is analysed. The rGO was used as the nanofiller for a chitosan 
nanocomposite, chitosan-rGO, which is enzymatically degradable and possesses the 
mechanical strength and controlled drug delivery required for potential uses in microneedle 
arrays. The effects of rGO addition and rGO concentration on the structure, glass transition 
temperature (Tg), crystallinity, mechanical properties, electrical properties, drug delivery 
performance and enzymatic degradation rate of chitosan were investigated and the optimised 
nanocomposite was subsequently used to form microneedle arrays.   
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Scheme 4.1: The experimental procedure to prepare chitosan-reduced graphene oxide (rGO) 
nanocomposites with the drug (FL) loaded onto the rGO nanosheets. During the reduction 
process, GO is dispersed in a chitosan solution; this promotes hydrogen and electrostatic 
bonding between the amine and hydroxyl groups of chitosan and the epoxy, carboxyl and 
hydroxyl groups of GO. The reduction procedure chemically grafts the chitosan onto the now-
reduced rGO. A drug, such as fluorescein sodium, can be introduced to the chitosan-GO 
mixture before reduction and loaded onto the chitosan-coated GO through hydrogen bonding 
or electrostatic forces [508].  
4.2 Experimental section 
4.2.1 Materials 
The following chemicals were reagent grade and used as purchased from Sigma Aldrich; acetic 
acid, sulphuric acid, hydrogen peroxide, potassium permanganate, sodium nitrate, fluorescein 
sodium, phosphate buffered saline, and graphite powder (≤ 20 mm). Chitosan powder (Mw ¼ 
100 000–300 000) was used as purchased from Fisher Scientific. Foetal calf serum (FCS) was 
kindly provided by Dr. Ingunn Holen of the University of Sheffield. 
4.2.2 Preparation of graphene oxide 
The method for making GO has been described before in Chapter 3. Briefly, GO was 
synthesized from a modified Hummers method [186,187]. Graphite (3 g) was added to 
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sulphuric acid H2SO4 (69 ml) and sodium nitrate NaNO3 (1.5 g). The mixture was stirred 
vigorously for 30 min in an ice bath. Potassium permanganate KMnO4 (9 g) was added slowly, 
and when fully added the mixture was heated to 35 oC and stirred for 12 h. Potassium 
permanganate (9 g)  was added to the mixture and stirred for 12 h before being poured over a 
mixture of ice (400 ml) and 30% hydrogen peroxide H2O2 (3 ml). The graphite oxide 
suspension was centrifuged at 8000 rpm for 1 h in an Eppendorf 5804 with the supernatant 
being discarded. The graphite oxide was dispersed in fresh distilled water for a total of five 
cycles to remove residue chemicals from the production process. Graphite oxide was dried in 
a vacuum oven and stored in powder form in a desiccator. When required, graphite oxide was 
exfoliated in distilled water for 2 h by a Fisherbrand sonication bath (230 V, 50 Hz) and 
centrifuged at 8000 rpm for 30 min to remove larger than desired particles. The supernatant 
dispersion was collected and lyophilized in a Labconco FreeZone Triad freeze-dryer to be 
stored in powder form in a desiccator 
4.2.3 Preparation of reduced graphene oxide 
1 g of chitosan was added to a 100 ml solution of 2 wt.% acetic acid in water and stirred 
overnight to allow for complete dissolution of the chitosan. 1 g of GO was dispersed in 100 ml 
of distilled water by intense stirring and sonication. The two solutions were combined and 
heated at 37 oC for 72 h under constant stirring. This solution was centrifuged at 8000 rpm for 
1 h in an Eppendorf 5804 to separate the reduced graphene oxide (rGO) flakes from the aqueous 
chitosan solution and then washed with 2% acetic acid solution for three cycles to remove the 
excess chitosan. The rGO was dispersed in the distilled water by a Fisherbrand sonication bath 
(230 V, 50 Hz).  
4.2.4 Drug loading onto reduced graphene oxide 
One gram of GO was dispersed in 100 ml of distilled water by intense stirring and sonication. 
Simultaneously, 1 gram of chitosan was added to a 100 ml solution of 2 wt.% acetic acid in 
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water. The two solutions were combined and stirred intensely for 5 h at room temperature to 
ensure bonding has occurred. FL powder (0.84 g) was added to the mixture and heated at 37 
oC for 72 h under stirring. Unbound FL and free chitosan in the supernatant were removed from 
the solution through intense centrifugation at 8000 rpm for 1 h in an Eppendorf 5804 and the 
rGO-FL powder was then washed with distilled water and acetic acid solution twice.   
4.2.5 Preparation of chitosan-graphene nanocomposites by in-situ reduction 
Chitosan was added to a solution of 2 wt.% acetic acid in water and stirred for 24 h (Scheme 
4.1). The required concentration (0.25, 0.5, 1, 2, 5, 7 and 10 wt.%) of GO was added to the 
chitosan and acetic acid solution. The temperature of the resultant suspension was then raised 
to 37 oC for 72 h under stirring to allow for the interaction of chitosan and GO and to reduce 
the GO. The suspension was degassed in a sonication bath for 30 min. The suspension was 
poured into a mould and allowed to air dry. Prior to testing, film was placed in an oven for 1 h 
at 50 oC.  
To prepare drug loaded rGO chitosan nanocomposites, the same procedure was applied 
with the required concentration (1 or 2 wt.%) of GO in water added to the chitosan and acetic 
acid solution and stirred for 5 h. After this, FL (1.2 wt.%) was added into the suspension which 
was subsequently heated at 37 oC for 72 h under stirring for the reduction of GO and bonding 
of FL onto the rGO. Due to the amounts of GO used to prepare the chitosan-rGO 
nanocomposites, the terms 1 wt.% and 2 wt.% rGO nanocomposites were used subsequently 
in this paper.   
4.2.6 Structural characterisation 
A Perkin Elmer Lambda 900 spectrometer was used for UV-Vis spectroscopy (1 nm 
resolution). A Perkin Elmer Spectrum 100 with a diamond attenuated total reflectance 
(diamond-ATR) unit was used for FT-IR spectroscopy at a resolution of 1 cm-1. A Stoe Stadi 
P with Cu Ka1 irradiation (0.15406 nm wavelength) was used for XRD. Measurements were 
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taken from 2–40 o (2θ) with a scanning speed of 1o min-1 at 40 kV and 35 mA. Atomic force 
microscopy of rGO sheets laid on a mica substrate was achieved through a Veeco Dimension 
3100 atomic force microscope with Olympus AC160TS probes in tapping mode at 0.5 Hz. A 
Coulter LS130 was used for laser scattering particle sizing from 0.1 to 900 μm, with particles 
analysed using 3 one minute runs of nanoparticles in an aqueous solution. Powders were tested 
in a Perkin Elmer Pyris 1 between 40 to 600 oC at 5 oC min-1 for thermogravimetric analysis 
under a nitrogen atmosphere. Raman spectroscopy was achieved using a Renishaw inVia 
Raman microscope at a wavelength of 785 nm between 50-4000 cm-1 with a 0.5 cm-1 resolution, 
with laser power reduced to 5% to avoid laser induced heating. A Perkin Elmer DSC 6 was 
used to analyse the glass transition temperatures of chitosan nanocomposites. Samples were 
initially raised from 30 oC to 200 oC at a rate of 30 oC min-1 in a nitrogen environment before 
cooling to 30 oC at a rate of 20 oC min-1 to remove the thermal history of the specimens. 
Thermographs were measured from the second heating which was identical to the first stage. 
The density of specimens (preheated at 60 oC in a vacuum oven for 6 h) was determined by gas 
pycometry using a Micromeritics AccuPyc II 1340 using 50 purge cycles of helium gas and 10 
density calculation cycles.  
4.2.7 Tensile testing  
Tensile testing was achieved with a Hounsfield twin column tensometer using a 1kN load cell 
and a 1 mm min-1 strain rate in accordance with ISO-527 (1 and 2). Specimens (n = 5) were of 
a dog bone shape with the narrow test section between grips measuring 22 mm in length, 2.7 
mm in width and 1mm in thickness. 
4.2.8 Electrical testing  
Chitosan nanocomposites of 0, 0.25, 0.5, 1, 2, 5, 7, 10 wt.% rGO were measured using a 
Thurlby DMM 1905a. Silver paint (RS 186-3600) was applied to the ends of test samples (n = 
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5) to form contact points. The device was calibrated using metal wire (steel, copper and 
aluminium). 
4.2.9 Drug release testing 
rGO-FL nanoparticles (40 mg) was placed in PBS solution (20 ml, pH = 7.5 or 4) at 37 oC. 
This solution was added to a dialysis bag (Fisher Scientific Biodesign Dialysis tubing DO14, 
Mw cut off = 14 kDa) which was then submerged in 100 ml of PBS of the same pH as within 
the dialysis bag. A known quantity of solution from the container was removed after every time 
step, making sure to replace it with the same amount of fresh PBS solution. UV-Vis 
spectroscopy in a Perkin Elmer Lambda 900 determined the release rates of the drug. The 
quantity of FL was determined by comparing the absorbance peaks at 320 nm with solutions 
of free FL of known concentration.  
Nanocomposite specimens (n = 5) were placed in a phosphate buffered saline (PBS) 
solution (30 ml) at 37 oC and gently agitated at 100 rpm in a Stuart SI500 shaking incubator. 
A known quantity (2 ml) of solution from the container was removed after every time step, 
making sure to replace it with the same amount of fresh PBS solution. UV-Vis in a Perkin 
Elmer Lambda 900 determined the release rates of the drug from the nanocomposite in neutral 
(pH = 7.4) and acidic (pH = 2, 5.5, and 6.5) conditions. The quantity of FL was determined by 
comparing the absorbance peak at 450 nm of the test samples with solutions of free FL of 
known concentration (from 0.001 to 1 mg ml-1) in water, similar to the procedure used to 
measure the quantity of FL in solution during the loading of the drug onto the GO.  
4.2.10 Enzymatic degradation analysis  
Enzymatic degradation tests have been described elsewhere [497,498]. Briefly, the polymer 
films were submersed in a PBS solution (pH = 7) at 37 oC containing the enzyme lysozyme at 
a natural concentration within the body, 1.5 μg ml-1  [449,499]. Samples were maintained at 37 
oC and were gently agitated. At regular intervals, each specimen was removed from the beaker, 
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washed with distilled water, dried in a vacuum oven, and the mass measured. The sample was 
placed into fresh PBS and lysozyme solution to maintain constant enzymatic activity. For each 
sample type, there were 5 specimens for mass analysis and two sacrificial specimens for 
characterization analysis. The stability of rGO and GO suspensions in biological mediums was 
tested by visual analysis of rGO and GO suspensions (concentration of 0.3 mg ml-1) in FCS, 
PBS and distilled water over 28 days. 
4.2.11 Microneedle preparation and analysis  
Microneedles containing 2 wt.% rGO-FL were created to assess the performance of rGO 
nanocomposites in transdermal drug release applications. Microneedle male moulds were 
designed through finite element analysis modelling using Autodesk Inventor Professional 2014 
and then produced on our behalf by Shapeways (USA). Microneedles were a 10 by 10 array of 
100 microneedles, with each microneedle consisting of a cylindrical base (starting diameter of 
310 µm tapering to 200 µm and a height of 150 µm), a main shaft (diameter of 200 µm and 
height of 300 µm), and a cone (tapering from 200 to 40 µm and a height of 150 µm) (Scheme 
4.2). Microneedles were prepared by filling female silicone moulds with excess amounts of 
high viscosity 2 wt.% rGO-FL chitosan mixture (Scheme 4.2), centrifuging the moulds at 8000 
rpm for 1 h and cleaning away the excess suspension from the mould [152]. The mould was 
allowed to air dry. The process of filling the mould and centrifuging was repeated twice more 
to guarantee that the cavities were fully filled.   
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Scheme 4.2: Procedure to create chitosan - 2 wt.% rGO-FL microneedle arrays.  
 Microneedles were mechanically tested for structural rigidity under compressive loads 
with a Hounsfield twin column tensometer using a 10 N and a 1 kN load cell with a 1 mm min-
1 strain rate. Images were taken of the compression testing with a Veho VMS-001 digital 
microscope under normal white light. The dissolution of FL from microneedles was visualized 
using pseudo-in vivo methods [120], with microneedles inserted into a hydrogel of gelatin (4.5 
g in boiling water (40 ml) and allowed to set before the upper surface was covered with paraffin 
tape). Images were taken of the dissolution of FL through the hydrogel with a Veho VMS-001 
digital microscope under normal white light and UV light (365 nm). 
  
103 
 
4.3 Results and discussion 
4.3.1 Characterisation of reduced graphene oxide 
 
Figure 4.1: (A) XRD curves for graphite, graphite oxide, GO, and rGO. (B) UV-Vis absorption 
spectra for GO, rGO created at 20 oC or 37 oC for 72 h or 90 oC for 9 h, and chitosan.  
As discussed in Section 2.4.2 (page 29), the oxidation procedure to create GO creates 
ample functional groups that improve the bonding of GO to other molecules [190] and give it 
excellent dispersibility within many solvents [191], though the oxidation procedure does 
reduce the mechanical and electrical conductivity properties [192–194]. By partially restoring 
the structure to that of pristine graphene by removing the functional groups created during 
oxidation, rGO can maintain the dispersibility of GO but also restore some of the material 
properties of pristine graphene. Figure 4.1A shows the XRD curves for graphite, graphite 
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oxide, GO, and rGO. Graphite, graphite oxide, and GO have been discussed in Chapter 3, 
Figure 3.1B. The creation of a broad peak for rGO at 2θ = 23o is synonymous with the creation 
of partially reduced rGO, where the crystalline structure has nearly returned to that of pristine 
graphene or graphite (2θ = 26o), which is in keeping with the literature [399].  
 
Figure 4.2: (A) FT-IR spectra for GO and rGO created at 37 oC for 72 h or 90 oC for 9 h. (B) 
TGA of GO, chitosan reduced rGO, and chitosan. 
Figure 4.1B shows the UV-Vis spectra of GO, rGO created at 20 oC or 37 oC for 72 h 
or 90 oC for 9 h, and chitosan. For GO, there are two noticeable peaks; the peak at 230-235 nm 
corresponds to the change in electronic state level from π→π* for C = C bonds, and the peak 
at 300 nm corresponds to the change in electronic state level from n→π* for C = O bonds 
[187,520]. The successful reduction can be seen for the rGO curve created at 37 oC for 72 h as 
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the shoulder peak of C = O bonds at 300 nm has been reduced and is no longer a noticeable 
feature of the curve. A shift has also occurred of the wavelength attributed to the π→π* change 
of C = C bonds, shifting to 260 nm due to the restoration of the π transition network that is seen 
in graphene nanosheets and CNTs [210]. These changes are similar to the rGO created by 
heating at 90 oC for 9 h, showing that body temperature reduction is a suitable alternative to 
high temperature reduction processes. There was no such shift in the peaks for the rGO curve 
created at 20 oC for 72 h suggesting this temperature did not reduce the GO in this time frame. 
The UV-Vis spectra for GO treated at 20 oC and 37 oC at different time steps (Figure 4.S1, 
Appendix 1) highlight the gradual reduction of GO when treated at 37 oC over 72 h. There is 
no change in the curve for GO treated at 20 oC which shows the importance of both the use of 
temperature and the functionalisation with chitosan to the reduction process. 
Figure 4.2A shows the FT-IR spectra of GO and rGO created at 37 oC for 72 h or 90 oC 
for 9 h. The rGO created at 37 oC or 90 oC possesses the same peaks, again showing the 
similarity between the two reduction processes and the effectiveness of the body temperature 
reduction method. The peak intensities of C-O bonds (1050-1060 cm-1), the C=O bonds (1700-
1750 cm-1) and the O-H bonds (3400 cm-1) from GO decrease significantly after reduction. The 
C=C bonds can be seen at 1600-1650 cm-1 with amino groups and C-OH bonds from the 
chitosan (1530 cm-1 and 1400 cm-1). The amino (-NH2) groups of chitosan react with the 
oxygenated groups (C=O and C-O) of GO to reduce the GO in rGO in a direct “redox” reaction, 
where chitosan is chemically grafted onto rGO sheets [214]. Besides chemical bonding, 
hydrogen bonding and electrostatic forces are also present between the remaining oxygenated 
functional groups of rGO and the amino and hydroxyl groups of chitosan [214]. This is shown 
in Scheme 4.1. 
Figure 4.2B shows the thermogravimetric analysis (TGA) curves of GO, chitosan and 
rGO which allows for a determination of the reduction in oxygen groups present on rGO and 
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the content of chitosan. Eliminating free water that was removed below 100 oC for all samples, 
the GO powder lost 45% of its mass during the first decomposition stage at 195-230 oC, while 
rGO lost 13% of its mass. This represents a 73% reduction in oxygen functional groups through 
the facile reduction process. The mass loss (33%) for the rGO between 280 and 320 oC can be 
mainly attributed to the degradation of the glucosamine in the chitosan coating [214], similar 
to pristine chitosan (mass loss of 39% between 280 to 320 oC). Taking into account these two 
mass losses, the mass loss of GO at this temperature range (3.2%), and the oxygen reduction 
degree, the chitosan content in the original rGO was estimated at 85%. 
 
Figure 4.3: Raman intensity curves for graphite, GO, and rGO. 
Raman spectroscopy, Figure 4.3, further confirms the successful reduction of GO into 
rGO at 37 oC. Transition for the G band from 1581 to 1590 to 1597 cm-1 for graphite, GO, and 
rGO respectively show a change in the e2g mode of sp
2 [210,216]. Similarly, the D band shifts 
from 1318 to 1322 to 1313 cm-1 for graphite, GO, and rGO respectively show a change in the 
breathing mode of  a1g symmetry [208]. The blue shift in the G band for rGO can be attributed 
to the partial reduction of oxide groups and the strong interaction between the rGO and chitosan 
[210,214,216]. 
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Figure 4.4: Laser scattering particle sizing of rGO nanosheets in an aqueous solution. (Inset) 
AFM image of a rGO nanosheet on a mica substrate The height profile for the AFM image 
shows a thickness of 3.5 nm for a single layer sheet, the edge of which is highlighted by red 
arrows. 
The hydrodynamic diameter of rGO was determined as 0.85 to 5 µm from laser sizing 
analysis (Figure 4.4), noting that the latter assumed the particles were spherical rather than in 
sheet form.  As identified through AFM (Figure 4.4 (Inset)), the thickness of each rGO 
nanosheet is ~3.5 nm, confirming the formation of a protective chitosan coating on graphene 
nanosheets as each nanosheet of GO is around 1 nm (Figure 3.1). 
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Figure 4.5: (A) TGA spectra for rGO, rGO-FL and FL powder showing the loading ratio of 
FL:rGO to be 0.26:1, once free water has been eliminated. (B) FT-IR spectra for rGO, rGO-FL 
and FL powder. 
Drug grafted rGO nanohybrids (rGO-FL) were created through mixing chitosan with 
GO for 5 h initially and then subsequently mixing with FL at ambient temperature, followed 
by reduction at 37 oC for 72 h and removal of the unbound FL. Bonding is through the carboxyl 
groups of FL with the amine and hydroxyl groups of chitosan and the epoxy, carboxyl and 
hydroxyl groups of GO. The loading ratio of FL:rGO was determined by TGA to be 0.26:1 
(Figure 4.5A). The success of the combined drug grafting and reduction procedure can be 
confirmed by FT-IR analysis (Figure 4.5B) that shows that characteristic peaks of both rGO 
(1050 cm-1, 1400 cm-1, 1530 cm-1)  and FL (840 cm-1, 1100 cm-1, 1450 cm-1) are present on the 
rGO-FL curve. The peak intensities of C=O (98% for both rGO and rGO-FL) and C-O (87% 
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for rGO and 92% for rGO-FL) were similar for both rGO and rGO-FL when the curves were 
normalised, which demonstrates that the reduction process was not hampered by the grafting 
of the drug and worked to create the rGO-FL hybrid. 
 
Figure 4.6: Drug release from rGO-FL powder in PBS solution (pH = 4 or 7.4) over 72 h. 
The cumulative release of FL from rGO-FL in PBS (pH = 4 and 7.4) over 72 h is shown 
in Figure 4.6. FL can be seen to diffuse from the rGO nanosheets in a PBS solution, with the 
maximum value of 10.2 mg ml-1 (91%) occurring around 72 h in a pH = 7.4 release medium. 
There was a quick initial release, with 2.78 mg ml-1 (25%) and 4.16 mg ml-1 (37%) released 
after 3 h and 8 h respectively, potentially allowing rGO bound drugs to be used for applications 
where a quick release is necessary. This initial release rate lowered until a plateau of 10.2 mg 
ml-1 (91%) was reached around 72 h. In an acidic medium, the release rate is much lower, 
achieving a maximum value of 1.2 mg ml-1 (11.1%) after 72 h. This compares to a value of 
3.18 mg ml-1 released in a neutral medium after 6 h. This pH sensitivity can be explained by 
the change of rGO dispersion in the medium. When in the neutral release medium, rGO 
nanosheets were well dispersed and stable in the medium due to electrostatic repulsion from 
the amine groups of its coating material chitosan as previously discussed [216]. When in the 
acidic release medium, chitosan is dissolved and so the electrostatic repulsion decreases, and 
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the electrostatic attraction, caused by the carboxyl and hydroxyl groups in GO and the salt in 
PBS, prevails. This leads to the aggregation of rGO sheets in the medium which prevents the 
efficient release of FL [513]. This pH sensitivity will allow for the drug grafted-rGO to be used 
for applications such as site specific drug delivery to regions like the colon, and prevent 
undesirable side effects by limiting the release of the drug in acidic areas like the stomach 
(gastric acid has a pH of  ~2 [521]). 
 
Figure 4.7: The biostability of the (A, C, E) GO and (B, D, F) rGO nanosheets in solutions of 
(A-B) distilled water, (C-D) foetal calf serum, and (E-F) phosphate buffered saline (pH = 7.4). 
For the rGO to be used for drug delivery in vivo, the rGO will have to be stable within 
bodily fluids. If it is not stable, it may aggregate and this will hinder the release of drug. The 
biostability (Figure 4.7) of the GO and rGO nanosheets in solutions of distilled water, foetal 
calf serum (FCS, pH = 7.4), and phosphate buffered saline (PBS, pH = 7.4) is shown over the 
course of 4 weeks. The rGO sheets remain stable and in dispersion within all of the fluids (B, 
D, F) , which is attributed to the chitosan coating. The GO sheets without a chitosan coating 
aggregated in the FCS (C) and PBS (E) which can be seen at the bottom of the containers, 
though they were stable in distilled water (A). Presumably the GO aggregated in the FCS 
solution due to the physical crosslinking of GO by proteins in the FCS and in PBS due to 
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electrostatic forces caused by the salt in PBS [210,522]. Chitosan maintained an electrostatic 
repulsion through the positively charged amine groups, allowing the rGO nanosheets to remain 
well-dispersed when in biological fluids [216]. 
4.3.2 Characterisation of chitosan-rGO nanocomposites 
 
Figure 4.8: FT-IR spectra of chitosan nanocomposites containing 0-10 wt.% rGO. 
The results from Section 4.3.1 show that GO was reduced by the body temperature reduction 
process, and so chitosan nanocomposites of 0, 0.25, 0.5, 1, 2, 5, 7, and 10 wt.% rGO were 
prepared by the same in-situ reduction process, i.e. the reduction of known quantities of GO in 
chitosan solution at 37 oC for 72 h and subsequent air drying. Figure 4.8A shows the FT-IR 
spectra of chitosan nanocomposites and their control samples of GO and rGO nanosheets. For 
the nanocomposites, strong peaks from the chitosan can be seen at 2800 cm-1 (N-H), 1633 cm-
1 (C=C), 1400 cm-1 (C-OH), 1000 - 1100 cm-1 (C-O), and at 1530 cm-1 (amino groups) 
[466,482], similar to the rGO control sample in Figure 4.2A. In comparison to chitosan-GO 
nanocomposites at the same concentrations, the spectra of these nanocomposites have a much 
weaker peak of the 1720 cm-1 C=O bonds (which can be clearly identified in the spectrum for 
GO), confirming successful reduction of GO into rGO. Chitosan-GO nanocomposites possess 
a prominent 1720 cm-1 C=O peak, even at low concentrations.  The C=C peaks have shifted 
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from 1633 cm-1  for pristine chitosan to 1629 cm-1 for the nanocomposites due to the presence 
of rGO and the peak for amino has shifted from 1546 cm-1 for pristine chitosan to 1539 cm-1 
for the nanocomposites. This is presumably due to the strong covalent bonding between the 
chitosan and the graphene nanosheets (Scheme 4.1) during the reduction process which utilizes 
the amino groups of chitosan and the hydroxyl and epoxy groups of GO [214]. 
 
Figure 4.9: XRD traces of chitosan nanocomposites containing 0-10 wt.% rGO with crystalline 
peaks highlighted with the symbol “C”. 
Figure 4.9 shows the XRD analysis of chitosan-rGO nanocomposites. Chitosan can be 
identified by the crystalline peaks at 2θ = 8, 11, and 18o and the broad, amorphous peaks at 2θ 
= 23o [396,397]. Crystallinity can be determined from Equation 3.1 (Chapter 3). The results of 
the crystallinity analysis are shown in Table 4.1, showing that the presence of rGO increases 
the crystallinity of the nanocomposites in relation to pristine chitosan (15.3%). The crystallinity 
increased in general as the rGO concentration increased to 7 wt.% (18.9%), before decreasing 
at 10 wt.% (17.7%). On one hand, the presence of rGO increased the nucleation of crystals 
within the chitosan matrix [504], while on the other hand it limited the mobility of polymer 
chains restricting rearrangements of the polymer chains into ordered crystalline structure. In 
these cases, the former was the dominant factor. In the case of the 10 wt.% rGO, the decrease 
in crystallinity in comparison to the 7 wt.% rGO nanocomposite may be due to the partial 
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aggregation of the rGO within the nanocomposite, thereby decreasing the number of viable 
nucleation points that would be possible if the rGO was fully exfoliated. The crystallinity data 
of chitosan-rGO nanocomposites are lower than those of chitosan-GO nanocomposites 
(Chapter 3) at the same graphene concentrations (32.0, 23.3, 25.4, 27.3, and 21.5% for 0.25-5 
wt.% GO), presumably due to the reduction process decreasing the chain mobility of the 
chitosan more substantially, arising from the covalent bonding in comparison to hydrogen 
bonding and electrostatic forces (chitosan-GO nanocomposites). 
Table 4.1: Crystallinity and glass transition temperature of chitosan-rGO nanocomposites 
rGO content / wt.% Crystallinity / % Glass transition temperature / oC 
0 15.3 134.1 
0.25 16.5 134.7 
0.5 18.1 138.5 
1 17.8 144.2 
2 18.1 160.9 
5 18.5 165.6 
7 18.9 171.9 
10 17.7 173.5 
 
Figure 4.10: DSC traces of chitosan nanocomposites containing 0-10 wt.% rGO. 
Figure 4.10 and Table 4.1 show the results of the DSC analysis of chitosan-rGO 
nanocomposites of varying rGO concentration. The presence of rGO significantly alters the 
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glass transition temperature (Tg) of chitosan, with a maximum increase of 39 
oC achieved for 
the 10 wt.% nanocomposite (173 oC versus 134 oC). The value for pristine chitosan is similar 
to the reported literature (140 oC) [523]. Similar large (30 oC) increases in Tg were observed in 
PMMA and were attributed to a good dispersion of graphene and to a strong bonding 
interaction between the graphene and the polymer [359]. The chemical bonding of the polymer 
chains to the rGO surface can restrict the movement of the polymer chains, increasing the 
temperature at which the polymer changes from a brittle state to a softer, rubber-like state. As 
well as the quality of bonding, the degree of exfoliation of the nanoparticles (higher degree of 
exfoliation equals a higher surface area and more bonding sites per gram) and the degree of the 
dispersion within the polymer matrix also affect the Tg [524,525]. 
 
Figure 4.11: Tensile stress versus strain curves of chitosan nanocomposites containing 0 - 5 
wt.% rGO. 
Representative curves for chitosan and rGO nanocomposite specimens of 0, 0.25, 0.5, 
1, 2 and 5 wt.% rGO are shown in Figure 4.11. Pristine chitosan undergoes a brittle failure, 
which is attributable to the mild heating process applied to prepare the chitosan film in the 
same manner as used to produce the chitosan-rGO nanocomposites. The heating process might 
cause the thermal crosslinking of the amino groups in chitosan [526], leading to an increase in 
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the E from 1 to 1.38 GPa, UTS from 24.2 MPa to 55.4 MPa and a small reduction in the εb 
from 14.5% to 8.2% in comparison to the values recorded in Chapter 3.  
Table 4.2: The mechanical properties of chitosan-rGO nanocomposites.  
GO content / wt.% E / GPa UTS / MPa Εb / % 
0 1.38 ± 0.15 55.4 ± 3.9 8.2 ± 1.7 
0.25 1.75 ± 0.25 73.6 ± 4.2 11.6 ± 1.2 
0.5 1.95 ± 0.26 41.1 ± 5.4 8.0 ± 1.7 
1 2.64 ± 0.15 80.9 ± 20.8 10.8 ± 1.0 
2 2.25 ± 0.43 65.6 ± 4.6 6.7 ± 0.6 
5 0.69 ± 0.28 9.5 ± 3.3 5.3 ± 2.0 
 
The introduction of rGO into chitosan has improved the Young’s modulus recorded for 
samples of 0.25-2 wt.%, from 1.38 GPa up to 2.64 GPa (Table 4.2). This is due to rGO being 
an effective nanofiller, with a high Youngs modulus over 180 GPa [527,528], a high aspect 
ratio and a high surface area. The UTS values of the nanocomposites of 0.25-2 wt.%, are in 
general higher than the pristine chitosan, increasing from 55.4 MPa up to 80.9 MPa, apart from 
the 0.5 wt.% nanocomposite that has a UTS of 41.1 MPa. Enhancements of the UTS may be 
attributed to the high strength of rGO and effective stress transfer originated from the strong 
covalent bonding between chitosan and rGO. Samples containing 0.25 and 1 wt.% rGO have a 
higher εb (11.6% and 10.8% respectively) and the 0.5 wt.% sample has a similar εb (8%) than 
pristine chitosan (8.2%), presumably due to a good dispersion of rGO within the 
nanocomposites and the mobility of rGO nanosheets during testing [369,400]. This is 
presumably due to the covalent bonding between rGO and chitosan which prevents the 
realignment of the chitosan chains when the nanocomposite is placed under strain, similar to 
other chitosan-rGO nanocomposites [209]. Samples containing 2 wt.% rGO failed at a slightly 
lower εb than pristine chitosan, which may be attributable to a poorer dispersion of rGO within 
the nanocomposite because of the higher rGO concentration.  
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The 5 wt.% rGO nanocomposite was brittle due to the inadequate dispersion of rGO 
within the nanocomposite and failed at a low E, UTS and εb. Nanocomposites with even higher 
rGO concentrations (7 wt.% and 10 wt.%) were too brittle to form into test specimens using 
the current procedure, and were therefore not tested.  
 
Figure 4.12: Halpin-Tsai modulus prediction estimates of chitosan nanocomposites, using both 
nominal and effective volume fractions of rGO in comparison with the experimental data. 
The modified Halpin-Tsai method (Equations 4.2 to 4.5) allows for the calculation of 
the Young’s modulus of nanocomposites with randomly orientated nanosheets [529,530]. 
𝐸 =  
1 +
2𝑙𝑟𝑔𝑜
3𝑡𝑟𝑔𝑜
× 𝜂1 × 𝑉𝑔
1 − 𝜂1 × 𝑉𝑔
                                                          (4.2) 
where: 
𝜂1 =  
𝐸𝑔
𝐸𝑝
− 1
𝐸𝑔
𝐸𝑝
+  
2𝑙𝑟𝑔𝑜
3𝑡𝑟𝑔𝑜
                                                                   (4.3) 
 
The nominal filler volume fraction, Vg, can be determined from: 
𝑉𝑔 =
𝑋
𝜌𝑔
𝑋
𝜌𝑔
+
100 − 𝑋
𝜌𝑝
                                                        (4.4) 
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where Eg and Ep are the Youngs modulus of chemically reduced GO (217.5 GPa, taken from 
the average Young’s modulus of rGO reported in two papers, 185 GPa [527] and 250 GPa 
[528]) and chitosan (1.38 GPa) respectively, X is the wt.% of rGO within the nanocomposite,  
lrgo and trgo are the length (1 µm) and thickness (3.5 nm) of the single rGO nanosheets taken 
from AFM and laser sizing analysis (assuming the nanocomposites are fully exfoliated within 
the matrix), and ρg and ρp are the densities of rGO and chitosan (3,120 kg m-3 and 1,458 kg m-
3 from gas pycometry of rGO and chitosan powder, respectively). The effective filler volume 
fraction, Vge, which takes into account the contribution of the adsorbed or attached polymer 
chains, can be determined from [506]: 
𝑉𝑔
𝑒 = 𝑉𝑔 × (1 + (𝑘𝑐 × 𝑅 × 𝐴 × 𝜌𝑔))                                       (4.5) 
where kc is a constant relevant to the ratio of the modulus of the adsorbed chitosan to the 
modulus of rGO and the thickness of the adsorbed layer (assumed as 0.22) [369,400,506], A is 
the specific surface area of chemically reduced GO (determined as 466 m2 g-1 by B.E.T. surface 
area analysis) [203], and R is the radius of gyration of chitosan chains (52.5 nm) [531]. The 
results of the calculations are shown in Figure 4.12. It can be seen that in general the modified 
Halpin-Tsai model for randomly aligned nanocomposites using the nominal volume fraction 
underestimated the nanocomposites with lower rGO concentrations while the theoretical values 
calculated using the effective volume fraction show good correlation, which is consistent with 
previous studies on polymer-graphene nanocomposites [369,400]. Unlike the effective volume 
fraction method, the nominal volume fraction method did not consider the contribution of the 
interface to the modulus, thus giving lower theoretical values. At higher rGO concentrations (2 
wt.%), the model with the effective volume fraction overestimated the experimental value, 
presumably due to the poorer dispersion of rGO sheets in the matrix. As previous described, 
this method assumes that the graphene sheets are fully exfoliated within the polymer matrix, 
which may not be the case for the 2 wt.% nanocomposite.  
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A high Young’s modulus and a high mechanical strength are both important for 
microneedles as they are key parameters to determine the buckling and bending force failure 
values. Another key parameter is a high content of rGO which will allow for a considerable 
quantity of bonded drug to be included into the microneedle. The strongest nanocomposite 
contained 1 wt.% rGO, with increases of 95.6% for UTS to 80.9 MPa and 91.3% for Young’s 
modulus to 2.64 GPa in contrast to pristine chitosan, whilst enhancing the ductility of pristine 
chitosan by 31.7%. The nanocomposite containing 2 wt.% rGO had an increase of 63.0% for 
Young’s modulus and a 18.4% higher UTS than the pristine chitosan, which are lower than the 
increases found for the 1 wt.% nanocomposite. The higher content of rGO in the 2 wt.% 
nanocomposite, however, offers a higher drug loading capacity relative to the 1 wt.% 
nanocomposite. So, both nanocomposites were chosen for drug release and enzymatic 
degradation analysis.  
 
Figure 4.13: Conductivity versus rGO concentration of chitosan nanocomposites containing 
0-10 wt.% rGO. 
The electrical conductivity of chitosan and rGO nanocomposites of 0, 0.25, 0.5, 1, 2, 5, 
7 and 10 wt.% rGO are shown in Figure 4.13. It has been shown previously that the diffusion 
of therapeutics from microneedle arrays can be improved by the process of iontophoresis [133–
135,532], which is the electro-repulsion of charged molecules by an electrical field from 
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one electrode towards the other electrode [62]. If the chitosan-rGO nanocomposites are 
suitably conductive, they may be used as combined iontophoresis-microneedle array 
devices with improved drug delivery, relative to conventional microneedle arrays. 
Conductivity can be measured by calculating the inverse of resistivity, shown in Equation 4.6. 
There is a significant increase in conductivity between the pristine chitosan and the 0.25 wt.% 
rGO nanocomposite, with similar values between the nanocomposites of 0.25 wt.% to 2 wt.% 
rGO, and further increases between 2 wt.% and 7 wt.% rGO. The initial, major conductivity 
increase is at 0.25 wt.% rGO, therefore this concentration is presumed to be the percolation 
threshold [403]. The maximum conductivity of 0.06 S m-1 was achieved at 7 wt.% rGO, with 
conductivity dropping at 10 wt.% rGO to 0.03 S m-1. All of the nanocomposites have a 
conductivity value similar to or higher than other conductive polymer-GO or rGO 
nanocomposites (Chapter 2, Table 2.3).  
Resistivity (Ωm)=Resistance (Ω )×
area (m2)
length (m)
                               (4.6) 
The reason behind the increase in conductivity is that graphene has a high electrical 
conductivity (electron mobility of 10,000 cm2 v-1 s-1) [179]. The dispersion and the degree of 
exfoliation are also important in order to avoid the formation of aggregates of graphite within 
the nanocomposites. With this in mind, the reduction in conductivity of the 10 wt.% in 
comparison to the 7 wt.% nanocomposite, despite having a higher concentration of rGO, can 
be attributed to a poorer dispersion and/or a lower degree of exfoliation within the 10 wt.% 
nanocomposite.  
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Figure 4.14: Cumulative drug release (mg) and percentage drug release (%) from rGO-FL 
nanocomposites (1 and 2 wt.% rGO) in a neutral (pH = 7.4) and acidic (pH = 4) environment. 
(B) Cumulative drug release (mg) from rGO-FL nanocomposites and Higuchi equation 
simulation of FL release from 1 wt.% and 2 wt.% rGO nanocomposites in pH = 7.4 PBS 
solution. 
Figure 4.14 shows the cumulative and percentage of total drug released in a neutral 
environment (pH = 7.4) and an acidic environment (pH = 4) over 168 h. Similar to the chitosan-
GO nanocomposites in Chapter 3, bonding rGO to FL within chitosan improves the drug 
release performance in comparison to pristine chitosan. This can be seen by comparing the 
chitosan rGO-FL nanocomposites to a hybrid of chitosan and free FL (Chapter 3) with the same 
quantity of FL. The chitosan-FL hybrid has a plateau after 120 h at 0.39 mg or 36% of the drug 
in the sample. The nanocomposites have both a quicker and more substantial delivery of the 
drug than the hybrid of chitosan and free FL, with the 2 wt.% nanocomposite achieving a 
maximum release of 91% of the available drug (1.09 mg) after 48 h and the 1 wt.% 
nanocomposite achieving a release of 75% (0.91 mg) after 24 h. The drug release from the 
nanocomposites plateaued and the cumulative release values remained effectively consistent 
until the end of the test.  
The nanocomposites of 1 wt.% and 2 wt.% rGO with a loading of 1.2 wt.% FL were 
tested for their pH responsive drug release performance (Figure 4.14). When submerged in 
acidic solution (pH = 4), the release of FL from the nanocomposites was reduced in comparison 
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to release profiles in neutral conditions (69.2% reduction for the 1 wt.% and 69.5% reduction 
for the 2 wt.% nanocomposite). Samples of pristine chitosan fully dissolved within less than 
12 h in the acidic medium which did not occur with the chitosan-rGO nanocomposites, showing 
that the presence of rGO nanosheets improves the resistance of chitosan to acid. Similar to the 
neutral condition test, rGO concentration affected the release performance of the 
nanocomposite with the 2 wt.% nanocomposite releasing 0.32 mg (or 27% of the available drug 
in the tested specimens) after 30 h and the 1 wt.% nanocomposite achieving a release of 0.28 
mg (or 24% of the available drug) after 48 h.  
The decrease in the release of FL from the rGO-FL into the acid medium compared to 
the case with the neutral medium, despite the low pH assisting in the swelling and presumably 
the partial dissolution of the chitosan nanocomposite, allows for pH sensitivity that will limit 
the release of the drug in areas of low pH, such as the stomach, and will increase the release in 
areas of neutral pH (e.g. the targeted disease area). The pH sensitivity of the nanocomposites 
is presumably due to the amine group in the chitosan coating of rGO when the rGO-FL is in 
the release medium. The amine group is important as it provides an electrostatic repulsion that 
prevents aggregation when in a neutral medium [216]. When this chitosan coating is partially 
dissolved in the low pH solution, the electrostatic repulsive forces are decreased substantially 
due to the degradation of the amine group to the point where the electrostatic attraction forces, 
between the carboxyl and hydroxyl groups on the rGO surface and the salt in PBS, are dominant 
and cause the rGO sheets to aggregate and hinder the release of FL [513,514]. 
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Figure 4.15: Cumulative drug release (mg) from rGO-FL nanocomposites and Higuchi 
equation simulation of FL release from 1 wt.% and 2 wt.% rGO nanocomposites in pH = 7.4 
PBS solution. 
The increase in drug release performance between the pristine chitosan and the 
chitosan-rGO nanocomposites may be explained by the effect that bonding FL to rGO has on 
the diffusion coefficient in water of FL, similar to the effect that was noted in Chapter 3 for the 
chitosan-GO nanocomposites. The hydrophilic chitosan reduced rGO sheets may have 
increased the diffusion coefficient of the rGO-FL in comparison to unbound FL. The Higuchi 
equation (Equation 3.3 and 3.7 from Chapter 3) simulation of FL release from pristine chitosan 
and from 1 wt.% and 2 wt.% rGO nanocomposites is shown in Figure 4.15. rGO-FL was 
released together from the nanocomposites into the PBS releasing medium due to physical 
adsorption of the FL onto rGO, where subsequently the FL will separate from the rGO as shown 
previously. When considering rGO-FL as the releasing agent, the Higuchi equations (Equations 
3.3 and 3.4) can be used to model the initial drug release from the rGO nanocomposites, with 
the diffusion coefficient rising from 0.42 × 10-5 cm2 s-1 for pristine FL to 0.27 × 10-4 cm2 s-1 
and 0.42 × 10-4 cm2 s-1 for the rGO-FL in the 1 wt.% and 2 wt.% nanocomposite respectively.  
As the FL content is constant but the rGO content varies from 1 wt.% to 2 wt.%, the 
drug loading ratio of FL onto rGO is presumably the cause of the different release profiles, 
similar to the chitosan-GO-FL nanocomposites in Chapter 3. The initial ratio of FL to GO in 
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the preparation of the nanocomposite is 0.55 for the 1 wt.% nanocomposite while it decreases 
to 0.38 for the 2 wt.% nanocomposite. Based on the maximum loading ratio of FL to rGO 
(0.26:1) and the amount of chitosan in the rGO (~ 85 wt.%), it can be considered that all the 
FL has been loaded onto the rGO sheets. So, the drug loading ratio in the 2 wt.% nanocomposite 
is lower than in the 1 wt.% nanocomposite. The higher rGO wt.% and the lower drug loading 
ratio of the 2 wt.% nanocomposite allows for a quicker diffusion of the FL from the rGO-FL 
nanohybrid. Drug loading ratio affects the bonding between the rGO and the drug, with lower 
drug loading ratios increasing the number of bonding sites between the rGO and the drug at a 
fixed mass of the drug. 
Chitosan and chitosan-rGO nanocomposites containing 1 wt.% and 2 wt.% rGO had 
their enzymatic degradation characteristics tested in a solution of lysozyme and PBS to 
simulate in vivo conditions (Figure 4.16A). After 7 days, pristine chitosan samples were at 49% 
of their original mass, while the 1 wt.% rGO nanocomposite was at 64% and the 2 wt.% rGO 
nanocomposite was at 62% of their original mass. As with the chitosan-GO nanocomposites of 
Chapter 3, initially the enzymatic degradation rate is rapid as there is an abundance of ideal 
acetyl units for lysozyme to degrade through the β-glycosidic linkages [497,516]. When these 
ideal degradation sites are consumed, the degradation rate slows down and plateaus. This can 
be seen by the decrease in enzymatic degradation rate, with the remaining mass for pristine 
chitosan dropping to 46, 44 and 40% after 2, 4, and 6 weeks. Similarly, the mass for 1 wt.% 
dropped to 60, 55, and 53% and the mass for 2 wt.% dropped to 59, 55, and 49% after 2, 4 and 
6 weeks respectively.  
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Figure 4.16: Mass change during enzymatic analysis of chitosan-rGO nanocomposites 
containing (A) 0 wt.% rGO, 1 wt.% rGO, and 2 wt.% rGO, and (B) chitosan-FL, and 2 wt.% 
rGO-FL nanocomposites over 4 weeks. 
The difference in mass loss between the pristine chitosan and the rGO nanocomposites 
can be explained by the “tortuous path” model explained in Chapter 3. The presence of the rGO 
improved the barrier properties of the nanocomposites. The enzymatic degradation is also 
hindered by the strong covalent bonding forces between the amine and hydroxyl groups of 
chitosan and the epoxy, carboxyl and hydroxyl groups of rGO that can restrict the chitosan 
chain movement, as shown in the DSC and XRD analysis, and hence slow the cleaving of the 
chains by the lysozyme. It is interesting to note that the barrier properties of the nanocomposites 
are not dependent on the rGO concentration in this case, with both nanocomposites possessing 
a similar enzymatic degradation path, presumably due to the decrease in dispersion and 
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exfoliation quality for the 2 wt.% nanocomposite negating the effect of the increased rGO 
weight percentage in comparison to the 1 wt.% nanocomposite.  
The inclusion of the drug into a nanocomposite also affects the enzymatic degradation 
rate, shown in Figure 4.16B. The inclusion of the drug quickens the enzymatic degradation rate 
and decreases the remaining mass at each time step in comparison to the nanocomposites 
without the drug. The difference can be attributed to both the dissolution of the drug from the 
samples and also the reduction in the bonding between the rGO and the bulk chitosan due to 
the presence of the drug. The remaining mass for 2 wt.% rGO-FL dropped to 27% after 1 week 
and plateaued at 23% after 4 weeks. At the end of the test there was only 16% of the original 
mass remaining, compared to 37% for the chitosan-FL.   
4.3.3 Chitosan-rGO Microneedle performance 
Microneedles were produced that contain chitosan-2 wt.% rGO-FL and these were subjected 
to compression and drug release tests. Figure 4.17 shows the microneedles successfully created 
by centrifuging highly viscous suspensions into female moulds.  
 
Figure 4.17: Optical microscopy images of the microneedles created from chitosan and 2 wt.% 
rGO-FL nanocomposites; (A) Overview of a microneedle array and (B) a close up which shows 
the shape of the individual microneedles.  
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Figure 4.18: (A) Compression test results for six microneedle arrays created from chitosan and 
2 wt.% rGO-FL nanocomposite material tested up to 10 N or a minimum distance between the 
two platens of 0.1 mm. (B) The images of the microneedle array on the stationary platen, (B-
1) before the compression test, (B-2) during the compression test with a load of 10 N, and (B-
3) after the compression test, showing no damage to the structure.   
Microneedles were tested for their structural rigidity under compressive loads, as shown 
in Figure 4.18. The microneedle tip design has a radius of 20 µm in order to guarantee that the 
microneedle is sharp enough to puncture the SC (which requires a pressure of 3.18 MPa [533]); 
by considering the radius of the microneedle and the pressure required, each individual 
microneedle needs to withstand 0.016 N of force without failing due to bending or buckling, 
or 1.6 N for the entire microneedle array. All the microneedle arrays tested survived the 
compressive force of 1.6 N without failing, as shown in Figure 4.18A. The sudden increase in 
force on the curve is taken as the point where the compressive platen is meeting resistance from 
the microneedle shaft as it tries and fails to buckle or bend to microneedle shaft. Up to this 
point, the platen was compressing the microneedle tip, slightly deforming it from its original 
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shape. A failure of the microneedle would be seen as a sudden drop in the force required to 
displace the platen vertically. Figure 4.18 B1-B3 shows a series of images taken before, during 
and after the compression testing of a microneedle array to 10 N, showing that the microneedles 
can survive a compressive cycle designed to simulate insertion into human skin. 
To test the force required to fail a microneedle, Figure 4.S2 shows compressive testing 
curves for microneedles using a 1 kN load cell with no limitation on maximum loads or 
minimum depths. The microneedles began to yield at a mean compressive force value of 37 N, 
the point at which is indicated by the relevant arrow on the curve. After this point, the individual 
microneedles are being crushed to a horizontal position after having failed by bending means 
(shown in the inset image). The compression testing indicates that the chitosan-rGO-FL 
microneedles are strong enough to withstand the force of insertion without the fear of buckling 
or bending of the individual microneedle shafts. 
 
Figure 4.19: Optical microscopy images of the dissolution of rGO-FL from microneedle arrays 
after insertion into a gelatin hydrogel for 6 h. (A-B) Cross section of the hydrogel after the 
microneedle array has been removed. The diffusion of rGO-FL can be seen by the presence of 
the green-yellow color which shows the depth and width of diffusion through the hydrogel. In 
(C-D), the holes left behind when the microneedle array pierced the hydrogel can be seen in 
the plan view of the hydrogel. Images (B) and (D) are under UV light (400 nm) which was 
used to better highlight the fluorescence of FL In contrast to gelatin. 
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Figure 4.19 shows optical microscopy images of the dissolution of rGO-FL from 
microneedle arrays after 6 h into paraffin film (simulating the SC) and a gelatin hydrogel 
(simulating the VE) [120]. The hydrogel contains water that will allow the drug to diffuse, 
much like the bodily fluids between cells in the VE. Once the microneedle array was removed 
with tweezers and the hydrogel cross-sectioned with a knife, the diffusion of rGO-FL can be 
seen in Figure 4.19 A-B as the green-yellow colour from which one can see the depth of 
diffusion (about 2 mm) through the hydrogel. Figure 4.19 C-D is a plan view of the upper 
surface of the hydrogel and the characteristic green-yellow colour of rGO-FL can be seen on 
the surface following diffusion of the rGO-FL from the microneedle into the hydrogel. Images 
(B) and (D) are under UV light (400 nm), which was used to better highlight the fluorescence 
of FL in contrast to gelatin. Of note in images (C) and (D) are the holes left behind by the 
microneedle points after insertion on the surface of the hydrogel sample. This confirms that the 
microneedles were sufficiently designed to withstand insertion and to penetrate the synthetic 
layers of the SC (paraffin film) and into the VE (the hydrogel). The microneedles also 
successfully released the rGO-FL into the hydrogel medium, showing that the chitosan rGO-
FL nanocomposites can potentially be used in microneedle arrays for transdermal drug 
delivery.  
4.4 Conclusions 
GO was successfully reduced to rGO by hydrogen and electrostatic bonding chitosan to GO in 
an aqueous suspension, followed by heating the chitosan-coated GO suspension at 37 oC for 
72 h. This biocompatible body temperature reduction process is comparable in reduction 
effectiveness to higher temperature (90 oC) processes; the lower temperature allowed for the 
reduction of GO in the presence of drugs and cells for the development of drug delivery systems 
and tissue constructs within biomedical and biological applications. The rGO produced was 
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stable in water, PBS and cell culturing media, and demonstrated pH-sensitive drug release 
profiles.  
The introduction of rGO to chitosan improved the mechanical properties and the 
conductivity of pristine chitosan, with the strongest nanocomposite containing 1 wt.% rGO 
showing an increase of 47% for Youngs modulus and 39% for UTS over pristine chitosan 
whilst maintaining the εb at 11.8%. The maximum electrical conductivity of 0.06 S m-1 was 
achieved at 7 wt.% rGO and the percolation threshold was found to be 0.25 wt.%. Similar to 
chitosan-GO nanocomposites, the chitosan-rGO nanocomposites had improved drug delivery 
properties over pristine chitosan in neutral conditions, and the nanocomposites showed a pH 
responsive release of the drug. The presence of rGO reduced the enzymatic degradation rate in 
comparison to pristine chitosan, due to a decrease in the permeability of the enzyme through 
the nanocomposite. Chitosan-rGO nanocomposites were formed into microneedle arrays and 
were shown to be strong enough in compression testing to survive the force of insertion through 
the SC. The microneedles could release the drug FL when inserted into a hydrogel, used to 
simulate the dermal layers of the body. 
The in-situ body temperature reduction of GO provides an efficient reduction method 
for the use of polymer-graphene composites in the biomedical sector. The enhancement of the 
mechanical, electrical, and the drug release performance attributed to the inclusion of rGO 
means that chitosan-rGO nanocomposites have high potential for use in enzymatically 
degradable microneedle arrays for transdermal drug delivery. The conductivity of the chitosan-
rGO nanocomposites may allow them to be used for electrically stimulated drug delivery 
applications, i.e. iontophoresis. Combining a microneedle made out of the chitosan-rGO 
nanocomposite with iontophoresis stimulation may increase the release of large MWt drugs 
from the nanocomposite relative to passive diffusion.  
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Chapter 5. Chitosan-graphene quantum dot nanocomposites  
5.1 Introduction 
In Chapters 3 and 4, GO and rGO have been used as the nanoparticles within the chitosan 
nanocomposites. GO and rGO have improved the mechanical properties of the chitosan, 
imparted pH sensitivity to the drug release, and in the case of rGO, increased the electrical 
conductivity to the nanocomposite. The addition of pH sensitivity and electrical conductivity 
to chitosan-graphene nanocomposites can make the nanocomposites useful for drug delivery, 
i.e. pH sensitive release within the bowels and electrically-stimulated, iontophoretic release, 
but neither nanoparticle can add the functionality of imaging/tracking of the bound drug in 
vivo. Graphene quantum dots (GQDs) have the potential to add this extra ability to 
chitosan-graphene nanocomposites. The GQDs have intrinsic PL properties that allow 
for the GQDs to be imaged under fluorescent light for the potential tracking of the GQDs 
(and any bonded drugs) through the body. They have a low cytotoxicity, unlike the 
semiconductor QDs discussed in Section 2.3.5. 
As well as being PL, GQDs are highly reduced rGO nanoparticles and were 
therefore thought to be an excellent choice for a filler within a nanocomposite; as 
discussed in Section 2.4.2, reducing GO to rGO can help to partially return some of the 
excellent properties of pristine graphene nanoparticles, such as electrical conductivity 
and mechanical strength, whilst keeping the functional groups that aid in the dispersion 
of GO. Increasing the conductivity of chitosan is important if the nanocomposites are to 
be used for iontophoretic/electrically stimulated drug release, and as such, the GQDs 
are an interesting nanoparticle to do so. For use as a microneedle array, the 
nanocomposite will need to be mechanically strong; this requirement will make use of 
the improved mechanical properties of the rGO-based GQD.  
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GQD were synthesised using previously reported methods [217] and 
characterised to determine their PL properties. Chitosan-GQD nanocomposites were 
assessed to determine the optimal wt.% of GQD to maximise the electrical conductivity, 
mechanical and enzymatic degradation properties. Microneedle arrays were formed 
from nanocomposites of chitosan and drug-coated GQDs. The nanocomposite 
microneedles were tested for mechanical integrity under simulated skin insertion 
conditions. Their ability to release small MWt drugs through passive diffusion and large 
MWt drugs through electrically stimulated iontophoresis was assessed.  
5.2 Experimental section 
5.2.1 Materials 
Chitosan powder (MWt = 100,000-300,000, Acros Organics), isopropanol alcohol 
(reagent grade), and phosphate buffered saline (PBS) tablets (pH = 7.4) were purchased 
from Fisher Scientific. The following chemicals were purchased from Sigma Aldrich: 
hydrochloric acid (36.5%), hydrogen peroxide (29-32% in H2O), acetic acid (> 99.7%), 
potassium permanganate (97%), sodium nitrate (> 99%), lysozyme (from chicken egg 
white, ~100,000 U mg-1), sulphuric acid (95-98%), fluorescein sodium (FL), graphite 
powder (≤ 20 µm), rhodamine B, norharmane (β-Carboline), lidocaine hydrochloride 
(LH, > 99%), trypsin from porcine (BioReagent grade), fluorescein sodium labelled – 
bovine serum albumin (BSA, BioReagent grade), 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) solution (1 mg ml-1 in PBS) and 
ethylenediaminetetraacetic acid (EDTA, BioReagent grade). Dulbecco’s modified eagle 
medium (DMEM), penicillin, streptomycin, and fungizone were purchased from Gibco 
Invitrogen (Paisley, UK). Fetal bovine serum was purchased from Advanced Protein 
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Products (Brierley Hill, UK). All chemicals were used as received unless otherwise 
described.  
5.2.2 Preparation of graphene quantum dots 
Graphene oxide was synthesized from a modified Hummers [187] method and subsequently 
purified, exfoliated and freeze dried as outlined before in Chapter 3. The aqueous GO 
suspension (with a raised pH of 8, ~ 3 mg ml-1) was treated in a Parr Series 4000 autoclave at 
200 oC for 10 h (pressure of boiling water at 201 oC = 1.6 MPa) to generate reduced graphene 
oxide quantum dots (GQDs), as described in the literature with some modifications [217]. The 
suspension was placed in a dialysis bag (Fisher Scientific Biodesign Dialysis tubing, Mw cut 
off = 3.5 kDa) and the residua chemicals were allowed to diffuse into the distilled water 
surrounding the dialysis bag. The GQD were collected in an aqueous suspension from the 
dialysis bag and lyophilised in a Labconco FreeZone Triad freeze-dryer to be stored as a 
powder in a desiccator.  
5.2.3 Cell viability 
All human skin and fat were collected and used on an anonymous basis with ethical permission 
from patients undergoing abdominoplasties or breast reductions from the Department of 
Plastics, Burns and Reconstructive Surgery, Sheffield Teaching Hospitals under a Human 
Tissue Authority research bank tissue license number 08/H1308/39. From the collected fat, 
mesenchymal stromal cells (MSC) were isolated and cultured in DMEM (containing foetal 
bovine serum, streptomycin (100 µg ml-1), fungizone (630 ng ml-1) and penicillin (100 units 
ml-1) [534].  
When the culture reached a 50% confluence, the cells were treated with a trypsin 
solution for 10 min to detach, collected and then the cell solution was centrifuged at 1000 rpm 
for 5 min to form a pellet (Hettich Rotafix 32A centrifuge). Cells were counted, with cells 
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seeded (10,000 per well) in a 48 well plate. Cells were incubated overnight in DMEM to allow 
for cell reattachment, after which the DMEM medium was replaced with MGQD suspensions 
(20, 50, 100, 200, 500 µg ml-1 in DMEM) for 6 h and 24 h incubation times (each testing 
iteration was tested in triplicate). At the end of each incubation time, cells were washed with 
PBS and then incubated in fresh DMEM until 72 h post-treatment when cells were assessed by 
the MTT-EDTA. Cells were incubated for 40 min at 37 oC, after which the formazan salt was 
eluded by acidified isopropanol. The optical densities of the resultant solutions were measured 
with a plate reader at 540 nm with a reference filter of 630 nm (Bio-Tek ELx800). Control 
samples of untreated cells in DMEM were taken as 100% viable, and the optical densities of 
the MGQD treated cells were compared to these values. An Olympus CK40 microscope was 
used for cell imaging.  
5.2.4 Cell viability and imaging 
Dermal fibroblast cells were isolated and cultured in DMEM in a 37 oC and 5% CO2 
environment [534]. After the cell culture was 50% confluent, the cells were separated from the 
well plates by a trypsin solution for 10 min and collected by centrifugation of the cell 
suspension at 1000 rpm for 5 min to form a pellet. Cells were seeded at 10,000 cells per well 
into a 48 well plate. To allow for reattachment, cells were incubated in DMEM overnight. The 
DMEM was replaced and the cells were incubated with GQD suspensions (50 µg ml-1 or 100 
µg ml-1 in DMEM) for an incubation time of 12 h. Cells were washed with PBS and then fixed 
with glutaraldehyde. A Leica TCS SP8 two-photon confocal microscope (excitation source 690 
nm, emission filter 360 nm) was used for imaging of cells. 
5.2.5 Drug loading onto graphene quantum dots 
LH or BSA was bonded to GQDs as follows: 0.3 mg ml-1 of GQDs was dispersed in 
distilled water through stirring and sonication. To this suspension, 0.3 mg ml-1 of LH or 
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BSA was added and stirred for 24 h before centrifugation (8000 rpm for 1 h) separated 
the GQD-LH or GQD-BSA from the supernatant containing the unbound drug. This 
GQD-LH or GQD-BSA was lyophilized in a freeze-dryer and then stored in a desiccator 
until further use.  
5.2.6 Preparation of nanocomposites 
Chitosan powder was dissolved in 2 wt.% acetic acid – water solution (15 mg ml-1) at 
room temperature for 24 h under stirring. The required amount of GQDs (0.25 wt.% - 2 
wt.%) was dispersed in distilled water and the suspension was added under stirring to 
the chitosan solution. The suspension was left to stir in a fume hood to evaporate most 
of the solvent until it became a viscous nanocomposite suspension of chitosan – GQD 
(~80 mg ml-1). The mixture was degassed in a vacuum oven for 1 h at room temperature 
and then poured into a petri dish to air dry. Chitosan film without GQDs was prepared 
in parallel. 
5.2.7 Characterisation of GQDs and chitosan-GQD nanocomposites  
A Veeco Dimension 3100 with Olympus AC160TS probes in tapping mode at 0.5 Hz was used 
for atomic force microscopy (AFM). A Brookhaven ZetaPALS (660 nm wavelength) was used 
for dynamic light scattering (DLS), with 3 cycles of 2 min runs on suspensions of 1 mg ml-1 
MGQD in KNO3 buffer (10 µM concentration). UV-Vis spectrometry (0.3 mg ml
-1) was 
achieved using a Perkin Elmer Lambda 900 spectrometer with a 1 nm resolution. PL 
spectroscopy was conducted using a Horiba Fluoromax 4 with excitation sources from 300-
400 nm and emission readings from 360-600 nm with a wavelength resolution of 2 nm. 
Photoluminescence quantum yield measurements used fluorescein sodium in 0.1 sodium 
hydroxide, rhodamine B in ethanol and 0.01% hydrochloric acid, and norharmane in 0.1 M 
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sulphuric acid as reference standards. Quantum yield measurements were taken by using 
Equation 5.1 [535], shown below: 
ɸqd= ɸst× 
Gradqd
Gradst
× 
ηqd 
2
ηst
2
                                                              (5.1) 
where “ɸ” is the fluorescence quantum yield, “Grad” is the gradient of the curve of emission 
versus absorbance, “η” is the refractive index for the solvent used in the solution, and “qd” and 
“st” are QDs and the standards used.  
PL lifetime analysis (1 mg ml-1) was achieved through Time Correlated Single 
Photon Counting (TCSPC): a Mira 900 Ti-Sapphire laser (10 W), with the wavelength 
halved through an A.P.E. Second Harmonic Generator, was used as the laser source, a 
Becker and Hickl SPC-830 was used as the single photon counting module with a 
Becker & Hickl GmbH PHD-400-N High Speed Photodiode Module as an electronic 
trigger, and an ID Quantique ID100-50 single photon detection module was used to 
detect the emission from the sample. Perkin Elmer Spectrum 100 with a diamond 
attenuated total reflectance unit was used for Fourier transform infrared (FT-IR) 
spectroscopy between 400-4000 cm-1 with a resolution of 1 cm-1. A Stoe Stadi P was 
used for X-ray diffraction (XRD) analysis with Cu Kα irradiation (0.154 nm 
wavelength), with operating parameters of 40 kV, 35 mA, and a scanning speed of 1 o 
min-1. A Micromeritics AccuPyc II 1340 was used to measure the density of the GQDs, 
achieved at room temperature (24 oC) by using 10 purge cycles and 10 calculation cycles 
of helium gas. 
Electrical conductivity (number of samples = 5) was measured using an Agilent 
Technologies 34401A digital multimeter, with contact points painted using silver paint 
(RS Components, RS 186-3600) and using a two probe method. The multimeter was 
calibrated by testing with various metals of known conductivity. The mechanical 
properties of chitosan nanocomposites were tested on a Hounsfield universal 
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mechanical testing machine using a 1 kN load cell and a 1 mm min-1 strain rate in 
accordance with ISO-527. Dog bone shaped test specimens (number = 5) were used, 
measuring 22 mm in length, 2.7 mm in width and 1 mm in thickness. Enzymatic 
degradation tests were carried out by placing nanocomposite film samples (number = 5) 
into 30 ml of 37 oC PBS solution (pH = 7.4) with a 1.5 µg ml-1 concentration of lysozyme 
[499]. Samples were maintained over the course of 8 weeks at 37 oC and agitated at 100 
rpm in a Stuart SI500 bioincubator. After each time step, specimens were removed, 
washed with distilled water, and dried before being weighed and placed into 30 ml of 
fresh PBS and lysozyme solution.  
Thermogravimetric (TGA) was achieved using a Perkin Elmer Pyris 1 with a 
nitrogen atmosphere with a flow rate of 20 ml min-1 from 40 to 700 oC at 5 oC min-1. A 
Perkin Elmer Lambda 900 spectrometer was used for UV-visible (UV-Vis) 
spectroscopy from 200-800 nm with a 1 nm resolution.  
5.2.8 Production of nanocomposite microneedles 
The production of microneedle arrays has been described before [151,152]. Briefly, the 
procedure consists of two parts: the filling of the main needle shaft with a 
nanocomposite containing a therapeutic and the filling of the needle base with a 
conventional nanocomposite. Female silicone moulds were filled with an excess amount 
of a highly viscous nanocomposite suspension of chitosan – GQD (~80 mg ml-1), with 
and without a therapeutic drug for testing of drug release and compression testing 
respectively. Centrifugation at 8000 rpm for 1 h was used to fill the microneedle-shaped 
cavities, with excess suspension cleaned from the surface. The microneedle arrays were 
placed inside a fume hood to air dry. This cycle was repeated 3 times to fill the needles. 
Once the needles were filled, the base of the needles was filled with high viscosity 
nanocomposite suspension (without drug), centrifuged for 1 h at 8000 rpm and dried in 
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a vacuum oven overnight at 40 oC. Upon drying, the exposed side of the microneedle 
array was gently sanded with fine sandpaper to remove spurs and gently removed from 
the female mould. Microneedles were stored in desiccators and prior to use were dried 
further at 40 oC overnight in a vacuum oven. Pristine chitosan microneedles were also 
fabricated for comparison.  
5.2.9 Compression testing of microneedles 
The microneedles were tested using a Hounsfield universal mechanical testing machine 
using a 10 N load cell and a 1 mm min-1 compression rate. Microneedle arrays were 
fixed to a steel plate and a second steel plate was used to uniformly compress the 
microneedle arrays (number = 5). 
5.2.10 Therapeutic release from microneedles 
Quantitative analysis of LH drug release was achieved through the use of UV-Vis 
spectroscopy (Perkin Elmer Lambda 900 operating at a resolution of 1 nm). Microneedle 
arrays (chitosan-1 wt.% GQD-LH, number = 5) were placed in 10 ml, 37 oC PBS 
solution (pH = 7.4) and tested over 6 h whilst being agitated at 100 rpm. The UV-Vis 
spectra of the released solutions were compared to the spectra of free LH in distilled 
water of known concentrations. 
5.2.11 Therapeutic release from microneedles with iontophoresis 
Microneedle arrays were created from a chitosan-1 wt.% GQD nanocomposite, with the 
GQDs coated with BSA. These microneedle arrays were used for iontophoretic release 
of the high MWt drug. The electrical circuit for the microneedle array was based on a 
prototyping circuit board (PCB). The power to the PCB was supplied by a PP3 9 V 280 
mAH nickel-metal hydride (Ni-MH) battery, with the battery snap-on connector linked 
to the PCB by solder-less jumper wires and an on-off switch (Scheme 5.1). A 2 kΩ 
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resistor was added to the circuit between the switch and the microneedle to lower the 
voltage across the circuit. 
  
Scheme 5.1: Schematic of the system used to analyse the effect that Iontophoresis has on the 
therapeutic release from a microneedle array. 
Electrically stimulated microneedles were created by mounting the chitosan-
GQD microneedle array to a microscopy glass-slide using double-sided tape. One 
jumper wire, feeding from the positive terminal, was arranged that its exposed end was 
fixed in contact with one side of the microneedle array. This was achieved by soldering 
the jumper wire to a crocodile clip; silver paint was applied from the microneedle array 
edge to the side of the glass-slide where the crocodile clip grasped the glass-slide. The 
second jumper wire, leading to the negative terminal, was submerged in the receiving 
medium (distilled water) into which the drug was to release. The glass-slide was 
submerged vertically in water up to the fixed microneedle array, with the crocodile clip 
and silver paint out of the water. This method ensured that the electrical flow was 
through the microneedle into the receiving medium.   
5.2.11 Biostability of GQDs and drug-loaded GQDs 
Suspensions of GQD, GQD-LH and GQD-BSA (0.3 mg ml-1) were dispersed in distilled 
water, PBS and FBS, and digital images were taken after 5 min, 2 h, 4 h, and 24 h.   
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5.3 Results and discussion  
5.3.1 Characterisation of graphene quantum dots 
 
Figure 5.1: (A) AFM image and height profile of GQDs, (B) DLS data of GQDs, 
showing a large count in the 40-60 nm region. 
GQDs were prepared through a hydrothermal reduction procedure (see Scheme 5.1). 
Figure 5.1A is an AFM image of the GQDs on a mica substrate, demonstrating that the 
GQDs are in general 50-55 nm in diameter, with an average diameter of 51.9 nm and an 
average height of ~1.5 nm. The GQDs are thinner than the chitosan-reduced rGO in 
Chapter 4 (3.5 nm) due to the hydrothermal route of reduction, i.e. no biomolecules were 
used. The GQDs are thicker, however, than the GO from Chapter 3 (~1 nm) that served 
as the precursor to GQD and pristine graphene that is estimated at ~0.34 nm thick 
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[536,537]. Presumably the thickness of the GQDs is due to the stacking of two or more 
of the rGO sheets together after the hydrothermal reduction due to aggregation as there 
was a substantial decrease in functional groups on the GQD surface compared to GO. 
This may lower the solubility in solvents, compared to GO, and therefore there may 
have been partial restacking. Figure 5.1B shows DLS analysis of the hydrodynamic 
diameter of GQDs, showing a large count of GQDs in the 40-60 nm region and a mean 
diameter of 54.8 nm. 
 
 
Figure 5.2: (A) PL and UV-Vis spectra showing the UV-vis absorption for GO and 
GQD, and PL excitation and emission wavelengths for GQD dots, and inset: (left) GQD 
in distilled water and (right) distilled water, showing the photoluminescent properties of 
GQDs under UV light (365 nm), and (B) PL lifetime data for GQD aqueous dispersion. 
 
141 
 
 The UV-Vis spectra of GO and GQD show that the 230 nm peak of GO (Figure 
5.2A, curve 1) remains for GQD (Figure 5.2A, curve 2), attributed to the π→π* 
conjugations of C=C [187], but GQD has an additional peak at 265 nm attributed to the 
π transition network of graphene being restored [210]. The GQDs also possess an 
absorption peak at 320 nm, in contrast to the 300 nm peak of GO, similar to other 
hydrothermally reduced GQDs [217]. This initially indicates GO has changed to rGO in 
the GQDs during the hydrothermal reduction and cutting process. The PL spectra of the 
GQDs are also shown in Figure 5.2A, showing the maximum excitation at 320 nm and 
the maximum emission at 420 nm, indicating a Stokes shift of 100 nm which is similar 
to previously reported values [217]. The excitation peak at 320 nm is linked to the triple 
carbenes in the zigzag structure of the GQDs [217,538]. The quantum yield for the 
GQDs is calculated at 9.4% (data shown in Figure S5.1 in S.I.), again similar to the 
published literature for GQDs (5.5-14%) [337,338,539]. The selectiveness of the GQDs 
to the excitation wavelength is depicted in Figure 5.S2, which confirms the strongest 
emission at the excitation wavelength of 320 nm, with the emission intensity reducing 
at other wavelengths. The inset to Figure 5.2A shows the GQDs fluoresce under UV 
light (365 nm) as opposed to no fluorescence for the control sample of distilled water. 
Figure 5.2B shows PL lifetime data for GQDs, showing that a 1 mg ml-1 aqueous 
suspension has a lifetime of 2.3 ns. This value is similar to other GQDs in the literature 
(1-10 nanoseconds) and to that of conventional QDs of CdSe/ZnS QDs[540–542] and 
CdTe QDs [18].  
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Figure 5.3: (A) MTT-ESTA cell viability results for GQD treated MSC. Concentrations 
were 20, 50, 100, 200, and 500 µg ml-1 and the incubation times were 3 h and 6 h. Results 
that are statistically similar (p < 0.05) to one another are shown with symbols (*, +, -). (B) 
Optical microscopy images for samples treated with (1) 0 (control), (2) 20, (3) 100, and 
(4) 500 µg ml-1. Images were taken 72 h after the 24 h incubation time.  
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MTT cell viability results for MSC treated with GQD concentrations of 20, 50, 
100, 200 and 500 µg ml-1 in DMEM for 3 and 6 h are shown in Figure 5.3A. For the 3 
h samples, the concentrations of 20-200 µg ml-1 are within 69-95% cell viability range, 
comparable to other GQD reports (70-80%) [15,309,338,339], with a dose dependent 
cytotoxic effect only occurring at 500 µg ml-1. Samples treated with 20 µg ml-1 for 3 h 
and 6 h had a cell viability of 95% and 96% respectively, with these values dropping to 
75-80% for 50 and 100 µg ml-1 for 3 h and 6 h. For the 200 µg ml-1 sample, the cell 
viability for 3 h is 69% but this drops to 43% for the 6 h incubation time, showing a 
time dependent cytotoxic effect. Figures 5.3 B1-B4 show optical microscopy images of 
MSC treated with 0-500 µg ml-1 GQDs for 24 h incubation time. It can be seen by 
comparing the control sample with no GQDs and the 20 µg ml-1 sample that the 
morphology, size and quantity of the MSC are consistent. However, the quantity of cells 
in the 100 µg ml-1 sample has decreased in comparison to the first two samples. The 
quantity of cells in the 500 µg ml-1 sample is even lower compared to the 100 µg ml-1 
sample, while the size and morphology of the cells have also changed compared to all 
the samples with lower concentrations. These results confirm that GQDs have limited 
cytotoxicity up to 100 µg ml-1 for 3 h or 6 h, but when exposed to 200 µg ml-1 or higher 
for 6 h or more the cells show signs of apoptosis and are reduced in size and quantity. 
Figure 5.4 shows optical and fluorescent microscopy images of dermal fibroblast 
cells cultured with GQD concentrations of 50 µg ml-1 and 100 µg ml-1 for a 12 h 
incubation time. By overlapping the fluorescent images with the optical images, it can 
be seen that some cells are fluorescent due to the presence of photoluminescent GQDs 
within the cells. The PL emission is stronger for the cells treated with 100 µg ml-1 of 
GQD, with the higher concentration of GQDs allowing more of the GQDs to be 
endocytosed into the cells, relative to the lower concentration sample. These results 
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confirm that the GQDs can potentially be used for in vivo cell imaging [309,543], as 
well as for tracking drugs when they are loaded onto the nanoparticles. Using fluorescent 
imaging, QDs have previously been tracked migrating through the vasculature in the 
body [17] and have been tracked during drug delivery [18]. 
  
Figure 5.4: Optical and fluorescent microscopy images of fibroblast cells treated with 
50 µg ml-1 and 100 µg ml-1 GQDs for a 12 h incubation time, showing the use of GQDs 
as fluorescent imaging agents. 
5.3.2 Characterisation of chitosan-GQD nanocomposites 
Figure 5.5A shows the FT-IR spectra of chitosan-GQD nanocomposites, from which 
chitosan can be identified through the N-H peaks at 2800 cm-1, C=C at 1640 cm-1, amino 
at 1535-1546 cm-1, C-OH at 1405 cm-1 and C-O at 1050-1100 cm-1 [482]. The amino 
peak shifts from 1535 cm-1 for pristine chitosan to 1546 cm-1 for the 1 wt.% chitosan-
GQD nanocomposite, and the C-O peaks shift from 1065 cm-1 and 1021 cm-1 for pristine 
chitosan to 1059 cm-1 and 1017 cm-1 for 1 wt.% chitosan-GQD due to hydrogen bonding 
between the amino groups of chitosan and the remaining oxygenated functional groups 
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on the GQDs [396,482]. The intensity of the main peaks, apart from a slight decrease in 
the amino and C-OH peaks, did not alter by a notable degree when the GQDs were 
introduced to chitosan, due to the relatively low content of GQDs within the 
nanocomposites relative to chitosan.   
 
Figure 5.5: (A) FT-IR spectra, (B) XRD traces of chitosan-GQD nanocomposites. The 
C’s in Figure 5.3B denote crystalline peaks from chitosan. 
 XRD traces (Figure 5.5B) allow for the crystallinity of chitosan to be measured 
as 59.9%, 51.1%, 54.6%, 56.1%, and 56.4% for chitosan and nanocomposites 
containing 0.25-2 wt.% GQDs, respectively, by using Equation 3.1 (Chapter 3). The 
presence of GQDs within the polymer presumably limits the mobility of some chitosan 
chains due to surface adsorption, hence restricting rearrangement of chitosan chains into 
146 
 
ordered chains to form crystallites and reducing the crystallinity [504], similar to the 
effect of GO within chitosan-GO nanocomposites in Chapter 3. The significant 
difference in crystallinity levels between chitosan-rGO (Chapter 4) and chitosan-GQD 
(Chapter 5) is presumably due to the deacetylation and the treatment procedure of the 
chitosan solution. As a reference, the crystallinity of the pristine chitosan for the 
chitosan-rGO series is much lower than the crystallinity of the pristine chitosan for the 
chitosan-GQD (15.3% versus 59.9%, respectively). The thermal treatment of the 
chitosan solution by heating at 37 oC for 72 h has decreased the crystallinity, due to 
thermal crosslinking as previously reported [544]. 
 
Figure 5.6: Electrical conductivity of chitosan-GQD nanocomposites as a function of 
GQD concentration. 
Figure 5.6 shows the electrical conductivity of the nanocomposites, with peak 
conductivity occurring at 1 wt.% GQDs and a percolation threshold occurring at around 
0.25 wt.%, similar to the percolation threshold of chitosan-rGO nanocomposites in 
Chapter 4. The low percolation threshold and the increase in conductivity for the 
nanocomposites compared to the pristine chitosan are due to the high reduction degree 
and the low thickness of the GQDs, which may have a conductivity close to that of 
pristine graphene [179]. The conductivity of the nanocomposite containing 1 wt.% 
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GQDs is 8.9 times of the original value for chitosan (0.0161 S m-1 versus 0.0018 S m-
1), and is comparable to other polymer-graphene nanocomposites with similar 
concentrations (0.001 to 0.01 S m-1) [209,545,546]. The decrease in conductivity for the 
2 wt.% GQD nanocomposite in contrast to the 1 wt.% GQD nanocomposite may be 
explained by the partial aggregation of GQDs within the nanocomposite. The difference 
in conductivity levels between chitosan-rGO (Chapter 4 and chitosan-GQD (Chapter 5) 
is presumably due to the crystallinity of the chitosan; it has been shown that the 
conductivity of chitosan films decreases with increased crystallinity [484]. The 
difference in crystallinity between the two chapters was previously discussed. Due to its 
relatively high conductivity and high GQD content which would facilitate a high drug 
loading within the nanocomposite, the 1 wt.% nanocomposite was chosen to undergo 
further analysis. 
 
Figure 5.7: Representative tensile stress-strain curves for chitosan and chitosan-1 wt.% 
GQD nanocomposite. 
  Figure 5.7 shows representative tensile testing curves for pristine chitosan and 
chitosan-1 wt.% GQD nanocomposite. The εb increase by ~37% from 15.5 (± 4.2) % for 
pristine chitosan to 21.2 (± 3.2) % for the 1 wt.% GQD nanocomposite, presumably 
because of both the orientation of GQDs towards the tension direction which absorbs 
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energy [400,505,547] and the change in crystallinity as previously discussed. The UTS 
for pristine chitosan is 62.5 (± 9.4) MPa, which increased by ~36% to 84.8 (± 11.8) MPa 
for the 1 wt.% GQD, courtesy of the strong interfacial interactions between chitosan 
matrix and GQD filler. Similarly, increases in the εb (4%) and UTS (27%) were noted 
for nanocomposites of poly(styrene-butadiene-styrene) with 1 wt.% CdTe QDs, 
attributed to the strong interfacial bond between the polymer and the QDs [437]. The E 
has remained similar despite the inclusion of 1 wt.% GQDs, with 1.48 (± 0.38) GPa for 
pristine chitosan compared to 1.45 (± 0.14) GPa for the nanocomposite. The similar E 
values may be attributed to the cancelling out of two opposing factors: the reinforcing 
effect of GQD nanofiller and the decreased crystallinity of the chitosan. GQD can have 
a reinforcing effect on chitosan arising from its high modulus [527,528] and high surface 
area, but it is not as effective a nanofiller as GO (Chapter 3) and chitosan-reduced rGO 
(Chapter 4) because of its smaller lateral size, lower aspect ratio, and the reduction in 
surface functional groups [548]. Countering this expected improvement from the 
presence of GQD, a lower crystallinity can result in a lower E value [483], thus causing 
the actual E value to remain effectively the same between the pristine chitosan and the 
nanocomposite. 
The enzymatic degradation profile of the 1 wt.% nanocomposite in a PBS 
solution containing the enzyme lysozyme is shown in Figure 5.8. Within the first week, 
the enzymatic degradation rate was higher for the 1 wt.% GQD nanocomposite than for 
the pristine chitosan, as can be seen by the lower remaining mass for the former. This 
initially quicker enzymatic degradation rate of the nanocomposite, relative to pristine 
chitosan, may be due to the lower crystallinity of the chitosan-GQD nanocomposite 
which promotes faster enzymatic degradation [486]. The effect that crystallinity has on 
enzymatic degradation can be seen by comparing the mass losses for pristine chitosan 
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between Chapter 4 (~50% loss) and Chapter 5 (~23%), with the lower crystallinity 
chitosan degrading faster. 
 
Figure 5.8: Enzymatic degradation profiles for chitosan and chitosan-1 wt.% GQD 
nanocomposite. 
After 28 days, both the pristine chitosan and the 1 wt.% chitosan-GQD 
nanocomposite were reduced to around 65% of their original mass. The similarity 
between the remaining mass of the pristine chitosan and the nanocomposite is due to the 
relatively low loading of GQD within the nanocomposite (just 1 wt.%) and the limited 
effect that the GQD had upon the permeability of the nanocomposite; it is reported that 
exfoliated, large aspect ratio nanoparticles can reduce the permeability of a 
nanocomposite due to the previously explained “tortuous path model” and this effect 
was evident in the enzymatic degradation studies in Chapter 3 and Chapter 4, but the 
GQDs have a low aspect ratio, as discussed in previously, and therefore have a limited 
effect on the permeability of the nanocomposite when present at this low wt.% loading. 
5.3.3 Chitosan-GQD nanocomposite microneedles 
Microneedle arrays of chitosan-1 wt.% GQD nanocomposite were formed by solution 
casting into moulds and subsequently drying. Optical microscopy images of chitosan-1 
wt.% GQD-LH microneedles can be seen in Figure 5.9A and 5.9B, showing the 
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alignment of the microneedles within an array as well as the main shaft and conical tip. 
As shown in Figure 5.9C, the five microneedle arrays tested can all withstand a 
compressive force of at least 10 N, showing that they are strong enough to withstand the 
compressive force of insertion into human skin. The microneedle arrays have not broken 
or bent noticeably after the tests (Figure 5.9C Inset) in comparison to their shape before 
the test (Figure 5.9B). 
 
Figure 5.9: (A) Vertical and (B) side view optical microscopy images of chitosan-1 
wt.% GQD-LH nanocomposite microneedle array. (C) Compressive force-displacement 
curves for chitosan-1 wt.% GQD microneedles. (Inset) Optical microscopy image of a 
chitosan-1 wt.% GQD microneedle array after compression testing to 10 N. The 
microneedles have not broken under the force applied. 
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The depth of penetration of the microneedle array was determined by inserting 
chitosan-GQD microneedles into chicken-skin and subsequently cross-sectioning the 
chicken skin (Figure 5.S3). Microneedle arrays were inserted by hand into chicken skin 
and left in situ for 1 h before examination. The microneedles were intact after insertion 
and the depth of penetration is typically 400-500 µm and the width of the channel 250-
350 µm. This confirms that the microneedles are strong enough to insert into skins. 
 
Figure 5.10: (A) TGA curves for GQDs, LH, and GQD-LH, and (B) the release rate of 
LH from chitosan and chitosan-1 wt.% GQD-LH microneedle shafts containing the 
same amount of LH. 
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 Figure 5.10A shows TGA curves for the GQDs, LH, and GQD-LH. The loading 
of LH onto GQDs was determined to be 0.12:1 from the residual masses of GQDs 
(91.5%), LH (0.3%) and GQD-LH (81.6%) at 500 oC, accounting for the absorbed 
moisture of the three materials. Taking into consideration this loading ratio of LH to 
GQDs, a desired amount of GQD-LH was added to chitosan solution to prepare a 
chitosan-GQD-LH nanocomposite suspension at a concentration of 1 wt.% GQDs. This 
nanocomposite suspension was then used to form the microneedle shafts for drug 
delivery testing, with the base of the microneedle patch made from the same 
nanocomposite but without the drug. To make control microneedle shafts of chitosan-
LH, a chitosan-LH solution was created with the same concentration of LH as in the 
chitosan-1 wt.% GQD-LH suspension. By restricting the LH to the microneedle shafts 
and not the base, all of the GQD-LH will enter the body through the bloodstream thus 
reducing the use of expensive drug in microneedle arrays. 
 Figure 5.10B shows the release rate of LH from the microneedle shafts of pristine 
chitosan and the chitosan-1 wt.% GQD nanocomposite containing the same amount of 
LH (11.5 µg). For the GQD-LH nanocomposite microneedles, the drug is bound to the 
surface of the GQDs, whereas in the chitosan-LH microneedles the drug was directly 
incorporated into chitosan. In the former, the GQD-LH was released together into the 
medium but it was shown in Chapter 4 that FL can diffuse away from rGO over time. 
After 1 h, ~23.0% (2.6 µg) of LH was released from the GQD-LH microneedle, with a 
maximum release of ~68.3% (7.9 µg) released after 7 h. This compares to ~18.1% (2.1 
µg) of LH after 1 h from the chitosan-LH microneedle, with a maximum release of 
57.4% (6.6 µg) released after 7 h. Up to 6 h, there is a similar drug release profile 
between the two sample types, but after 6 h the nanocomposite microneedles obtained 
a quicker and more substantial release than the polymer microneedles. Similar 
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improvements in the release of drugs from chitosan nanocomposites containing a drug 
with GO or rGO have been noted in Chapter 3 (Page 83) and Chapter 4 (Page 118); this 
was attributed to an increase in the diffusion coefficient of the drug when bonded to GO 
or rGO compared to the free drug, which is presumably the same cause of the improved 
drug delivery from the GQD-LH microneedle. 
 
Figure 5.11: (A) TGA curves for GQD, BSA, and GQD-BSA and (B) release of BSA 
from chitosan-GQD microneedles, with and without the effect of iontophoresis.  
  LH is a drug with a low MWt of 288 Da. Another low MWt drug, FL, was shown 
to successfully diffuse from polymer films and microneedles in Chapter 3 and Chapter 
4. Some therapeutics are of a much higher MWt than LH or FL, for example BSA with 
a MWt of ~60 kDa. Herein, the feasibility of releasing BSA bonded to GQD from a 
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microneedle array is assessed. The quantity of BSA bonded to the GQD was determined 
from TGA (Figure 5.11A). As a significant amount of BSA still remained even at 700 
oC, the mass losses for GQDs (8.9%), BSA (66.1%) and GQD-BSA (43.6%) during the 
major degradation step of BSA (220-500 oC), taking into account of the absorbed 
moisture, were used to determine the loading ratio of BSA onto GQDs (BSA:GQD) of 
0.29:1. 
Curve 1 of Figure 5.11B shows the passive release of BSA from the microneedles 
into the release medium (distilled water) over 24 h. There was only minimal diffusion 
of the drug (7.6% of the available drug, or 0.6 µg) into the medium within the tested 
period of time. This is due to the difficulty in passive diffusion of large MWt 
therapeutics like BSA from its carrier; it was noted previously that the higher the MWt 
and the degree of deacetylation of chitosan, the lower the release of BSA from chitosan 
[549]. A similar low diffusion of BSA was noted from other polymer carriers, such as 
PMMA nanoparticles [550], with ~20% release over 24 h, and from alginate-
montmorillonite microparticles, with ~13% over 175 min [551]. In order to improve the 
release of the large MWt therapeutic, a microneedle that uses iontophoresis, the electro-
repulsion of charged molecules by an electrical field from one electrode towards the 
other electrode [62], was created as per Scheme 5.2. Iontophoresis has been previously 
used to improve upon the passive diffusion of low (dexamethasone, ~400 Da) [532] and 
medium (insulin, ~5800 Da) [133] MWt drugs and proteins/peptides [134,135] from 
microneedle arrays. Curve 2 of Figure 5.8B shows that for the iontophoresis-effect 
microneedle array (operating at 21.3 mV and 1.5 mA), the final drug release after 24 h 
was greatly improved in comparison to passive diffusion to 94.5%, or 7.4 µg of the 
available drug.  
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Figure 5.12: Digital photos showing the release of BSA from the microneedle into 
distilled water over 24 h for (left) passive diffusion and (right) electrically stimulated 
diffusion. 
The effect of iontophoresis is shown visually in Figure 5.9, verifying the results 
of Figure 5.8. The left container contains a microneedle array made of chitosan-1 wt.% 
GQD-BSA which was submerged in the release medium (distilled water) and allowed 
to passively diffuse into the release medium over 24 h. The right-hand-side container 
contains a microneedle with the iontophoresis set-up. The strong, yellow staining of FL 
on the BSA (Figure 5.S4, Appendix 1) can be seen within the release medium after 6 h 
and this effect grows stronger over the 24 h with the iontophoresis. However, there is 
no obvious colour change in the standard set-up for passive diffusion. The 
iontophoresis-effect microneedle has released markedly more BSA into the medium 
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than the standard microneedle did, as seen by the stronger colour. This implies that 
iontophoresis offers an approach to deliver large MWt therapeutics through a 
microneedle array, and the chitosan-GQD nanocomposites are excellent candidates for 
this purpose. 
5.3.4 Biostability of the GQD-drug released from the microneedle 
 
Figure 5.13: (A) The biostability of GQD (1-3), GQD-LH (4), and GQD-BSA (5), in 
(1) distilled water, (2) phosphate buffered saline (pH=7.4), and (3-5) foetal bovine 
serum. (B) Long term stability of GQD-LH in foetal bovine serum over 10 days, 
showing that the drug coated GQD remains relatively stable over 10 days.  
After the GQD-drug is released into the fluid, it is important to assess their stability for 
future clinical applications. Figure 5.13A shows suspensions (0.3 mg ml-1) of GQD (A, 
B, C), GQD-LH (D), and GQD-BSA (E), in (A) distilled water, (B) PBS (pH=7.4), (C-
E) FBS. GQDs can be seen to remain stable in water up to 4 h and with negligible 
aggregation of larger particles after 24 h, and to experience no aggregation in PBS for 
up to 24 h. There was a small aggregation of GQDs in FBS after 5 min, possibly due to 
the aggregation of larger particles or due to the crosslinking of GQDs via hydrogen 
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bonding of –COOH of GQDs with the proteins in the FBS [522], but the quantity of 
aggregation does not increase up to 24 h. In contrast, the GQD-LH was stable up to 3 
days in FBS (Figure 5.13B), experiencing barely any aggregation due to electrostatic 
repulsion from the positive ionic charge of LH [63]. This suspension remained relatively 
stable between 3 days and 10 days, with only little aggregation. As chitosan is also 
cationic, it is expected to enhance the stability of GQDs too, like what we previously 
found for chitosan-coated rGO nanosheets [552]. GQD-BSA was stable up to 5 min and 
then agglomerated heavily before 2 h. This is presumably due to the crosslinking 
between GQD-BSA nanoparticles themselves, forming larger particles; albumin is a 
protein found in blood serum, and the same hydrogen bonding that allowed GQD to 
bond to BSA may cause physical crosslinking between GQD-BSA. 
Chitosan-GQD microneedles were also tested for their biostability in FBS over 
6 h. The results (Figure 5.S5) show that the chitosan within the microneedle array is 
stable within FBS, similar to previous reports [553]. 
5.4 Conclusions 
Graphene quantum dots, created by the hydrothermal reduction of a graphene oxide 
aqueous suspension, were 50-55 nm in diameter and ~1.5 nm in height, possessed 
photoluminescent properties and were shown to be minimally cytotoxic to adipose 
derived MSCs and be able to act as a contrast agent for fluorescent imaging of cells.  
 Chitosan – GQD nanocomposites were prepared by solution casting. The 
addition of GQDs increased the electrical conductivity relative to pristine chitosan by 
7.9 times. The enzymatic degradation rate of the chitosan – GQD nanocomposite was 
similar to pristine chitosan 28 days after the test started. The UTS of chitosan increased 
from 62.5 MPa to 84.8 MPa and the elongation to break from 15.5% to 21.2% by the 
addition of 1 wt.% GQDs, with the Young’s modulus remaining consistent. The 
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presence of GQD did not impede the enzymatic degradation of chitosan, with similar 
masses remaining after 28 days for both pristine chitosan and the nanocomposite, though 
initially the nanocomposite had a quicker enzymatic degradation rate than chitosan. 
 When formed into microneedles, the chitosan – 1 wt.% GQD nanocomposite 
shows promise as a transdermal drug delivery device. The microneedle arrays withstood 
the force of insertion into the body and released the painkiller lidocaine hydrochloride 
more substantially than pristine chitosan microneedles (68.3% of the available drug was 
released compared to 57.4%). Large molecular weight drugs like bovine serum albumin 
could be released from the nanocomposite microneedle under electrical stimulation, 
with an increase from 7.6% to 94.5% of the available drug released after 24 h for 
standard and iontophoresis-effect microneedles respectively.     
 GQDs and GQD-LH were shown to be stable in distilled water, phosphate 
buffered saline, and foetal calf serum over 24 h. GQD-LH remained stable in foetal 
bovine serum for up to 10 days, due to the LH imparting an electrostatic repulsion effect 
on the GQDs. 
 Bonding therapeutics to photoluminescent, electrically-conductive GQDs and 
integrating the drug-laden GQDs into a degradable polymer such as chitosan forms a 
nanocomposite that can be used in a microneedle array, creating a universal, 
multifunctional drug delivery platform for enhanced and controlled drug delivery that 
can be potentially utilised to deliver both small and large molecular weight therapeutics 
and be monitored through bio-imaging. 
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Chapter 6. Magnetic iron oxide-reduced graphene oxide quantum 
dots 
6.1 Introduction 
The chitosan-GQD nanocomposites in Chapter 5 were an improvement over the chitosan-GO 
and chitosan-rGO nanocomposites of Chapters 3 and 4 as they offered increases in electrical 
conductivity and mechanical properties over pristine chitosan, while also offering new 
functionality with the imaging/tracking of the drug within the body. In the form of 
microneedles, chitosan-GQD nanocomposites could release small and large (under electrical 
stimulation) MWt drugs. The GQDs, however, only possess one mode of imaging (fluorescent) 
and cannot be targeted to a specific site through external means. Ideally, the nanoparticles 
would have multiple modes of imaging as the depth of tissue penetration and the resolution of 
different imaging methods varies; for example, fluorescent imaging has a poorer depth of 
penetration in comparison to M.R.I., while M.R.I. has a lower resolution than fluorescent 
imaging [554,555]. They should also be responsive to external stimulation to allow for targeted 
drug delivery, and should have low cytotoxicity. 
The aim of this chapter was to synthesise a new type of graphene based nanoparticle 
that will add these desired new functionalities to the nanocomposites. Superparamagnetic iron 
oxide-reduced graphene oxide quantum dots (from herein known as magnetic graphene 
quantum dots, or MGQDs) with these properties were synthesized through a green, 
hydrothermal method which simultaneously reduced and shattered nanoparticles of GO coated 
with IO. The structure and morphology of the MGQDs were analysed. MGQDs were assessed 
for their ability to offer dual-modality imaging through M.R.I. and fluorescent imaging, as well 
as the targeting of the delivery site of MGQD-bound drugs by their superparamagnetic 
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properties. Owing to their strong NIR irradiation absorbance, the MGQDs were also 
investigated as cancer photothermal therapy agents.  
 
Scheme 6.1:  Synthesis procedure for magnetic graphene quantum dots (MGQD). Aqueous 
solutions of ferrous chloride tetrahydrate and ferric chloride hexahydrate are stirred into a GO 
aqueous suspension; the mixture is reacted for 2 h under a nitrogen atmosphere at ambient 
temperature to form GO-IO nanoparticles. The GO-IO aqueous suspension undergoes 
hydrothermal reduction in an autoclave for 10 h at 200 oC to create MGQDs.   
6.2 Experimental section 
6.2.1 Materials 
The following chemicals were used as purchased from Sigma Aldrich; sulfuric acid (95-98%), 
hydrogen peroxide (29-32% in water), potassium permanganate (97%), sodium nitrate (> 
99%), ferrous chloride tetrahydrate (> 99%), hydrochloric acid (36.5%), ferric chloride 
hexahydrate (97%), fluorescein sodium, graphite powder (≤ 20 µm), rhodamine B, 
norharmane, lidocaine hydrochloride (> 99%), porcine trypsin (BioReagent), 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) solution (1 mg ml-1 in 
phosphate buffered saline (PBS)), and ethylenediaminetetraacetic acid (EDTA, BioReagent). 
Dulbecco’s modified eagle medium (DMEM, 500 ml, Gibco Invitrogen (Paisley, UK) was used 
with fetal calf serum (FCS, Advanced Protein Products, Brierley Hill, UK), penicillin (100 
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units ml-1), streptomycin (100 µg ml-1), and fungizone (630 ng ml-1) from Gibco Invitrogen 
(Paisley, UK). Isopropanol alcohol (reagent grade) and PBS tablets (pH = 7.4) were acquired 
from Fisher Scientific UK. 
6.2.2 Preparation of graphene oxide-iron oxide nanoparticles 
Graphene oxide was synthesized from a modified Hummers method [33]. GO-IO was prepared 
according to methods described in the literature with some modifications [267,279]. The 
freeze-dried GO powder (1 g) was dispersed in 150 ml of distilled water through stirring and 
sonication for 1 h and the pH of the suspension was raised to pH = 8 with the addition of 
ammonium hydroxide NH4OH. Separately, ferrous chloride tetrahydrate FeCl2-4H2O (5.4 g) 
and ferric chloride hexahydrate FeCl3-6H2O (4 g) were dissolved in 135 ml distilled water. The 
GO suspension and the solution of IO precursors were added together, ammonium hydroxide 
was added drop wise until a pH = 10 was reached, and then the mixture was stirred for 2 h 
under a nitrogen atmosphere at ambient temperature. The precipitate, IO coated graphene oxide 
(GO-IO), was washed with distilled water, ethanol and dichloromethane to remove residual 
chemicals before being re-dispersed in distilled water (~ 3 mg ml-1) by sonication for 1 h in a 
Fisherbrand (230V 50Hz) sonication bath.  
6.2.3 Preparation of reduced graphene oxide-iron oxide quantum dots 
The aqueous GO-IO suspension (~ 3 mg ml-1) was treated in a Parr Series 4000 autoclave at 
200 oC for 10 h (pressure of boiling water at 201 oC = 1.6 MPa) to generate reduced graphene 
oxide-iron oxide quantum dots (MGQDs). The suspension was placed in a dialysis bag (Fisher 
Scientific Biodesign Dialysis tubing, Mw cut off = 3.5 kDa) and the residual chemicals were 
allowed to diffuse into the distilled water surrounding the dialysis bag. The MGQD were 
collected in an aqueous suspension from the dialysis bag and lyophilised in a Labconco 
FreeZone Triad freeze-dryer to be stored as a powder in a desiccator. As a control, IO (with a 
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raised pH of 8) was autoclaved at 200 oC for 10 h to produce autoclaved iron oxide (A-IO) for 
a comparison study. GQDs from Chapter 5 were also used as a control in this chapter. 
6.2.4 Drug loading onto quantum dots 
LH (0.1 mg) was added to a suspension of MGQDs (0.1 mg ml-1) under stirring for 48 h. The 
suspension was centrifuged at 9000 rpm for 1 h, after which the supernatant (containing the 
unbound drug) was removed and the precipitate was re-dispersed in water. This process was 
repeated several times to remove the unbound drug. The MGQD-LH was then freeze-dried and 
stored in a desiccator. 
6.2.5 Characterisation  
Transmission electron microscopy (TEM), energy dispersive X-ray spectroscopy (EDS), and 
selected area electron diffraction (SAED) were achieved using a Philips Technai T20 electron 
microscope operating at an accelerating voltage of 200 kV. High resolution TEM (HR-TEM) 
was carried out using a JEOL 2010F field emission gun TEM operating at an accelerating 
voltage of 200 kV. TEM samples were prepared by evaporating a diluted suspension (~ 0.01 
mg ml-1) onto a holey amorphous carbon coated copper grid (mesh size = 400). Electron energy 
loss spectroscopy (EELS) spectra were acquired on the JEOL 2010F using a Gatan image filter 
in image coupled mode with an energy dispersion of 0.5 eV per pixel. Atomic force microscopy 
(AFM) was carried out on a Veeco Dimension 3100 with Olympus AC160TS probes in tapping 
mode at 0.5 Hz, using a diluted suspension (~ 0.01 mg ml-1) evaporated onto a freshly cleaved 
mica substrate. Dynamic light scattering (DLS) was performed on a Brookhaven ZetaPALS 
(660 nm wavelength), with 3 cycles of 2 min runs on suspensions of 1 mg ml-1 MGQD in 
distilled water.  
X-ray diffraction (XRD) was performed on a Stoe Stadi P with Cu Kα irradiation (0.154 
nm wavelength), with operating parameters of 40 kV, 35 mA, and a scanning speed of 1o min-
1. Raman spectroscopy between 50-3000 cm-1 with a resolution of 0.5 cm-1 was achieved with 
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a Renishaw inVia Raman microscope using a 514.5 nm wavelength laser. Fourier transform 
infrared (FT-IR) spectroscopy between 400-4000 cm-1 with a resolution of 1 cm-1 was 
performed on a Perkin Elmer Spectrum 100 with a diamond attenuated total reflectance unit. 
Thermogravimetric analysis (TGA) from 40 to 1000 oC at 5 oC min-1 was implemented with a 
Perkin Elmer Pyris 1 with a nitrogen atmosphere (20 ml min-1).. A Micromeritics AccuPyc II 
1340 was used to measure the density of the MGQDs, achieved at room temperature (24 oC) 
by using 10 purge cycles and 10 calculation cycles of helium gas.  
UV-visible light (UV-Vis) spectroscopy of nanoparticle suspensions in distilled water 
(0.3 mg ml-1 concentration) from 200-800 nm with a 1 nm resolution was achieved with a 
Perkin Elmer Lambda 900 spectrometer. Photoluminescence spectroscopy was conducted 
using a Horiba Fluoromax 4 with excitation sources from 300-400 nm and emission readings 
from 360-600 nm with a wavelength resolution of 2 nm. Photoluminescence quantum yield 
measurements used fluorescein sodium in 0.1 NaOH, rhodamine B in ethanol and 0.01% HCl, 
and norharmane in 0.1 M H2SO4 as reference standards. Quantum yield measurements were 
taken by using Equation 1 [35], shown below: 
ɸ
qd
= ɸ
st
× 
Gradqd
Gradst
× 
ηqd 
2
ηst
2
                                                      (6.1) 
where “ɸ” is the fluorescence quantum yield, “Grad” is the gradient of the curve of emission 
versus absorbance, “η” is the refractive index for the solvent used in the solution, and “qd” and 
“st” are quantum dots and the standards used (fluorescein sodium, rhodamine B and 
norharmane). PL lifetime analysis (time correlated single photon counting) was achieved with 
irradiation from a frequency doubled Mira 900 Ti-Sapphire laser (10 W), a single photon 
counting module (Becker and Hickl SPC-830), an electronic trigger (Becker & Hickl GmbH 
PHD-400-N High Speed Photodiode Module), and the emission was detected by an ID 
Quantique ID100-50 single photon detection module. The magnetic hysteresis loop was created 
using a Quantum Design MPMS-XL 5 superconducting quantum interference device (SQUID), 
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operating at 37 oC to simulate in vivo conditions and between +/- 20,000 Oe (2 T) in 200 Oe 
intervals. A Siemens Trio TIM 3 Tesla M.R.I. was used to measure the T2 relaxation times of 
the MGQDs, with the echo time, TE = 15.2, 30.4, 45.6, 60.8, 76, 91.2, 106.4, 121.6, 136.8, 152, 
167.2 milliseconds and the relaxation time TR = 3000 milliseconds.  
6.2.6 Cell viability and imaging 
Human skin was obtained with ethical permission from patients undergoing abdominoplasties 
or breast reductions from the Department of Plastics, Burns and Reconstructive Surgery, 
Sheffield Teaching Hospitals. All tissue was collected and used on an anonymous basis under 
a Human Tissue Authority research bank tissue license number 08/H1308/39. 
Dermal fibroblast cells were isolated and cultured, as described previously [36], in 
DMEM at 37 oC and 5% CO2 environment. When the culture was 50% confluent, the cells 
were collected by treating with a trypsin solution for 10 min and centrifuging the cell 
suspension to form a pellet at 1000 rpm for 5 min using a Hettich Rotafix 32A centrifuge. Cells 
were counted, with cells seeded (10,000 per well) in a 48 well plate. Cells were incubated 
overnight in DMEM to allow for cell reattachment, after which the DMEM medium was 
replaced with MGQD suspensions (20, 50, 100, 200, 500 µg ml-1 in DMEM) for 6 and 24 h 
incubation times (each testing iteration was tested in triplicate). At the end of each incubation 
time, cells were washed with PBS and then incubated in fresh DMEM until 72 h post-treatment 
when cells were assessed by the MTT-assay of metabolic activity. Cells were incubated for 40 
min at 37 oC, after which the formazan salt was eluded by acidified isopropanol. The optical 
densities of the resultant solutions were measured with a plate reader at 540 nm with a reference 
filter of 630 nm (Bio-Tek ELx800). Control samples of untreated cells in DMEM were taken 
as 100% viable, and the optical densities of the MGQD treated cells were compared to these 
values. 
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An Olympus CK40 microscope and a Leica TCS SP8 two-photon confocal microscope 
(excitation source 690 nm, emission filter 360 nm) were used for cell imaging. For the two-
photon fluorescent imaging, the cells were incubated with either 50 µg ml-1 or 100 µg ml-1 
MGQDs for 12 h before the cells were fixed with glutaraldehyde. 
6.2.7 Drug release from MGQDs 
A 10 ml PBS suspension (37 oC, pH = 7.4) of MGQD-LH (1 mg ml-1 MGQD-LH) was inserted 
into a Spectrum Labs Float-A-Lyzer G2 dialysis tube with pore sizes between 0.1-0.5 kDa. 
This dialysis tube was floated vertically in a sealed container of pristine PBS solution (550 ml, 
37 oC, pH = 7.4). This container was placed within a Stuart SI500 bio-incubator, maintained at 
37 oC and agitated at 100 rpm. At set time points, 3 ml of PBS solution was taken from the 
outer container (and subsequently replaced with 3 ml of fresh PBS) and analysed with a Perkin 
Elmer Lambda 900 (resolution of 1 nm).  The acquired spectra were compared to the 
absorbance values of free LH of known concentration (ranging from 0.06-1 mg ml-1) in PBS. 
6.2.8 Photothermal measurements 
The temperature of aqueous suspensions of MGQDs and GQDs (1.5 ml, concentration of 50 
µg ml-1 and 100 µg ml-1) under irradiation from a NIR continuous laser (wavelength: 808 nm; 
laser power: 2, 5, 7.5 W cm-2) was measured as a function of time. Distilled water was also 
studied as a control. 
Photothermal experiments on HeLa cells incubated with suspensions of MGQDs and 
GQDs were carried out with a near-infrared continuous laser (wavelength: 808 nm; laser 
power: 2.5 W cm-2). HeLa cells were seeded to a density of 5000 cells per well of a 96 well 
culture plate (BD Falcon, U.S.). Cells were incubated at 37 oC in a 5% CO2 atmosphere for 24 
h to allow for reattachment. After incubation, the cell culture medium was replaced by the 
MGQD or GQD suspension (100 µl of cell medium with a 50 µg ml-1 suspension of MGQD or 
GQD). After 4 h incubation with the QDs, the cells were irradiated by a laser for 20 min or 30 
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min. After incubation overnight, the QD suspension medium was removed and the cells were 
washed twice with PBS. To test the viability of the cells after irradiation, 100 µl of CCK-8 
solution was added to each well and the cells were incubated for 2 h. The optical density of the 
cell solution was read on a microplate reader (Varioskan Flash, Thermo Scientific), with 
measurements taken at 450 nm. 
2.9 Biostability 
MGQD and MGQD-LH were dispersed in distilled water, PBS and FCS at a concentration of 
50 µg ml-1. Suspensions were imaged using a digital camera after predetermined intervals.   
6.2.10 Statistical analysis 
Statistical analysis (p < 0.05) and graphing were completed through MatLab 2012a software. 
Size analysis of TEM images was conducted through ImageJ software, with 60 separate 
samples taken over several images. 
6.3 Results and discussion 
6.3.1 Structure 
Figure 6.1 shows TEM (A-1 and A-2) and AFM (Figure 6.1B, Inset) images of MGQDs. The 
synthesized MGQDs have an average diameter of 41.8 (± 8.1) nm from the TEM images, and 
an average diameter of 45.2 (± 10.3 nm) and a height of 2.3 nm (± 0.07 nm) from AFM. The 
MGQDs are identifiable in the TEM images in dark contrast (Figure 6.1A1-1A2) on the 
amorphous carbon film support due to the presence of high density IO (4.9 – 5.2 g cm-3 for 
magnetite [556]) within the MGQDs as well as mass-thickness contrast, similar to the 
identification of IO on GO-IO reported in the literature [280]. DLS results (Figure 6.1) show a 
mean hydrodynamic diameter of 61.4 nm, with a significant count within the 45-90 nm range. 
It is larger than the average diameters obtained from AFM and TEM, which can be accounted 
for by the presence of larger nanoparticles (i.e. agglomerates) in the polydisperse MGQD water 
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suspension [557]. The diameter of the MGQDs is larger than hydrothermally reduced GQDs 
(5-25 nm) previously reported by other groups [217,558,559], but these papers use either a 
longer hydrothermal treatment time (24 h) [558,559] or an additional oxidation procedure to 
further reduce the size of their GO before the hydrothermal treatment [217]. The diameter is, 
however, similar to that of the GQDs (51.9 nm) prepared by the same oxidation and 
hydrothermal treatment method in Chapter 5. 
 
 
Figure 6.1: (A) TEM images of MGQDs, showing that the QDs are approximately 40-50 nm 
in diameter, (B) DLS size analysis of MGQD aqueous suspension, showing the majority of 
MGQDs are within the 45-90 nm diameter range; (Inset) AFM image of MGQDs, showing an 
average height of 2.3 nm and an average width of 45.2 nm. 
As described previously, the average thickness of the MGQDs from AFM is 2.3 nm, 
which is thicker than the reported thickness of graphene (0.37 nm [500]), rGO (~0.8 nm [213]) 
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or the GQDs prepared using the same hydrothermal reduction method (1.5 nm (Chapter 5)). 
This suggests that the IO coating on the MGQD surface is likely 0.8 – 1.9 nm thick. IO growth 
on GO was reported to be smaller than pristine IO growth due to the dispersed nucleation of 
Fe3+ by the oxygen functional groups (C=O) of GO [560], and a similar effect may have 
occurred during the synthesis of the IO on the GO-IO followed by reduction of GO into rGO 
during hydrothermal cutting. 
 
Figure 6.2: EDS spectrum of the MGQD presented in Figure 2 (A-2), showing a composition 
of carbon, oxygen, and iron; (inset) the SAED pattern of the MGQD, confirming the presence 
of iron oxide. 
The composition of the MGQD in Figure 6.1A-2 can be seen in the EDS spectrum in 
Figure 6.2, which confirms the presence of iron (0.72, 6.42, and 7.08 keV) [561,562]. The 
oxygen (0.54 keV) was from the IO and the residual oxygenated groups in the hydrothermally 
reduced GO while carbon (0.3 keV) was from the rGO and carbon-coated copper grids (0.94, 
8.06, and 8.92 keV) [561,563]. The SAED pattern (Figure 6.2, Inset) has the ring patterns 
associated with (220) and (104) diffraction peaks of magnetite and hematite (α-Fe2O3) 
respectively [564,565].  
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Figure 6.3: XRD traces of GO, IO, GO-IO, GQDs, A-IO, and MGQDs. 
The results from XRD (Figure 6.3) confirm that the MGQDs are characterized by both 
rGO and a mixture of magnetite, maghemite, and hematite. GO has been oxidized from graphite 
and is largely exfoliated (weak (002) peak at 2θ = 10.6o) [187]. IO is crystalline, with a (220) 
peak at 2θ = 30.7o, a strong (311) peak at 2θ = 35.5o, a (400) peak at 2θ = 43.2o, a (422) peak 
at 2θ = 57.2o, and a (511) peak at 2θ = 62.5o [565–568]. This corresponds with the JCPDS 19-
0629 card for magnetite, as IO possesses the (311), (220), (511) and (422) peaks that are 
common to both magnetite and maghemite but lacks of the characteristic (210), (211) and (213) 
peaks of maghemite (JCPDS 39-1346) [565,569]. GO-IO displays a distinct (311) peak from 
the IO, with the other peaks at a lower intensity, showing that the magnetite is formed before 
the hydrothermal treatment, as previously reported [279]. The GQDs were structurally 
characterised briefly in Chapter 5 as consisting of rGO. From Figure 6.3, GQDs are 
characteristic of rGO ((002) peak at 2θ = 25.4o) [399], which is almost a return to the 
value of pristine graphite 2θ = 26o from Chapter 3. The value for GQD is closer than the 
value for rGO in Chapter 4, which was recorded as 2θ = 23o, as the hydrothermal 
reduction method is more efficient at reducing the GO than the biomolecule-method due 
to the higher reduction temperature. A-IO is a mixture of magnetite, maghemite, and 
hematite (the α- mineral form of maghemite), with the (311), (220), and (422) peaks from the 
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IO, maghemite specific peaks (210), (211), (213), and hematite characteristic peaks (021), 
(110), (024) (JCPDS 33-0664) indicated on the curve [565,570]. The presence of hematite is 
caused by the partial topotactic oxidation of magnetite at 200 oC during autoclaving [571]. The 
MGQD curve shows a change in structure from both GQD and A-IO. rGO can be identified by 
the weak (002) peak at 2θ = 21.6o. This peak has shifted by 3.8o when compared to the GQD 
curve, which may stem from the reaction of GO and IO during autoclaving that may have 
altered the crystalline structure (vide infra) [284]. The effect of rGO within the MGQDs has 
caused a reduction in intensity of the (311) and (511) peaks from IO, a new (440) peak at 2θ = 
76.0o common to magnetite and maghemite, and the introduction of a (104) peak at 2θ = 38.3o, 
a (113) peak at 2θ = 45.5o, and a (300) peak at 2θ = 78.1o, all from hematite [565]. 
  
Figure 6.4: Raman spectra of GO, IO, GO-IO, GQDs, A-IO, and MGQDs. 
A further analysis of the crystal structure of the MGQDs and the structural change 
during autoclaving was performed through Raman spectroscopy of GO, IO, GO-IO, GQDs, A-
IO and MGQDs (Figure 6.4). GO can be identified by the G band at 1591 cm-1 (E2g mode) and 
the D band at 1322 cm-1 (A1g) [210]. The IO is a mixture of magnetite and maghemite, with the 
maghemite caused by the local extreme heating of the IO powder by the laser source as it was 
not identified in the XRD analysis [572,573]. The peak at 300 cm-1 and the broad peak at 660 
cm-1 are assigned to magnetite T2g and A1g, while the peaks at 217, 283 and 401 cm
-1 are 
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attributed to hematite A1g(1), Eg(2 + 3), and E2g(4) [571,572,574]. The GO-IO spectrum is a 
combination of the characteristic peaks of the GO and IO spectra, again showing the successful 
seeding of IO crystals onto the GO nanosheets.  
GQDs can be identified by the G band at 1594 cm-1 (E2g mode) and the D band 
at 1359 cm-1 (a1g), with the ratio of the intensities of the D peak to the G peak decreasing 
relative to GO, showing an increase in the sp2 carbon structure of pristine graphene and 
graphite. It is noteworthy that the final values for the GQD are different, in particular 
the D peak, than those recorded for chitosan-reduced rGO from Chapter 4 (1359 cm-1 
and 1594 cm-1 for GQD vs. 1313 cm-1 and 1597 cm-1 for rGO). The GQD D-peak at 
1359 cm-1 is close to the accepted edge D-peak for pristine graphene (~1350 cm-1 
[575,576]), confirming the result of XRD (Figure 6.3) that showed GQD as closer to 
pristine graphite than the chitosan-reduced rGO. A-IO is characterized as a mixture of 
magnetite and hematite, with a magnetite peak at 653 cm-1 [572,577] and a hematite peak at 
619 cm-1 [565,572,577], and with additional goethite (α-FeOOH, the hydrated form of 
hematite) peaks at 924 cm-1 and at 1442 cm-1 [578]. MGQDs can be seen to be magnetite (656 
cm-1) [572,577], maghemite (broad peak at 500 cm-1) [572,577], hematite (peaks at 218, 287, 
402, and 604 cm-1) and rGO (G peak at 1588 cm-1) [210]. The Raman spectrum of the MGQDs 
is closer to GO-IO than to A-IO. Presumably this is because the IO within the MGQD is 
magnetite, like with GO-IO while the A-IO is mainly composed of maghemite and hematite. 
The IO of MGQD is in the form of a film on the surface of the MGQD as previously described, 
and only has one outer surface exposed to the effects of the hydrothermal treatment, unlike the 
A-IO particles which have all the surfaces exposed. This reduces the effect of the hydrothermal 
reaction on the IO on graphene surface, leading to a different chemical composition. 
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Figure 6.5: FT-IR spectra of GO, IO, GO-IO, GQDs, A-IO, and MGQDs. 
The chemical bonds and chemical interactions within the nanoparticles can be identified 
through FT-IR spectra of the nanomaterials, as shown in Figure 6.5. GO has C-O bonds at 1043 
cm-1, C=C bonds at 1621 cm-1 and C=O bonds at 1720 cm-1. On the IO spectrum, a peak for 
the Fe-O bond is present at 551 cm-1 [279]. For the GO-IO, the synthesis procedure of IO on 
the GO has led to the shift of the C=C aromatic bonds of the GO from 1621 cm-1 to 1593 cm-1 
and to the creation of O-C=O bonds at 1415 cm-1 [579]. The Fe-O peak has been maintained 
and is at 527 cm-1. The GQD curve shows a reduction in functional groups in comparison to 
GO, with the peaks barely visible on the curve, confirming the reduction of GO to rGO. A-IO 
possesses 622 and 537 cm-1 peaks attributed to Fe-O peaks [574]. MGQDs have 646, 619 and 
462 cm-1 peaks attributed to Fe-O bonds from magnetite, maghemite and hematite, a C=C peak 
at 1564 cm-1 and O-C=O peak at 1406 cm-1 peak that are similar to GO-IO, and 1086 and 1012 
cm-1 peaks attributed to C-Fe bonds confirming the chemical bonding between rGO and IO 
[574].  
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Figure 6.6: TGA curves of GO, IO, GO-IO, GQDs, A-IO, and MGQDs. 
Figure 6.6 shows the TGA curves of the MGQD and its control samples in a nitrogen 
atmosphere. TGA suggests that GO is oxidized graphene (dissociation of epoxide and hydroxyl 
groups at ~200 oC is 23% of the total dry mass). IO has limited dissociation of ~5% (similar to 
magnetite) as it does not possess any functional groups on the surface to be dissociated [580]. 
GO-IO is a mixture of GO and IO with a main mass loss (27% of the dry mass) at ~780 oC, 
attributed to the reaction of IO with carbon from rGO to release CO and CO2 gases [581]. GQD 
is rGO (reduced mass loss as compared to GO at ~200 oC, 0.5% of the total dry mass) 
[210]. The 0.5% mass loss compares favourably to the 13% mass loss for chitosan-
reduced rGO for the same temperature range. A-IO has a major mass loss between 400 and 
500 oC (~19% of the dry mass) that is attributable to the phase transformation from maghemite 
to hematite; this phase transformation may be accompanied by other transformations such as 
conversion of maghemite to an intermediate product magnetite [565,581–583]. Similar to A-
IO, the MGQDs have a mass loss step at ~450 oC, with 20% of the dry mass. This mass loss 
does not occur in magnetite, so maghemite is not present on the IO or GO-IO as previously 
discussed. At ~620 oC, there is a minor mass loss (4% of the dry mass), which could be due to 
the reaction between α-Fe2O3 and carbon of graphene [583], resulting in the release of CO and 
CO2. The major mass loss at ~780 
oC in the curve for GO-IO has moved to ~910 oC (with a 
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loss of 24% of the dry mass), which may be the result of autoclaving that has caused phase 
transformation of the IO and the chemical bonding between IO and rGO.  
The density of the MGQDs was measured through pycometry as 3.66 (± 0.006) g cm-3 
for MGQDs. In comparison, the density of GQDs was 1.66 (± 0.006) g cm-3, slightly higher 
than that for chitosan-reduced rGO (1.46 g cm-3, Chapter 4) because of the absence of chitosan 
in the GQDs. The increase in density of the MGQDs over the value of GQDs is due to the 
higher density of the IO within the MGQD structure, e.g. 4.9 – 5.2 g cm-3 for magnetite [556]. 
By using the rule of mixture and considering the density of IO is 5 g cm-3, the amount of IO in 
the MGQDs is estimated at 60 vol.% or about 82 wt.%. 
6.3.2 Photoluminescent and magnetic properties 
  
Figure 6.7: UV-Vis spectra for GO, IO, GO-IO, GQDs, A-IO and MGQDs (0.3 mg ml-1 
concentration in distilled water). 
The photo-physical properties of the nanoparticles were characterized using steady-state UV-
Vis spectroscopy. As shown in Figure 6.7, MGQDs and GQDs have absorbance peaks at 270 
nm and 320 nm, with the MGQDs also exhibiting the characteristic absorbance trait of A-IO 
in the wavelength region 400 to 500 nm. 
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Figure 6.8: (A) Photoluminescence spectra of MGQDs showing the excitation wavelengths 
versus emission wavelengths; (Inset) Photoluminescent imaging of (left) PBS and (right) 
MGQDs in PBS under 360 nm light; (B) PL lifetime data for MGQDs in an aqueous suspension 
(1 mg ml-1). 
The emission characteristics of the MGQDs are presented in Figure 6.8A. Here, 
excitation of the MGQDs at 320 nm (corresponding to the peak in the excitation spectrum) 
yields an emission spectrum with a peak at 398 nm. This emission value is slightly lower than 
that (420 nm) observed for the GQDs prepared by the same hydrothermal method (Chapter 5). 
Quantum yield measurements (using Equation 6.1) gave a value of 7.9% for the MGQDs, 
similar to the published literature for GQDs (5.5-14%) prepared by other groups 
[15,337,338,539] and slightly lower than the GQDs prepared using the same method (9.4%) 
(Chapter 5). The MGQD result, in comparison to the GQD values, suggest the presence of IO 
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slightly quenches the luminescence of GQDs. The photos in the inset confirm the 
photoluminescence (PL) properties of the MGQDs (right), in contrast to the control sample of 
PBS solution. MGQDs, in a 1 mg ml-1 aqueous suspension, have a PL lifetime of 1.9 ns (Figure 
6.8B), similar to GQDs and conventional QDs in the literature (range of 1-10 ns) [18,540–542], 
and slightly lower than the GQDs prepared using the same method (2.3 ns) (Chapter 5). 
Previously reported GQDs with attached IO (GQD-IOs) did not possess PL properties 
as they synthesized GQDs first and then attached IO [584]. Coating of IO onto the GQDs 
quenched the fluorescence of GQDs, which is similar to the quenching behavior of gold 
nanoparticles bonded to semiconductor QDs [585]. It was theorized that a QD would have its 
fluorescence quenched by a non-radiative energy dissipation process from the bonded 
nanoparticles, and not explicitly through a decrease in the radiative (PL) properties of the QD 
itself [585,586]. In our process the GO-IO was synthesized first and then reduced to MGQDs; 
the reduction procedure broke the GO-IO into small QDs, with the edges of the core-GQD 
within the MGQD now exposed. These edges have a zigzag structure that contain triple 
carbenes [538] which are linked to the electron orbital transition at 320 nm [217], and so the 
PL properties of GQDs are preserved. 
The magnetic hysteresis loop of MGQDs (Figure 6.9A), determined with a SQUID, 
illustrate that they possess no residual magnetization and are superparamagnetic. The saturation 
magnetization of the MGQDs was 7.31 emu g-1, comparable to other magnetic nanoparticles 
(4.62 emu g-1) [279]. As demonstrated in Figure 6.9A (Inset), the MGQDs can be drawn 
towards a magnet from a resting position. Figure 6.9B is the T2 relaxation time of MGQDs 
from M.R.I., with the slope of the relaxation time determined as 4.16 mM-1 s-1. In 
comparison, the slope of the relaxation time of magnetite can vary from 35.48  to 114 
mM-1 s-1 [587,588], maghemite had a slope of 43.3 mM-1 S-1 [589], and gadolinium-doped 
graphene and a GO-IO-manganese oxide nanoparticle had slopes of 108 mM-1 s-1 [590], and 
177 
 
65.9 − 103 mM-1 s-1 [591], respectively. The relaxation time slopes of nanoparticles that contain 
IO vary due to the different Fe concentrations of the nanoparticles used [587,588,591]. Figure 
6.9B (Inset) shows digital images of MGQDs as contrast agents as a function of 
increasing Fe concentration. The results of the PL and magnetic properties tests confirm 
that the MGQDs can potentially be used for dual-modality fluorescent and M.R.I. 
applications. 
 
Figure 6.9: (A) Magnetic hysteresis loop of MGQDs and (Inset) digital images of the 
effect of external magnetic stimulation upon MGQD powder, (left) before and (right) 
after a magnet is placed beside it. (B) T2 relaxation time of MGQDs from M.R.I. and 
(Inset) digital images of MGQDs as contrast agents, as a function of increasing Fe 
concentration. 
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6.3.3 Cell viability and imaging 
 
 
Figure 6.10: MTT cell viability results for MGQDs treated fibroblast cells. Concentrations 
used were 20, 50, 100, 200, and 500 µg ml-1 in DMEM medium and the initial incubation times 
were 6 h and 24 h. Cells were then washed and cultured for a further 72 h before viability was 
assessed. Bars with the same symbols (*, +, -) were statistically similar to each other (p < 0.05). 
Optical microscopy images of the cells were taken 72 h after an initial 6 h incubation with 
MGQDs. Concentrations used were (B-1) 0 (control), (B-2) 20, (B-3) 50, (B-4) 100, (B-5) 200, 
and (B-6) 500 µg ml-1. 
MGQDs were found to have limited cytotoxicity up to a concentration of 50 µg ml-1 in MTT 
cell viability tests (Figure 6.10A). Suspensions of MGQDs of 20 and 50 µg ml-1 in DMEM 
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gave cell viability levels of  70-75% compared to cell culture on tissue culture plastic at an 
initial 6 h and 24 h incubation times, suggesting that they have a low cytotoxicity. The cell 
viability values for MGQDs are similar to those recorded for pristine IO nanoparticles used for 
M.R.I. imaging (80% for 50 µg ml-1) [275] and other GQDs reported before that are used for 
fluorescent imaging (70-80%) [15,309,338,339]. There is a dose dependent cytotoxic effect, 
with a decrease in cell viability when the concentration of MGQDs is raised from 50 µg ml-1 
to 500 µg ml-1. The visual effects of acute exposure (6 h incubation) to MGQDs shown in 
Figures 6.10B-1 to 6.10B-6 for cells which were subsequently cultured for a further 72 h. Cells 
which had encountered 20 and 50 µg ml-1 MGQDs grew well showing no long term adverse 
effects while cells which were exposed to concentrations of 100, 200 and 500 µg ml-1 did not 
recover and increase in number over the 72 h (Figures 6.10B-4 – 6.10B-6). Many of these cells 
are seen as the compact, white, and circular nodes: an appearance that was previously reported 
to indicate apoptosis [246]. The cell viability of nanoparticles can be improved upon by 
passivation with a coating of a biocompatible organic compound, with amine functionalized 
GQDs [337] and IO functionalized by pullulan [275] and  dimercaptosuccinic acid [276] 
significantly improving the cell viability of the respective nanoparticles.  
Figure 6.11 shows fibroblast cells under 345 nm irradiation that have been treated with 
(A-C) 50 µg ml-1 and (D-F) 100 µg ml-1 of MGQDs for 12 h. Figure 6.11 C and F are overlaid 
white light (Figure 6.11 A and D) and fluorescent light (Figure 6.11 B and E) images, showing 
that the emission of fluorescent light is from within the cells which suggests that the MGQDs 
entered the cells for both suspension concentrations. The emission is concentration dependent, 
with the emission from the cells stronger when treated with 100 µg ml-1 of MGQDs than with 
50 µg ml-1; the higher concentration of MGQDs in the suspension allowed for more MGQDs 
to be absorbed into the cells, but higher concentrations have been shown to be cytotoxic after 
a long period of incubation (Figure 6.10A). Nevertheless, at 50 µg ml-1 it is still possible to 
180 
 
image the nanoparticles. When surface-treated with a passivation agent, MGQDs at a higher 
concentration such as 100 µg ml-1 may also be used without incurring toxicity to cells. 
 
Figure 6.11: Optical microscopy images of fibroblast cells after an initial 12 h incubation with 
MGQDs. Concentrations used were (A-C) 50 µg ml-1 and (D-F) 100 µg ml-1. (A) and (D) are 
the fibroblast cells under normal light, and (B) and (E) are under fluorescent light. (C) and (F) 
are an overlay of the white and fluorescent light images. 
6.3.4 Drug delivery 
The chemical bonding of the anesthetic lidocaine hydrochloride (LH) (Figure 6.12A, inset) 
onto MGQDs to form MGQD-LH is mainly through π-π stacking between the aromatic rings 
of the MGQDs and LH [592]. Figure 6.S2 shows the transposing of LH peaks onto MGQD in 
FT-IR (6.2S1A) and Raman (6.S1B) spectra, showing that the LH is adsorbed to the surface of 
the MGQDs. A comparison of TGA curves of MGQD-LH and LH (Figure 6.12A) and MGQD 
(Figure 6.5) allow for the quantity of the drug in MGQD-LH to be estimated as 23.8%, giving 
an estimated loading ratio of LH:MGQD of 0.31:1. The drug release profile (Figure 6.12B) 
determined that the release of LH from MGQD-LH into the PBS achieved ~100% (106.9 ± 
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13.1%) of the total drug available, or 5.09 (± 0.63) mg ml-1, at 8 h, after which the test was 
terminated.  
  
 
Figure 6.12: (A) TGA curves for MGQD-LH and LH (Inset: chemical structure of LH). (B) 
The release of LH from MGQD-LH over the course of 8 h. 
To determine if the diffusion of LH from the MGQD follows Fickian law, Equation 6.2 
was used [132]: 
𝑄𝑡
𝑄𝑇
= 𝐾 × 𝑡𝑛                                                                     (6.2) 
in which Qt is the amount of drug released at the time “t”, QT is the total amount of drug 
released during the experiment, K is the diffusion coefficient and n is the diffusion release 
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exponent. It was found that the values of 0.56 µg s-1 and 0.55 for K and n best fit the 
experimental data presented in Figure 6.12B. This shows that the diffusion of the LH from the 
MGQD was not Fickian but anomalous [233] at pH = 7.4, similar to the diffusion of 
doxorubicin from GO [235] and rhodamine B from GO into a solution of pH = 4.5 [234]. These 
results indicate that a drug can be bonded to the surface of MGQDs and then be gradually 
released from the MGQDs into the body. It has been previously shown in the literature that 
similar nanoparticles like carbon QDs [340], GO [249] and IO [266] can be extracted from the 
blood and collect in the spleen/bladder to be excreted from the body through urine.  
6.3.5 Photothermal properties 
There is a possibility of using the MGQDs for cancer photothermal therapy, where the MGQDs 
absorb NIR light and convert it to heat that can be used to kill cancer cells locally [593]. To 
assess their potential for this application, suspensions of MGQDs in distilled water, together 
with GQD suspensions and distilled water control sample, were irradiated with a 2, 5, and 7.5 
W cm-2 NIR laser (wavelength: 808 nm) for a period of time. 
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Figure 6.13: Temperature increase difference between (A) MGQD suspensions, (B) GQD 
suspensions, and distilled water (control) under NIR 808 nm laser irradiation with varying 
power. 
The results (Figure 6.13) show that the temperature of the QD suspension increases with 
increasing laser power as well as QD concentration. After 20 min under 5 W cm-2 irradiation 
power, it can be seen that the temperature of the 50 µg ml-1 MGQD suspension increases by 
32.6 oC, compared to 8.9 oC for the water control sample and 8.4 oC for the 50 µg ml-1 GQD 
suspension. This can be attributed to the higher absorption of the MGQDs in the NIR range 
(700-800 nm, Figure 6.6) than the GQDs; this higher absorption is due to the presence of IO 
on the MGQDs. After 20 min, the suspension of 50 µg ml-1 MGQDs at 7.5 W cm-2 achieved a 
temperature increase of 46.3 oC; this is comparable to the increase of the 100 µg ml-1MGQD 
suspension (49.4 oC) after 16 min at 5 W cm-2 irradiation. This concentration and laser power 
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dependent result shows that the MGQDs can be used as an effective photothermal ablation 
agent at a low concentration that was determined to have low cytotoxicity (Figure 6.10). The 
differences in suspension concentration, irradiation time, and irradiation power make direct 
comparisons between previously reported photothermal therapy agents difficult. But, generally 
MGQDs compare well to other nanoparticles that are structurally and elementally similar, in 
particular GO-poly(ethylene glycol) (PEG) [245], rGO-PEG [245], GO-IO [280], and IO [587]. 
MQGDs also compare well to other photothermal agents such as carbon nanotubes [159] and 
gold nanoparticles [594].  
 
Figure 6.14: CCK-8 cell viability of HeLa cells incubated with 50 µg ml-1 MGQD or GQD 
suspensions and irradiated with a  2.5 W cm-2 NIR laser (wavelength: 808 nm) for 0 min, 20 
min, or 30 min. Control cells were pristine HeLa cells without QD treatment. 
The photothermal therapy results suggest that the MGQDs could be potentially used for 
the ablation of tumours, where the presence of MGQDs within the tumour will raise the 
temperature and kill tumour cells locally [593]. MGQDs and GQDs were incubated for 4 h 
with HeLa cells for in vitro photothermal ablation studies (Figure 6.14). Under 2.5 W cm-2 NIR 
laser irradiation, untreated HeLa cells can be seen to have a similar cell viability, with statistical 
insignificance, to the untreated, non-irradiated cells. This shows that laser irradiation alone at 
this power density will not reduce the viability of the HeLa cells. The presence of MGQDs, 
without irradiation, reduced the cell viability of HeLa cells to 68.2%, compared to 83.8% for 
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GQDs. These two values are lower than the values for fibroblast cells (Figure 6.10) due to 
different types of cell and incubation conditions used. MGQDs could have a higher cytotoxic 
effect on HeLa cells than on dermal fibroblast cells because of a higher susceptibility of HeLa 
cells to reactive oxide species than for the fibroblast cells, similar to the differing cell viability 
results for IO when incubated with mesothelioma cells and mice fibroblast that was attributed 
to reactive oxide species damage [273]. There is a time dependent decrease in cell viability, 
with a more substantial decrease in cell viability occurring when the HeLa cells that were 
treated with MGQDs were irradiated for 30 min than for 20 min (cell viability of 40.9% versus 
62.3%, respectively). GQDs, under irradiation, did not reduce the cell viability of the HeLa 
cells by as much, achieving a reduction to 83.1% and 74.2% for 20 min and 30 min irradiation 
time, respectively. This difference between the GQDs and the MGQDs is in accordance with 
the temperature increases from the photothermal measurement.  
Previously, QDs such as CuS [595,596] were used as photothermal ablation agents 
under irradiation with a 808 nm laser, with the QDs reducing the viability of HeLa cells [595] 
and of U87 glioblastoma cells [596]. When irradiated for 5 min with a 12 W cm-2 NIR laser, 
around ~65% of the tumour tissue in mice treated with CuS QDs showed signs of necrosis 
[596]. rGO-IO nanosheets achieved the full ablation of 4T1 tumours in mice that were treated 
with a 5 min exposure of 0.5 W cm-2 near-infrared laser irradiation [282]. In comparison to 
these results, our MGQDs are not as efficient as photothermal ablation agents under the laser 
irradiation conditions that we use, but they do offer bimodal imaging, with intrinsic M.R.I and 
fluorescent imaging capability. Also by increasing the laser power density (but still within the 
safe-use range), the photothermal ablation effect of the MGQDs may be improved. 
3.5 Biostability 
The stability of the MGQDs in biological fluids, including water, PBS and FCS, was assessed 
and the results are shown in Figure 6.15. It can be seen that pristine MGQDs partially aggregate 
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in distilled water and PBS (pH = 7.4) within 2 h, with larger particles falling to the bottom of 
the container, but the remaining particles remained stable in suspension as the quantity of 
aggregates did not increase with time up to 24 h. The IO on the surface of MGQD is 
hydrophobic [597] and aggregates in water and in PBS. MGQDs in FCS aggregated 
significantly within 2 h, presumably due to the crosslinking of MGQDs by hydrogen bonding 
of the proteins in the FCS with the remaining –COOH groups on MGQD edges [522].  
 
Figure 6.15: The biostability of (A-C) MGQDs and (D) MGQD-LH suspensions in solutions 
of (A) distilled water, (B) PBS (pH=7.4), (C-D) FCS. (E) MGQD-LH biostability in FCS over 
10 days, showing that the drug coated MGQD is relatively stable in biological fluid over the 
test period of time. 
The coating of LH onto the MGQD surface has reduced this crosslinking effect and 
greatly improved the biostability of the MGQD over 10 days (Figure 6.15E), with minimal 
further aggregation of the MGQD-LH after the initial 2 h. In solution, LH maintains a positive 
ionic charge [63], and in FCS the LH coating prevents the MGQDs from aggregating through 
187 
 
electrostatic repulsion. Coating the MGQDs with another ionic biopolymer, such as chitosan, 
may also improve the stability of the MGQDs, similar to the improvement afforded to chitosan-
coated rGO (Chapter 4), as well as decreasing the cytotoxicity of the MGQDs [253]. 
6.4 Conclusions 
The synthesis of MGQDs through the hydrothermal reduction of a water suspension of GO-IO 
nanoparticles was shown. The MGQDs were found to be around 45 nm in diameter and 2.3 nm 
high from TEM and AFM, with a composition of carbon, oxygen, and iron identified from EDS 
and EELS. Iron oxide was coated onto the graphene surface as a thin film and maybe also as 
individual particles within the bulk MGQDs. A mixture of iron oxides (magnetite, maghemite, 
and hematite) and rGO was formed during the hydrothermal reduction process, as determined 
from XRD, Raman spectroscopy, FT-IR and TGA. MGQDs emitted violet light with a 
wavelength of 398 nm when excited at 320 nm, showing excellent photoluminescent 
properties. They were also superparamagnetic, as determined by magnetic hysteresis analysis, 
and could act as a T2 contrast agent in M.R.I. applications.  
Dermal fibroblast cells which had encountered a concentration of 50 µg ml-1 or lower 
of MGQDs grew well and showed no long term adverse effects. The MGQDs (50 µg ml-1 or 
100 µg ml-1) entered the cells after incubation for 12 h and could be detected by fluorescent 
imaging. A model drug was successfully bonded to the MGQDs, with a loading ratio of 0.31:1 
(LH:MGQD), as characterized by FT-IR, Raman spectroscopy and TGA. The full release of 
the drug from the MGQD surface was achieved within 8 h. MGQDs, under NIR irradiation, 
generated a higher temperature than GQDs or distilled water due to the presence of iron oxide 
which is a more effective NIR absorber, and could achieve more significant temperature 
increases at a low concentration and laser power. This higher NIR absorption allowed for the 
MGQDs to reduce the cell viability of cancer cells during in vitro laser ablation experiments 
by a greater amount than was possible with GQDs. Ionic drug coated MGQDs were shown to 
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have a better stability in FCS than uncoated MGQDs, which showed the coated MGQDs were 
relatively stable in FCS over the test period (10 days). 
 These results demonstrate that the MGQDs have a low cytotoxicity and they retained 
the photoluminescent properties of GQDs which, in conjunction with the superparamagnetic 
properties from IO nanoparticles, would allow for fluorescent and M.R.I. dual-modality 
imaging in biomedical applications without the need to use an additional fluorescent dye. 
Meanwhile, the MGQDs could be used as a targeted drug carrier via the physical bonding of a 
therapeutic to the MGQDs and the subsequent release of the therapeutic at the desired site by 
external magnetic stimulation, and as an effective potential agent for cancer photothermal 
therapy. 
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Chapter 7. Chitosan-magnetic graphene quantum dot 
nanocomposites  
7.1 Introduction 
In Chapter 6, magnetic graphene quantum dots (MGQDs) were synthesised and 
characterised. The MGQDs offered additional functionality when compared to graphene 
quantum dots (GQDs); the MGQDs were both photoluminescent and superparamagnetic 
which allows for the MGQDs to be used for dual-modality imaging (fluorescent and 
M.R.I.) and they could be manipulated for targeted drug delivery purposes. 
Furthermore, the reduction of the GO during the MQGD formation process should 
return some of the ideal mechanical and electrical conductivity properties of pristine 
graphene that GO loses during the oxidation procedure. For these reasons, the addition 
of MGQDs to chitosan to form chitosan-MGQD nanocomposites should be an 
interesting material for use within microneedle arrays.  
In Chapter 5, microneedle arrays made from chitosan-GQD nanocomposites 
proved to be successful, with the added electrical conductivity of the nanocomposite 
allowing the microneedle arrays to be used for iontophoresis-stimulated drug delivery 
of large MWt drugs. In this chapter, the chitosan-MGQD nanocomposites will be tested 
for their suitability to use within a microneedle array as their superparamagnetic and PL 
properties would make the microneedle arrays capable of delivering MGQD-bound 
small and large MWt drugs that could be tracked and manipulated in vivo.  
 An additional aim of this chapter is to improve the usability of the microneedle 
arrays. The release of the encapsulated therapeutic from polymer microneedle arrays 
typically is dependent upon the enzymatic degradation or the dissolution rate of the 
polymer. If the enzymatic degradation or dissolution time is too long, the use of a 
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microneedle array may be impractical, and the placement of a patch on the skin for a 
substantial amount of time may also cause irritation [598]. To counter this problem, this 
chapter will assess the design of a microneedle array that allows for the quick separation 
of the microneedle shafts from the base within 5 min. This was achieved by the 
introduction of a disc section at the base of the microneedle shaft that was made from 
the water soluble polymer PEG; when the PEG is dissolved, the microneedles are no 
longer attached to the base of the array and can therefore remain within the skin after 
the base patch has been removed. The structural effect that this design change had to the 
microneedle array rigidity was assessed and it was shown that the modification did not 
impede the mechanical or drug release properties of the original microneedle array. 
7.2 Experimental section 
7.2.1 Materials 
The following chemicals were reagent grade and used as purchased from Sigma Aldrich; 
acetic acid (> 99.7%), sulphuric acid (95-98%), hydrogen peroxide (29-32% in H2O), 
potassium permanganate (97%), sodium nitrate (> 99%), lidocaine hydrochloride (LH, 
> 99%), ferrous chloride tetrahydrate (FeCl2-4H2O, > 99%),  ferric chloride hexahydrate 
(FeCl3-6H2O, 97%), fluorescein sodium (FL), lysozyme (from chicken egg white, 
~100,000 U mg-1),  fluorescein sodium labelled – bovine serum albumin (BSA, 
BioReagent grade), polyethylene glycol (PEG, of 10k Da, 20k Da, and 35k Da MWt) 
and graphite powder (≤ 20 µm). Chitosan powder (Mw = 100,000-300,000, Acros 
Scientific) was used as purchased from Fisher Scientific. Phosphate buffered saline 
(PBS) tablets (pH = 7.4) were purchased from Thermo Fisher Scientific. 
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7.2.2 Preparation of magnetic graphene quantum dots 
 The method to prepare MGQDs has been discussed previously in Chapter 6. Briefly, 
GO was synthesised from graphite using a modified Hummers method [187], purified 
by washing with distilled water, exfoliated in distilled water, and lyophilised in a freeze 
drier (Labconco FreeZone Triad). FeCl2-4H2O (5.4 g) and FeCl3-6H2O (4 g) were 
dissolved in 135 ml distilled water. GO (1 g) was stirred and sonicated in 150 ml distilled 
water for 1 h, and ammonium hydroxide was used to raise the pH to 8. The two solutions 
were added together and the pH was raised to 10 by ammonium hydroxide. Under a 
nitrogen atmosphere, the solution was stirred for 2 h. The resultant precipitate, GO-IO, 
was washed with distilled water and ethanol. GO-IO was dispersed in distilled water, (~ 
3 mg ml-1), and the solution was hydrothermally reduced in a Parr Series 4000 autoclave 
(200 oC for 10 h at 1.6 MPa). A dialysis bag (Fisher Scientific Biodesign Dialysis tubing, 
Mw cut off = 3.5 kDa) was used to separate the quantum dots from larger particles. 
MGQDs were collected from the surrounding solution and lyophilised for storage.  
7.2.3 Drug loading onto magnetic graphene quantum dots 
Equal quantities of MGQD and either LH or BSA were added to distilled water to form 
an aqueous suspension of 0.1 mg ml-1 and stirred for 48 h. To remove the unbound 
therapeutic, the suspension was centrifuged (8000 rpm for 1 h) and dispersed in fresh 
distilled water several times. The resultant powder was lyophilised for storage. 
7.2.4 Preparation of nanocomposites 
The required amount (to form 0.25-5 wt.% nanocomposites) of the QDs (whether they 
be MGQD, MGQD-LH, or MGQD-BSA) was dispersed with stirring and sonication in 
distilled water. Simultaneously, chitosan powder was added to 2 wt.% acetic acid in 
distilled water to form a 2 wt.% solution. When the chitosan was fully dissolved 
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(typically left overnight at room temperature under stirring), the MGQD suspension was 
added under intense stirring and left stirring to allow the suspension to increase in 
viscosity (chitosan concentration of ~80 mg ml-1). The mixture was degassed in a 
vacuum oven for 1 h at room temperature and poured into a mould to air dry.  
7.2.5 Characterisation of chitosan-MGQD nanocomposites  
Fourier transform infra-red (FT-IR) spectroscopy was achieved with a resolution of 1 
cm-1 between 400-4000 cm-1 on a Perkin Elmer Spectrum 100 with a diamond attenuated 
total reflectance (ATR) unit. X-ray diffraction (XRD) analysis on a Stoe Stadi P with 
Cu Kα irradiation (0.154 nm wavelength) was used with the following operating 
parameters: 40 kV, 35 mA, and a scanning speed of 1o min-1. 
 A Hounsfield twin column universal testing machine was used to mechanically 
test the nanocomposites with a 1 kN load cell and a 1 mm min-1 strain rate in accordance 
with ISO-527. Test specimens (number of specimens per material (n) = 5) were punched 
from nanocomposite film and were dog-bone shaped (neck section = 20 mm long, 2.6 
mm wide, and 1 mm thick). Electrical conductivity was measured with an Agilent 
Technologies 34401A digital multimeter (n = 5) with electrode contact points painted 
using silver paint (RS 186-3600). The samples used were the dog-bone tensile 
specimens, prior to mechanical testing, with the electrode contact points placed at either 
end of the neck section. Mass loss due to enzymatic degradation over 8 weeks of 
nanocomposite specimens (n = 5) in 37 oC PBS solution (pH = 7.4) with a 1.5 µg ml-1 
concentration of lysozyme [499], was recorded with an analytical balance (Sartorius M-
power AZ124) and a Stuart SI500 bioincubator agitating at 100 rpm. After each time 
step, the specimens were washed with distilled water and dried in a vacuum oven 
overnight before weighing, after which they were placed into fresh PBS and lysozyme 
solution. 
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7.2.6 Production of nanocomposite microneedles 
 
Scheme 7.1: Experimental procedure to create a (A) conventional and (B) detachable chitosan-
MGQD microneedle arrays. 
Conventional microneedle arrays were created in a two-step process as outlined 
in Scheme 7.1 [151,152], with the filling of the main needle shaft and the filling of the 
needle base as two separate processes. First, viscous nanocomposite solution (~80 mg 
ml-1) was used to fill the moulds (Scheme 7.1A-2). To ensure that the solution filled the 
full microneedle (tip and shaft), the moulds were centrifuged at 8000 rpm for 1 h. Excess 
solution was cleaned from the surface and the moulds were left to air dry (Scheme 7.1A-
3). The process of filling, centrifuging and drying the mould was repeated twice more 
to ensure the shaft was fully formed (Scheme 7.1A-(4-7)). Secondly, the base was filled 
with a viscous pristine chitosan solution, centrifuged for 1 h at 8000 rpm and dried in a 
vacuum oven (Scheme 7.1A-8). Upon drying, the microneedles were gently removed 
from the female mould and stored in desiccators. 
To allow for the rapid detachment of the microneedle shaft from the base in the 
presence of bodily fluid, detachable microneedle arrays (Scheme 7.1B) were created 
with a ring of PEG at the base of the shaft. These arrays were created in a manner similar 
194 
 
to the standard microneedle arrays (Scheme 7.1B), but with one extra step: after the 
microneedle shaft has been filled with the nanocomposite mixture and dried, a highly 
viscous water solution of PEG is applied to the mould and excess solution scraped off. 
The moulds are then centrifuged for 1 h at 8000 rpm and dried in a vacuum oven. The 
base of the microneedles was created as standard, i.e. filled with high viscosity pristine 
chitosan solution, centrifuged for 1 h at 8000 rpm and dried in a vacuum oven. 
7.2.7 Characterisation testing of microneedles 
A Swift M10L microscope was used for optical microscopy images. Compression 
testing of the microneedles was carried out with a Hounsfield twin column universal 
testing machine with a 10 N load cell. The compression rate was 1 mm min-1. Two metal 
plates were used as the platens; the microneedle array was attached to a fixed platen and 
a second platen was attached to the load cell and was used to uniformly compress the 
microneedle arrays (n = 5) [120]. The penetration of the microneedle arrays was 
measured in full-thickness chicken by cross-sectioning the specimen using a microtome 
(Brunel bench microtome) after they were embedded in a Labonord Q-Path paraffin 
embedding medium. 
Chitosan – 2 wt.% MGQD-LH microneedle arrays (n = 5) were placed in 30 ml 
of PBS solution (37 oC, pH = 7.4) and agitated at 100 rpm. LH drug release was 
measured at set time points by collecting 3 ml of the solution and analysing it with UV-
Vis spectroscopy (Perkin Elmer Lambda 900 operating at a resolution of 1nm), having 
replaced the taken solution with 3 ml of fresh PBS. The curves for each time point were 
compared to curves of free LH in PBS of known concentrations.  
 Chitosan – 2 wt.% MGQD-BSA microneedle arrays were tested for both passive 
diffusion and electrically stimulated diffusion of MGQD-BSA. For passive diffusion, 
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the microneedle array (n = 5) was placed in 100 ml of distilled water (37 oC). BSA drug 
release was measured using UV-Vis spectroscopy, similar to the procedure to measure 
LH release. Electrically stimulated testing of chitosan – 2 wt.% MGQD-BSA 
microneedles was outlined previously in Chapter 5. Briefly, microneedle arrays were 
mounted to a microscopy slide using double-sided tape, with contacts made from silver 
paint to connect the microneedle array to the outer edge of the microscopy slide. The 
circuit, based on a prototyping circuit board, consists of a PP3 9 V 280 mAH nickel – 
metal hydride battery, a 2 kΩ resistor, an on/off switch, and two electrodes. The positive 
electrode was a crocodile clip that was used to connect the silver paint at the outer edge 
of the microneedle array to the circuit (the crocodile clip was not in direct contact with 
the microneedle array, and instead was in contact with the silver paint that touched the 
side of the microneedle array). The second electrode was submerged in the container of 
distilled water. The glass-slide was submerged vertically to a point where only the 
microneedle array was in the water and not the silver paint or the crocodile clip. The 
electrical flow, therefore, was through the microneedle array and not through the 
crocodile clip or the silver paint. 
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7.3 Results and discussion  
7.3.1 Characterisation of nanocomposites 
Characterisation of the MGQD nanoparticles was reported in Chapter 6. MGQDs were shown 
to possess PL and superparamagnetic properties for fluorescent imaging and M.R.I., and to 
respond to external magnetic stimulation for targeted drug delivery. The MGQDs were ~40 nm 
in diameter and 2-2.5 nm thick, and consisted of a core of a GQD coated with a shell containing 
a mixture of several IOs, namely maghemite, magnetite and hematite.  
  
Figure 7.1: (A) FT-IR spectra and (B) XRD traces of chitosan-MGQD nanocomposites.  
MGQDs were dispersed within chitosan at concentrations of 0.25-5 wt.%. FT-IR 
spectra are shown in Figure 7.1A, showing the characteristic peaks of chitosan (N-H peaks at 
2800 cm-1, C=O peak at 1720 cm-1, C=C peak at 1640 cm-1, amino peak at 1535-1546 cm-1, C-
OH peak at 1405 cm-1 and C-O at 1050-1100 cm-1) [482]. The characteristic peaks of MGQDs 
are shown as C=C at 1564 cm-1, O-C=O at 1406 cm-1, and C-Fe peaks at 1086 cm-1 and 1012 
cm-1 [574]. There are shifts in certain bonds when MGQDs are added to chitosan, for example 
the amino peak shifts from 1545 cm-1 for pristine chitosan to 1538 cm-1 for 1 wt.% MGQD, the 
C=C peak shifts from 1636 cm-1 for pristine chitosan to 1631 cm-1 for 1 wt.% MGQD and the 
C-O peak shifts from 1060 cm-1 for pristine chitosan to 1063 cm-1 for 1 wt.% MGQD. These 
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shifts can be attributed to both the hydrogen bonding that occurs between the chitosan (amino 
group) [396,482] and the MGQDs (Fe-O and O-C=O) and for the C-O peak shift there is the 
possible overlapping of peaks between the C-O peaks of chitosan and the C-Fe peaks of the 
MGQDs. The shifts are accompanied by a change in intensity of the C=C, amino, C-OH and 
C-O peaks for the nanocomposites, with the absorbance of all the peaks increasing from 0.25 
wt.% to 2 wt.% as the MGQD wt.% increased. 
 
Figure 7.2: XRD traces of chitosan-MGQD nanocomposites.  
In Figure 7.2, XRD traces of the nanocomposites can be seen. Typically, the chitosan 
peaks (crystalline and amorphous) are the only peaks present for both the pristine chitosan and 
the nanocomposites up to 2 wt.% MGQDs. The diffraction peaks from the MGQDs can be seen 
in the 5 wt.% nanocomposite due to the high wt.% of MGQDs present. These peaks are the 
(213) peak from maghemite, the (104) from hematite, and (422) and (511) from magnetite 
(Chapter 6). The other MGQD specific peaks may be present but too weak to clearly identify 
at this wt.%. From the chitosan-specific crystalline peaks that are identified on curve 1 of 
Figure 7.2, the crystallinity percentage can be determined from Equation 3.1 (Chapter 3). This 
gives crystallinity values for 0-5 wt.% MGQDs nanocomposites of 34.1%, 27.3%, 27.3%, 
27.1%, 26.3%, and 25.5% respectively, showing a decrease in crystallinity with increasing 
wt.% of MGQDs. Graphene based nanoparticles have been shown previously to reduce the 
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crystallinity of chitosan-GO in Chapter 3 and chitosan-GQD nanocomposites in Chapter 5; in 
this instance, the decrease is presumably due to MGQDs restricting the chitosan chain 
movement due to the surface absorption and bonding [504].  
 
Figure 7.3: Electrical conductivity of chitosan-MGQD nanocomposites.  
The electrical conductivity of the nanocomposites was measured, with a maximum 
conductivity of 0.0035 S m-1 achieved at 5 wt.% MGQD versus 0.0018 S m-1 for pristine 
chitosan (Figure 7.3). There was no significant increase in conductivity when the MGQDs 
wt.% increased from 0.25 wt.% to 2 wt.% MGQDs. The conductivity of the 5 wt.% MGQD 
nanocomposite is lower than that recorded for chitosan-GQD nanocomposites (e.g. 1 wt.% 
GQD = 0.0161 S m-1, Chapter 5). The difference between nanocomposites formed of highly 
reduced GQD and of MGQD is due to the presence of IO on the surface of the MGQDs. IO 
can improve the conductivity of polymers [417,420,421], but graphene is more conductive than 
IO [179,599]. The shape, size, the dispersion degree of the MGQD and the volume fraction of 
graphene in the nanocomposite are other important factors that affect the electrical conductivity 
of a nanocomposite [366]. From Chapter 6, it can be seen that MGQDs are both thicker than 
GQDs at ~2.5 nm versus ~1.5 nm and of a higher density than the GQDs which means that 
there is a lower volume fraction of MGQDs within the nanocomposite for a given wt.% (3.66 
g cm-3 for MGQD in comparison to 1.66 g cm-3 for GQD).  
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Figure 7.4: (A) Representative tensile curves and (B) enzymatic degradation rate for 
pristine chitosan and 0.5 wt.%, 1 wt.%, and 2 wt.% MGQD nanocomposites. 
Figure 7.4 shows representative tensile stress-strain curves for pristine chitosan and 
chitosan nanocomposites. The Young’s modulus (E) is 1.48 (± 0.38) GPa, the UTS is 62.5 (± 
9.4) MPa, and εb is 15.5 (± 4.2) % for pristine chitosan. The 0.5 wt.% and 1 wt.% MGQD 
nanocomposites can be seen to have a lower UTS than pristine chitosan, with average values 
of 48.9 (± 3.4) MPa and 49.8 (± 4.1) MPa, respectively. The E of the 0.5 wt.% and 1 wt.% 
MGQD nanocomposites are 1.19 (± 0.07) GPa and 1.32 (± 0.16) GPa respectively. The 2 wt.% 
MGQD nanocomposite has a UTS and E that is statistically similar (p < 0.05 confidence level) 
to pristine chitosan, with an E of 1.45 (± 0.27) GPa and a UTS of 60.6 (± 7.25) MPa. The 5 
wt.% MGQD nanocomposite was found to be too brittle to be mechanically tested. 
The influential factors are the crystallinity of the chitosan and the effectiveness of the 
MGQDs as reinforcing nanofillers. The crystallinity of a polymer can affect its mechanical 
properties [483], and the nanocomposites of 0.25-2 wt.% have a lower crystallinity than the 
pristine chitosan, potentially reducing the strength and stiffness of the nanocomposites. As 
discussed previously, QDs such as MGQDs and GQDs may not be as effective a nanofiller as 
GO or rGO due to its smaller aspect ratio (they have both got a smaller diameter than GO or 
rGO and are both thicker than GO). MGQDs are also denser than rGO and GQD which means 
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that there is a lower volume fraction of MGQD nanoparticles within the nanocomposite for a 
given wt.% of nanofiller. MGQDs do, however, have a rGO backbone (reported E of 185 GPa 
[527] to 250 GPa [528] to 305 GPa [390]) and a shell of IO (E reported as 200-250 GPa 
depending on the crystal orientation [600]). There is also a strong bonding interface between 
the MGQDs and the chitosan (as shown in Figure 7.1). At a 2 wt.% loading, there is a sufficient 
concentration of MGQDs to efficiently transfer the load through the chitosan (which may not 
have been the case with the 0.5 wt.% and 1 wt.% nanocomposites).  
The effect of crystallinity upon the chitosan and the effectiveness of the MGQD can be 
seen to effectively cancel each other out for the 2 wt.% nanocomposite. The εb is 13.3 (± 3.9) 
% for 0.5 wt.%, 15.5 (± 4.5) % for 1 wt.%, and 18.2 (± 4.6) % for 2 wt.% MGQD 
nanocomposites. The 17.4% increase in εb for the 2 wt.% MGQD nanocomposite over chitosan 
is not as big an increase as for the εb increase (37%) for the chitosan-1 wt.% GQD 
nanocomposite from Chapter 5, which also had a 36% increase in UTS unlike the chitosan-
MGQD nanocomposite, which is presumably due to the differences between MGQD and GQD 
in terms of size and density, as discussed previously. In comparison to chitosan, the increase 
in εb can be explained by the reduction in the crystallinity of the chitosan in the chitosan-
MGQD nanocomposite and the MGQDs may possess a degree of mobility within the 
nanocomposite when the nanocomposite is under tension, which will absorb energy 
[369,400,505]. 
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Figure 7.5: Enzymatic degradation rate for pristine chitosan and 0.5 wt.%, 1 wt.%, and 
2 wt.% MGQD nanocomposites. 
Pristine chitosan and the 0.5 wt.%, 1 wt.% and 2 wt.% nanocomposites were subjected 
to a enzymatic degradation test to determine the effect of MGQD concentration on the 
enzymatic degradation rate of chitosan. Figure 7.5 shows the effect that increasing the MGQD 
concentration has upon the remaining mass of chitosan at each time-step when subjected to 
enzymatic degradation. Chitosan samples were reduced to 61.6% of their original mass after 
49 days, while 0.5 wt.%, 1 wt.% and 2 wt.% were reduced to 54.1%, 54.9% and 56.2% 
respectively.  
It was previously noted in Chapters 3 and 4 that the inclusion of graphene nanosheets 
impeded the enzymatic degradation rate of nanocomposites through the previously discussed 
“tortuous path” model. This was not the case with the smaller MGQDs, as the nanocomposites 
can be seen in Figure 7.2B to have a higher enzymatic degradation rate than pristine chitosan 
and therefore the MGQDs did not impede the enzyme from permeating through the chitosan, 
similar to the chitosan-GQD nanocomposites in Chapter 5. For the chitosan-MGQD 
nanocomposites, the difference in the final mass of the samples is statistically insignificant, 
showing that the enzymatic degradation rate is not concentration dependent. The decrease in 
remaining mass between pristine chitosan and the MGQD nanocomposites is due to the lower 
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crystallinity of the nanocomposites compared to pristine chitosan and the possible diffusion of 
some of the MGQDs from the nanocomposite into the PBS solution [486,601].  
7.3.2 Chitosan-2 wt.% microneedle arrays  
 
Figure 7.6: Optical microscopy images of the CH-MGQDs microneedle array; (A) side 
view, (B) plan view of the microneedle array, and (C) compression testing of CH-
MGQDs microneedle arrays. (Inset) Side view of CH-MGQDs microneedle array after 
insertion into chicken skin. 
The 2 wt.% MGQD nanocomposite was selected for use as a microneedle array as the 
nanocomposite had better mechanical properties than the other nanocomposites, close to 
pristine chitosan, while the high wt.% did not hinder the enzymatic degradation characteristics 
and would allow for a higher quantity of drug to be loaded into the nanocomposite relative to 
lower wt.% nanocomposites. Chitosan-2 wt.% MGQDs nanocomposites were used to form 
microneedle arrays for the delivery of small and large MWt drugs into the body via transdermal 
drug delivery. Figure 7.6A and 7.6B show optical microscopy images of the chitosan-2 wt.% 
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MGQD microneedle array (from here on known as CH-MGQD microneedle array), showing 
the plan and side profile of the microneedle arrays. The microneedle arrays were tested by 
compressive testing to 10 N to verify their structural integrity under the force of insertion, as 
seen in Figure 7.6C. A failure of the microneedle shaft would be seen as a substantial drop in 
the compressive force required to compress the microneedle array. The inset of Figure 7.6C 
shows the CH-MGQDs microneedle arrays during insertion into chicken skin by hand, 
confirming that these CH-MGQDs microneedle arrays were strong enough to survive the force 
of insertion into the skin. The depth of penetration of the microneedle array into the chicken 
skin can be determined as approximately 500 µm, similar to previously reported penetration 
values for chitosan-GQD microneedles in Chapter 5. 
To allow for the microneedles to detach from the microneedle array base, a disc of the 
water soluble polymer PEG was included at the base of the microneedle shaft. Incorporating a 
section of pristine PEG to the base of the microneedle may have a negative impact upon the 
microneedle rigidity. Different MWt PEG polymers (MWt = 10 kDa, 20 kDa, and 35 kDa) 
were investigated for the effect that they would have on the structural integrity of the 
microneedle arrays. Higher MWt PEG was not tested as the systemic clearance of PEG from 
the body is reduced as the MWt increases [602] and there is a reduced dissolution rate when 
the MWt increases [603]. Figure 7.7A shows representative curves of the compressive testing 
of pristine chitosan microneedle arrays with the addition of a small ring of PEG between the 
main microneedle shaft and the base. It can be seen that the 10k Da MWt PEG microneedle 
array deformed substantially in comparison to pristine chitosan; the low MWt PEG offered 
limited mechanical strength to the base of the microneedle when under compression. The 20k 
Da microneedle arrays retained similar levels of deformation to the pristine chitosan sample 
due to the stronger mechanical properties of the 20k Da PEG relative to the 10k Da PEG.  
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Figure 7.7: Compression testing of (A) chitosan and various MWt PEG and (B) CH-
MGQDs with 35k Da PEG microneedle arrays. 
The microneedle arrays containing 35k Da PEG were less ductile than the pristine 
chitosan microneedle arrays, due to the rigidity of the high MWt PEG. A strong base is 
important to the usability of microneedle arrays, preventing the fracture or bending during 
insertion. The 35k Da PEG proved to be the strongest base material of the materials tested and 
the force versus displacement curve of the chitosan-35 k Da PEG microneedle was similar to 
the pristine chitosan-2 wt.% MGQD microneedle array in Figure 7.6C. With this in mind, the 
35k Da PEG was chosen to be used in this nanocomposite microneedle array. 
The compressive testing results of the CH-MGQD with 35k Da PEG (from here on 
known as CH-MGQD-PEG) microneedle arrays are shown in Figure 7.7B, which shows that 
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the addition of a PEG ring to the base of the microneedle main shaft does not deteriorate the 
strength of the microneedle array in comparison to conventional CH-MGQD microneedle 
arrays, and the compression curves are similar to the CH-MGQD microneedle arrays without 
PEG. 
  
Figure 7.8: Side view of a CH-MGQD-PEG microneedle array, with (A) before and (B) 
after 5 min in the presence of water, showing the successful detachment of the 
microneedle shaft from the base. (C) After insertion of the microneedle array into 
chicken skin for 5 min, the successful detachment of the microneedle shaft from the 
base can be seen again. 
Figure 7.8 shows the detachment of the microneedle main shaft from the array base 
when the CH-MGQD-PEG microneedle array was mounted to a glass slide and had two drops 
of distilled water applied to the upper surface. After 5 min, the water had caused the 
microneedle to swell and upon further inspection the microneedle shafts were no longer 
connected to the microneedle base. The mounds at the base of the microneedle shaft can be 
seen to have remained, as seen in Figure 7.8B. The region where PEG was deposited would 
have been between the mound and the main shaft. This shows that the microneedles can be 
detached within 5 min when in the presence of water or bodily fluid within skins by placing a 
ring of PEG between the main shaft and the base. Other images of microneedle separation are 
shown in Figure 7.S1 (Appendix 1). As a further proof of concept test, the CH-MGQD-PEG 
microneedle array was inserted into chicken skin (Figure 7.8 C) for 5 min, and it can be seen 
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that the microneedles have separated from the main base. This further confirms that the PEG 
separation method can work after insertion into skin.  
 
Figure 7.9: Release of LH from microneedle arrays of CH-MGQD or CH-MGQD-PEG 
over 7 h. The release from both microneedle types can be seen to be very similar in 
profile. 
   For the delivery of small MWt therapeutics, LH (288 Da) was chosen as the model 
drug. The drug was bonded (via hydrogen bonding and π-π stacking) to the surface of the 
MGQDs, with a loading ratio of 0.31:1 (LH:MGQD) determined from Chapter 6. Microneedle 
arrays containing chitosan and 2 wt.% MGQD with bonded LH were tested for the release of 
LH (Figure 7.9). Two types of microneedle arrays were tested; CH-MGQD-PEG and CH-
MGQD. It can be seen that the two types of microneedle array are initially (up to 4 h) very 
similar in terms of quantity of drug released and the rate at which it was released, after which 
the CH-MGQD-PEG released less LH than the CH-MGQD microneedle array (after 6 h, 
CH-MGQD released 12.3 µg or 76.6% of the available drug and CH-MGQD-PEG released 
9.4 µg or 59.4%). After this time-point, the microneedles were no longer fully intact and the 
test was stopped. The difference in final delivery quantity between the two types of 
microneedle array is presumably due to the separation of the microneedles from the base, as 
the same amount of drug-containing chitosan-2wt.% MGQD was used in both types of 
microneedles (i.e. three centrifuge cycles) and therefore the results should be identical. It is 
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possible that some of the microneedle shafts for the CH-MGQD-PEG may have become 
buoyant after 4 h after detaching from the base and floated to the surface of the PBS. This 
problem would not occur during in vivo treatment as the microneedles would be embedded in 
the skin prior to the separation. This test focused on the release of MGQD-LH from the 
microneedle array; it has been shown in Chapter 6 that LH could be fully released from 
MGQDs over 6 h. 
 
 
Figure 7.10: (A) TGA curves for the determination of the loading of BSA onto MGQDs 
and (B) the passive diffusion and electrically stimulated release of BSA from 
microneedle arrays.  
To study the release of large MWt drugs from the CH-MGQD microneedles, MGQDs 
were bonded to the therapeutic BSA (~60k Da MWt). Iontophoresis could not be achieved 
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with CH-MGQD-PEG microneedles as the PEG ring would cause the detachment of the main 
microneedle shaft containing the drug before the drug could be released. Figure 7.10A shows 
the TGA curves of MGQDs, BSA, and MGQD-BSA. This shows that there is a 9.5%, or 0.10:1 
BSA:MGQD, loading of BSA in MGQD-BSA, as determined from the mass loss of MGQD-
BSA between 220-400 oC, accounting for both the loss of BSA over this temperature range 
(52.8%) and for absorbed water, in both cases. This MGQD-BSA was used to form CH-
MGQD microneedles which were subsequently tested for passive diffusion release of 
BSA over 1440 min (24 h), as shown in Figure 7.10B. The passive diffusion release of 
BSA was limited, with only 0.5 µg or 10.7% released after 8 h and 1.2 µg or 25.7% released 
over 24 h. Similar passive drug release performance from the BSA loaded CH-MGQD-
PEG microneedle array is expected. 
This low level of release can be improved by using electrical stimulation, as 
shown in Chapter 5, where the use of electrical stimulation offered a significant 
improvement over standard diffusion release of BSA from chitosan-GQD microneedles. 
A similar improvement was noted for the CH-MGQD microneedles, with 1.9 µg or 40.7% 
released over 8 h and 4.5 µg or 96.4% released over 24 h, with the final value markedly higher 
than the 1.2 µg after 24 h for the passive diffusion microneedle array. Figure 7.11 shows the 
difference in release visually, with passive diffusion shown in the left container and 
electrically stimulated release in the right hand container. The yellow colour of the FL 
labelled BSA (Figure 5.S2, Appendix 1) can be seen in the right hand container after 4 
h, with the colour becoming more vibrant at 6 h and 8 h. After 24 h, the colour of the 
right hand container is a combination of the strong yellow from the FL release and the 
black of the MGQD (Figure 6.4, inset). The water in the left container does not exhibit a 
strong yellow colour as the amount of BSA released from the passive diffusion microneedle 
array was substantially lower. The results of the drug test in Figure 7.10B show that chitosan 
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- 2 wt.% MGQD microneedle arrays can be used for the release of large MWt drugs 
through electrically stimulated diffusion; this ability is due to the nanocomposites being 
electrical conductive which allows for the current to flow through the nanocomposite in 
order to transfer the therapeutic from the nanocomposite into the target medium, such 
as with normal iontophoretic devices and their electrodes [62]. The results shown in 
Figure 7.9 and Figure 7.10 show that chitosan-MGQD nanocomposites are capable of 
the efficient and strong release of small and large MWt drugs when in the form of a 
microneedle array. 
 
Figure 7.11: Visual representation of the difference in release of BSA by either passive 
(left) or electrically stimulated (right) release.  
7.4 Conclusions 
Iron oxide - reduced graphene oxide QDs (MGQDs) were shown in Chapter 6 to be 
capable of dual-modality imaging, targeted drug delivery, and photothermal ablation. 
Polymer nanocomposites of chitosan-MGQDs were developed for transdermal drug 
delivery applications such as a combined iontophoretic-microneedle array device where 
the nanocomposites would need to be both electrically conductive and mechanically 
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strong to survive insertion into the skin; the MGQDs would be used after release from 
the microneedle for the imaging/tracking of the drug. 
The addition of 2 wt.% MGQDs to chitosan increased the electrical conductivity 
by 25%. The 2 wt.% MGQD nanocomposites has a statistically similar UTS and E to 
chitosan and a higher εb. Microneedle arrays need to be biodegradable and the 2 wt.% 
MGQD nanocomposite has a quicker initial enzymatic degradation rate than pristine 
chitosan. These results show that, while the MGQD may not offer an improvement to 
the mechanical properties, the added benefits of combining MGQDs with chitosan (such 
as improved electrical conductivity and increased enzymatic degradation) are not met 
with the disadvantage of a reduction in mechanical properties. Compression testing of 
the chitosan-MGQD nanocomposite microneedles confirmed that they were strong 
enough to survive the force of insertion into the skin layers. Cross-sections of chicken 
skin samples were used to determine the depth of penetration of the microneedle array 
as 500 µm. 
Drug release from polymer-based microneedles is dependent upon the enzymatic 
degradation or the dissolution rate within bodily fluids of the polymer, which may be 
prohibitively long. Chitosan-MGQD nanocomposite microneedles were modified with 
a ring of PEG at the microneedle base; the microneedles were shown to rapidly detach 
from the base within 5 min in the presence of water or bodily fluid, with no effect on 
the mechanical strength of the microneedle arrays under compressive loading. The 
microneedles can stay in the body and release the MGQD-bound drug. 
The chitosan-MGQD microneedle arrays, both conventional and detachable, 
were tested for their ability to release a small MWt drug. The conventional chitosan-
MGQD microneedle array released 76.6% within 6 h, more than the detachable 
microneedle array (59.4%), proving that the chitosan-MGQD nanocomposite can be 
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used for drug delivery. There was a marked improvement in the delivery of large MWt 
drugs when the conventional microneedles were electrically stimulated to create a 
microneedle array-iontophoretic type device. The total percentage of drug released 
increased from 25.7% for passive diffusion to 96.4% over 24 h for the microneedle 
array-iontophoretic type device; showing that the ability to efficiently release large MWt 
drugs from the nanocomposite was only achievable by using electrical stimulation of 
the conductive films.  
Microneedles formed from chitosan-MGQD nanocomposites have potential for 
use in medicine; the use of MGQDs as a drug carrier allows for therapeutics of small or 
large MWt to be bonded to the nanoparticle, subsequently targeted by an external 
magnetic field to a site of release whilst being monitored by M.R.I. or fluorescent 
imaging. The electrical conductivity of chitosan-MGQD nanocomposites can be used 
for the electrically stimulated release of large MWt drugs, allowing for chitosan-MGQD 
microneedle arrays to be a universal delivery platform for therapeutics of many different 
sizes and their subsequent targeting and monitoring. 
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Chapter 8. Overall conclusions and future work 
8.1 Overall conclusions 
This thesis has focused on the synthesis and characterisation of graphene derivatives and 
chitosan-graphene nanocomposites, and on quantifying the changes in material properties that 
adding these graphene derivatives into pristine chitosan can achieve. In each individual chapter, 
key findings have been discussed at that level but certain findings and trends are common 
throughout the thesis. From these common trends, one major conclusion can be ascertained: 
graphene can alter the mechanical properties, the electrical conductivity, the crystallinity, the 
enzymatic degradation rates, and the drug release rates of the nanocomposites relative to the 
pristine polymer.   
Graphene acted as an effective reinforcement filler to increase the mechanical 
properties of chitosan, with changes in the E, UTS, and εb recorded for the chitosan-graphene 
nanocomposites attributed to the high aspect ratios, high surface areas, and high Young’s 
modulus of graphene. Graphene is also a very electrically conductive nanoparticle, and when 
incorporated into a polymer nanocomposite, the resultant nanocomposites have improved 
electrical conductivity when compared to pristine chitosan and percolation thresholds were 
achieved at low graphene concentration levels. 
Graphene affects the crystallinity of the nanocomposites, relative to pristine chitosan, 
which can influence the mechanical properties and the enzymatic degradation rate. The 
lowering of the crystallinity is attributed to the restriction of the chitosan chains by the graphene 
derivatives through surface absorption and bonding between the graphene and the chitosan, 
preventing the rearrangement of chitosan chains into ordered molecular chains for 
crystallisation. An increase in crystallinity was attributed to the crystallite nucleation effect of 
the graphene. Additionally, the presence of nanoparticles within a nanocomposite can 
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influence the enzymatic degradation of the nanocomposite by increasing the barrier properties 
due to the tortuous path model, where the high aspect ratio sheets are effective nanoparticles 
to limit the permeation of enzymes through the nanocomposite. 
The release of the drug from a nanocomposite was both quicker and more substantial 
than that recorded for pristine chitosan; this improvement was attributed to the increase in the 
diffusion coefficient of the drug as a result of bonding the drug to graphene. Improvements in 
stimulus response were also noted for the chitosan-graphene nanocomposites in comparison to 
the pristine chitosan; the nanocomposites displayed a pH sensitive release of the drug, with a 
considerably lower drug release when the nanocomposite was in an acidic environment, as well 
as the electrically stimulated release of large MWt drugs that microneedles containing chitosan-
graphene nanocomposites can be used for the delivery of both small and large MWt drugs. The 
increase in conductivity for the chitosan-graphene nanocomposites as if the nanocomposites 
were not conductive, iontophoretic stimulation would not be possible and subsequently the 
nanocomposites could not be used to deliver large MWt drugs. 
Due to the improvements in mechanical, electrical conductivity, and drug 
release/delivery/tracking performance, chitosan-graphene nanocomposites are ideal materials 
for use in biomedical applications such as microneedle arrays or drug-release films and 
coatings, and the graphene derivatives themselves may find use as drug carriers that are capable 
of tracking and targeting a drug to a target site in vivo. 
8.2 Future work 
The design of the microneedle array could be improved in future work. These improvements 
could be an increase in the number of microneedles in an array (from 10 × 10 to 50 × 50, for 
example). This is the obvious way to increase the graphene-bound delivery dosage per 
microneedle array administration, but this can be met by usability issues; future research work 
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may focus on whether all of the microneedles in a larger array could be applied evenly at once 
by hand alone, and if not, how to achieve this with an a applicator instead of a hand.  
Other possible improvements in the design could be to the depth of penetration of the 
microneedles; this might be through lengthening the microneedle shaft, but this would require 
compression studies to determine if buckling or bending is now a possible failure mode. 
Additional studies could also analyse the pain felt by patients when this particular design of 
microneedle is applied, if human trials could be arranged. If the microneedle is too long, it 
might interact with the nerves below the viable epidermis, and therefore cause pain.  
The design of the microneedle array may be modified by widening the gap between 
microneedles in the array. This would benefit the insertion of the microneedles by preventing 
clogging by debris that might accumulate during insertion. It may also reduce the damage to 
the skin, with further spaced microneedles more likely to cleanly puncture the skin than to tear 
the skin. The effect that widening the spacing would have would require further in vitro skin 
penetration analysis and possible human or relevant animal trials to determine the effect that 
microneedle spacing has on skin healing. Testing would also be needed to determine whether 
all of the microneedles could be applied at once by hand, or whether the array is too large and 
an applicator is needed.  
Alternative tip shapes might improve cutting performance and make the microneedle 
sharper, requiring a lower force to insert the array. These changes would need human or 
relevant animal trials to determine the effect that microneedle spacing has on skin healing. The 
best design could be determined and then utilised in future iteration of the microneedle array. 
Within this thesis, polymer-graphene nanocomposites have been typically studied for 
drug testing at 1 wt.% or 2 wt.% ,and with the loading of drugs onto graphene typically in the 
20-40% range, this means that the quantity of drug within a nanocomposite is limited. A 
solution to this problem may be to introduce unbound drug into the nanocomposite. The effect 
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of graphene on the release of this free drug from the polymer could be studied. In this scenario, 
graphene would not be bound to the drug but may still affect the drug release rate by decreasing 
the permeability of the release medium through the polymer, and the drug loading within the 
nanocomposite would be higher than that possible for graphene-bound drug loaded 
nanocomposites. This drug release testing will show if graphene will inhibit or improve the 
free drug release from nanocomposites with, for example, a ~40% loading versus pristine 
chitosan with the same drug quantity, but without graphene. This may overcome some of the 
problems with low graphene content and still allow graphene to be a structural reinforcement 
and to be used to make electrically conductive nanocomposites to allow for electrically 
stimulated drug release.  
In vivo testing of the microneedle arrays and the release of the nanoparticles may be 
required to study the effects of nanoparticles delivered through this route. Although the 
literature states that graphene can be removed from the body, the application of graphene 
through the dermal layers has not been sufficiently studied as of yet. This testing might take 
the form of a ‘bio-distribution’ test where the quantity of accumulated graphene is measured at 
certain points of the body over the course of several weeks, as well as in the excretions of the 
test subject.  
In this thesis, in vitro testing and characterisation analysis showed the potential of the 
MQGDs, but in vivo testing would be required to fully study the combined targeting and 
imaging/tracking of the MGQDs and to assess their usefulness to biomedicine. 
 The GQDs and MGQDs could be developed further, with their cytotoxicity lowered by 
passivation with biomolecules. An in vitro biostability test will determine which biomolecules 
enhance the biostability of the QDs in bodily fluids when coated to the surface. The 
biomolecules may, however, hamper the fluorescent imaging capability of the QDs by 
fluorescence quenching, which will need to be investigated.  
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The magnetic properties of the MGQDs could be improved. Currently, the magnetic 
portion of the MGQDs is a mixture of iron oxides with varying magnetic strengths. Ideally, the 
magnetic properties of the MGQDs could be optimised by keeping the iron oxide solely 
magnetite. This may require an alteration in the production parameters (such as a lower 
autoclave temperature or the use of inert gases in the hydrothermal treatment to prevent 
oxidation to other forms) to prevent the production of different IO types that may be less 
magnetic than magnetite.  
 The hydrothermal treatment might also be modified by increasing the pressure of the 
inert gases beyond that which is possible with steam from the 200 oC water. The increase in 
gas pressure within the autoclave may reduce the size of the QDs to a smaller size than currently 
possible. This may also allow the treatment temperature to be reduced from 200 oC to a lower 
temperature. 
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Appendix 1. Supplemental figures 
 
Figure 3.S1: Tensile test of a steel specimen.  
 
Figure 3.S2: 3D-AFM image of GO-FL sheet from Figure 3.5, emphasising the roughness and 
unevenness of the FL coating on the GO. 
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Figure 4.S1: UV-Vis spectra of rGO over 72 h at (A) 20 oC and (B) 37 oC. 
 
 
Figure 4.S2: Compression testing to failure of microneedle arrays using a 1 kN load cell with 
no limitation on maximum loads or minimum depths. The point where the microneedles are 
believed to have fully failed is indicated by the relevant arrow. After this point, the individual 
microneedles are being crushed to a horizontal position after having failed by bending means. 
(Inset) One of the fully failed microneedle arrays can be seen with the individual needles at an 
orientation closer to horizontal than to vertical. 
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Figure 5.S1: Data for photoluminescence (PL) quantum yield measurements. 
 
Figure 5.S2: PL spectra showing the selectivity of GQD emission to the excitation wavelength. 
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Figure 5.S3: Optical microscopy images of chitosan - 1 wt.% fluorescein sodium coated 
graphene quantum dot (GQD-FL) nanocomposite microneedle arrays that were inserted into 
full thickness chicken skin: (A) pristine chicken skin, (B) after the insertion of a chitosan - 1 
wt.% GQD microneedle array. Microneedle arrays were inserted into full-thickness 
chicken skin by hand and were kept for 1 h, after which the skin was prepared for cross-
sectioning by treating with ethanol for 10 min to displace water and then embedding in 
Labonord Q-Path paraffin embedding medium (melting temperature is 57 oC). The 
samples were then cross-sectioned using a microtome (Brunel bench microtome) and 
the cross sectioned samples were transferred to microscopy glass slides and re-heated to 
57 oC to remove the embedding medium from the samples. Optical microscopy was 
through an optical microscope (Swift M10L, Swift Optical Instruments). 
 
Figure 5.S4: Digital image of fluorescein sodium labelled bovine serum albumin (BSA) (~0.08 
µg ml-1, similar to curve 2 after 24 h in Figure 5.7B), showing the characteristic colour of BSA-
FL and confirming the medium solutions presented in Figure 5.8 (after 24 h) mainly contain 
the BSA coated FL. 
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Figure 5.S5 Optical microscopy image of microneedle arrays before and after submersion in 
foetal bovine serum (FBS) and subsequent air drying. By comparing the 0 h and 6 h images, 
the size of the microneedles remains similar after immersion showing no stability problems for 
the microneedles in FBS. 
 
 
 
Figure 6.S1 (A) FT-IR spectra and (B) Raman spectra for LH, MGQDs, and MGQD-LH. 
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Figure 7.S1: Optical microscopy images of four separate microneedles of the CH-MGQD-
PEG microneedle arrays, after 5 min in the presence of water. The main shaft detached after 
the PEG dissolved in the presence of water.  
 
